Unchanged

Summary of findings {#CD003650-sec1-0001}
===================

Summary of findings for the main comparisonMultiple micronutrients compared to placebo for adults with HIV infection**Multiple micronutrients compared to placebo for adults with HIV infectionParticipant or population:** adults with HIV infection (with and without concurrent tuberculosis, with and without ART) **Settings:** all settings **Intervention:** multiple micronutrient supplementation (standard or high dose daily) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboMicronutrientsMortality**\
Follow‐up: 8 to 24 months**100 per 100091 per 1000** (72 to 115)**RR 0.91**\
(0.72 to 1.15)2897 (7 trials)⊕⊕⊝⊝ **low**^1,2,3,4^\
due to indirectness and imprecisionMultiple micronutrients may have little or no effect on mortality**Hospital admissions**\
Follow‐up: 11 to 18 months**139 per 1000120 per 1000**\
(85 to 170)**RR 0.86**\
(0.61 to 1.22)881\
(2 trials)⊕⊝⊝⊝ **very low**^1,4,5^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on hospital admissions**CD4 cell count**\
Follow‐up: 6 weeks to 2 yearsThe mean in the placebo groups ranged from\
**147 to 483 cells/mm**³The mean in the multiple micronutrient group was\
**26.40 cells/mm**³ **higher**\
(22.91 lower to 75.70 higher)---1581 (6 trials)⊕⊕⊝⊝\
**low**^1,3,6^\
due to indirectness and inconsistencyMultiple micronutrients may have little or no effect on CD4 cell count**Viral load**\
Follow‐up: 6 weeks to 2 yearsThe mean in the placebo groups ranged from\
**4.1 to 5.4 log~10~copies/mL**The mean in the multiple micronutrient groups was\
**0.10 log~10~copies/mL lower**\
(0.26 lower to 0.06 higher)---840\
(4 trials)⊕⊕⊕⊝ **moderate**^1,7^\
due to indirectnessMultiple micronutrients probably have little or no effect on viral load**Nutritional status**\
Follow‐up: 4 weeks to 1.9 years------Not pooled1007 (3 trials)⊕⊝⊝⊝ **very low**^1,8,9^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on nutritional status parametersThe basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** ART: antiretroviral therapy; BMI: body mass index; CI: confidence interval; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^2]

Summary of findings 2Vitamin A compared to placebo**Vitamin A compared to placebo for adults with HIV infection currently taking ART or notParticipant or population:** adults with HIV infection **Settings:** any **Intervention:** vitamin A (single dose or daily dose) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboVitamin AMortality**---------(0 trials)------**Morbidity**---------(0 trials)------**CD4 cell count (cells/mm**³**)** Follow‐up: 6 to 8 weeks------Not pooled464 (2 trials)⊕⊕⊝⊝ **low**^1,2,3,4^\
due to risk of bias and indirectnessVitamin A may have little or no short‐term effect on CD4 cell count**Viral load (log~10~copies/mL)** Follow‐up: 6 to 8 weeks------Not pooled495 (3 trials)⊕⊕⊝⊝ **low**^1,2,3,4^\
due to risk of bias and indirectnessVitamin A may have little or no short‐term effect on viral load**Change in vitamin A concentrations (µmol/L)** Follow‐up: 6 to 8 weeks------Not pooled495\
(3 trials)⊕⊕⊝⊝ **low**^1,3,4,5^\
due to risk of bias and indirectnessVitamin A may increase blood concentrations of persons with HIV with low baseline concentrations\*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** ART: antiretroviral therapy; CI: confidence interval; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^3]

Summary of findings 3Vitamin D compared to placebo**Vitamin D compared to placebo for adults with HIV infectionParticipant or population:** adults with HIV infection **Settings:** any **Intervention:** vitamin D (repeated single doses or daily dose with or without additional calcium) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboVitamin DMortality**\
Follow‐up: 12 months**254 per 1000292 per 1000**\
(165 to 513)**RR 1.15**\
(0.65 to 2.02)131 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^\
due to indirectness and imprecisionWe don\'t know if vitamin D supplements have any effect on mortality**Morbidity**---------(0 trials)------**CD4 cell count (cells/mm**³**)** Follow‐up: 16 weeks to 12 months------Not pooled288 (4 trials)⊕⊕⊝⊝ **low**^1,4^\
due to indirectnessVitamin D supplements may have little or no effect on CD4 cell count**Viral load (log~10~copies/mL)**\
Follow‐up: 12 monthsThe mean in the placebo group was\
**3.78**The mean in the multiple micronutrient groups was\
**0.66 lower**\
(1.37 lower to 0.05 higher)---28 participants\
(1 trial)⊕⊝⊝⊝ **very low**^1,5,6^\
due to indirectness and imprecisionWe don\'t know if vitamin D supplements have an effect on viral load**Change in 25(OH) vitamin D concentrations (ng/mL)** Follow‐up: 16 weeks to 12 months------Not pooled299 (4 trials)⊕⊕⊕⊝ **moderate**^1,7,8^\
due to indirectnessVitamin D supplements probably increase blood 25(OH) vitamin D levels\*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^4]

Summary of findings 4Zinc compared to placebo**Zinc compared to placebo for adults with HIV infectionParticipant or population:** adults with HIV infection **Settings:** any **Intervention:** zinc (daily or weekly dose) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboZincMortality** Follow‐up: 6 to 18 months**110 per 1000135 per 1000**\
(58 to 315)**RR 1.24** (0.53 to 2.86)433 (3 trials)⊕⊝⊝⊝ **very low**^1,2,3^\
due to indirectness and imprecisionWe don\'t know if zinc supplements have any effect on mortality**Rate of diarrhoea** Follow‐up: 18 months------**OR 0.40** (0.18 to 0.87)231\
(1 trial)⊕⊝⊝⊝ **very low**^1,4,5^\
due to indirectness and imprecisionWe don\'t know if zinc supplements have any effect on the frequency of diarrhoea**Change in CD4 cell count (cells/mm**³**)**\
Follow‐up: 1 to 18 months------Not pooled431 (4 trials)⊕⊕⊝⊝ **low**^1,2,6^\
due to indirectness and inconsistencyZinc supplements may have little or no effect on CD4 cell count**Change in viral load (log~10~copies/mL)**\
Follow‐up: 1 to 18 months------Not pooled400 (3 trials)⊕⊕⊝⊝ **low**^1,2,7^\
due to indirectness and imprecisionZinc supplements may have little or no effect on viral load**Change in blood zinc concentrations**\
Follow‐up: 1 to 18 months------Not pooled484\
(4 trials)⊕⊕⊕⊝ **moderate**^1,2,8^\
due to indirectnessZinc supplements probably increase blood zinc concentrations of persons with HIV with low baseline concentrations\*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; RR: risk ratio; OR: odds ratio; HR: hazard ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^5]

Summary of findings 5Selenium compared to placebo**Selenium compared to placebo for adults with HIV infectionParticipant or population:** adults with HIV infection **Settings:** all settings **Intervention:** selenium (daily dose) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboSeleniumMortality**---------(0 trials)------**Hospital admissions** Follow‐up: 12 months**309 per 1000124 per 1000** (65 to 232)**RR 0.4** (0.21 to 0.75)186 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^\
due to risk of bias, indirectness, and imprecisionWe don\'t know if selenium supplements reduce hospital admissions**Change in CD4 cell count (cells/mm**³**)**\
Follow‐up: 9 to 24 months------Not pooled1187 participants (4 trials)⊕⊕⊝⊝ **low**^4,5^\
due to risk of bias and imprecisionSelenium supplements may have little or no effect on CD4 cell count**Change in viral load (log~10~copies/mL)**\
Follow‐up: 24 months------Not estimable439 participants (1 trial)⊕⊕⊝⊝ **low**^6,7^Selenium supplements may have little or no effect on viral load**Change in selenium concentrations (µg/L)** Follow‐up: 6 to 12 months------Not pooled527 (3 trials)⊕⊕⊝⊝ **low**^4,8,9^Selenium supplements may increase blood selenium concentrations\*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** ART: antiretroviral therapy; CI: confidence interval; RR: risk ratio; HR: hazard ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^6]

Background {#CD003650-sec1-0002}
==========

Description of the condition {#CD003650-sec2-0001}
----------------------------

Despite a substantial decrease in the number of new HIV infections during the past decade, recent estimates from the United Nations Joint Programme on HIV/AIDS (UNAIDS) indicate that 35 million people were still living with HIV worldwide in 2013 ([@CD003650-bbs2-0120]). The HIV/AIDS pandemic has severely affected sub‐Saharan Africa, more than any other part of the world. With about a tenth of the world\'s population, the region is home to more than two‐thirds of all people living with HIV worldwide, an estimated 24.7 million adults and children ([@CD003650-bbs2-0120]). Globally, more than one‐third of HIV‐positive adults receive antiretroviral therapy (ART) ([@CD003650-bbs2-0120]). Earlier initiation of ART, in line with recent recommendations, is a challenge to implement in many countries, especially those in resource‐limited settings ([@CD003650-bbs2-0123]).

Adults living with HIV may also have micronutrient deficiencies, particularly those from communities at high risk of food insecurity since diets are frequently inadequate to meet the recommended daily requirements ([@CD003650-bbs2-0098]). A recent review reported that people living with HIV who experience food insecurity tended to have lower CD4 counts than their counterparts ([@CD003650-bbs2-0089]). Deficiencies of micronutrients are more pronounced in individuals with advanced disease, as a consequence of reduced nutrient intake due to AIDS and opportunistic infections, and excessive losses due to diarrhoea, malabsorption, and parasitic infections. Furthermore, in sub‐Saharan Africa, a region severely affected by the HIV/AIDS pandemic, protein energy malnutrition (PEM) is common. PEM refers to inadequate protein and energy intake and is usually associated with multiple micronutrient insufficiency ([@CD003650-bbs2-0103]).

Description of the intervention {#CD003650-sec2-0002}
-------------------------------

Micronutrient supplements are either single or multiple formulations of vitamins and trace elements.

How the intervention might work {#CD003650-sec2-0003}
-------------------------------

Micronutrients play a critical role in the maintenance of a functional immune system. The interactions between micronutrients and the components of the immune response are multifaceted and complex [@CD003650-bbs2-0094]; [@CD003650-bbs2-0110]). Several observational studies have suggested that micronutrient deficiencies may hasten clinical disease progression in HIV‐positive adults. Low blood levels of vitamin A, B12, zinc, and selenium have been related to increased HIV progression ([@CD003650-bbs2-0100]; [@CD003650-bbs2-0106]; [@CD003650-bbs2-0118]) or death in this population ([@CD003650-bbs2-0091]; [@CD003650-bbs2-0092]; [@CD003650-bbs2-0114]). Most participants in these earlier studies were not receiving ART at the time. More recently, vitamin D deficiency, which is assessed by low 25‐hydroxy vitamin D levels, has been associated with increased disease progression of untreated ([@CD003650-bbs2-0069]) or treated HIV disease ([@CD003650-bbs2-0117]; [@CD003650-bbs2-0121]), and impaired CD4 cell count recovery of HIV‐positive men and women on antiretroviral therapy (ART) ([@CD003650-bbs2-0090]; [@CD003650-bbs2-0112]).

Widespread micronutrient supplementation may lessen the effects of concurrent micronutrient deficiency and help to reduce the morbidity and mortality due to HIV ([@CD003650-bbs2-0115]). It has also been suggested that micronutrient supplementation may enhance the CD4 cell responses of individuals on ART who demonstrate adequate viral suppression ([@CD003650-bbs2-0119]).

Assessing the effectiveness of micronutrient supplementation in participants with inflammation requires special consideration. Acute inflammation results in the redistribution of micronutrients due to changes in plasma proteins and may therefore impact on the validity of nutrient biomarkers, such as serum micronutrient concentrations ([@CD003650-bbs2-0110]).

Why it is important to do this review {#CD003650-sec2-0004}
-------------------------------------

A previous version of this Cochrane review included 30 trials: 20 trials of single micronutrient supplements (vitamin A, vitamin D, zinc, and selenium) and 10 of multiple micronutrient supplements. Eight trials were undertaken in child populations and four trials were conducted among pregnant and lactating women ([@CD003650-bbs2-0126]). The review found no conclusive evidence that micronutrient supplementation effectively reduces or increases morbidity or mortality in HIV‐positive adults.

The HIV/AIDS pandemic has had a major impact on global health, nutrition, and overall socioeconomic development. An update of the review based on recent, valid research is therefore important. Micronutrient supplements have potential benefit for people living with HIV infection. However, in order to understand the magnitude of this benefit and how supplements should be positioned alongside the proven advantages of antiretroviral drugs, a robust evidence‐base to guide policy and practice is required.

At the request of the World Health Organization (WHO), two separate Cochrane Reviews on the role of micronutrient supplementation were published for HIV‐positive pregnant women ([@CD003650-bbs2-0116]) and children ([@CD003650-bbs2-0104]). The primary focus of this Cochrane review is therefore on the role of micronutrient supplementation in HIV‐positive non‐pregnant adults.

Objectives {#CD003650-sec1-0003}
==========

To assess whether micronutrient supplements are effective and safe in reducing mortality and HIV‐related morbidity in HIV‐positive adults (excluding pregnant women).

Methods {#CD003650-sec1-0004}
=======

Criteria for considering studies for this review {#CD003650-sec2-0005}
------------------------------------------------

### Types of studies {#CD003650-sec3-0001}

Randomized controlled trials (RCTs) of micronutrient supplements compared with placebo, no treatment, or other supplements (including variations in quantity or formulation).

### Types of participants {#CD003650-sec3-0002}

HIV‐positive adults, defined as people ≥ 15 years of age who were HIV‐positive ([@CD003650-bbs2-0122]). Two other Cochrane reviews have addressed micronutrient supplementation for HIV‐positive children and pregnant women ([@CD003650-bbs2-0104]; [@CD003650-bbs2-0116]). We included trials that recruited both HIV‐positive adults and children if 80% or more of the participants were HIV‐positive adults.

We included trials that recruited antiretroviral therapy (ART)‐naive participants, as well as those that recruited participants on ART. Since the objective of this Cochrane Review is on the adjunctive role of micronutrients on mortality and HIV‐related morbidity, we excluded studies that were primarily designed to investigate the role of micronutrients for the treatment of HIV‐positive participants with metabolic morbidity related to ART. A Cochrane review on treatment for dyslipidaemia in HIV infection is in progress ([@CD003650-bbs2-0107]).

We included trials conducted in populations with and without HIV infection if outcome data were available for HIV‐positive participants.

We included trials that involved participants with tuberculosis with and without HIV infection if outcome data were available for participants with HIV, regardless of whether the trial authors stratified the randomization of trial participants according to HIV infection status. We excluded studies that did not report outcome data for HIV‐positive participants.

### Types of interventions {#CD003650-sec3-0003}

We included trials of micronutrient supplementation that included vitamins (A, D, E, C, B1, B2, niacin, B6, B12, K, folate, beta‐carotene), trace elements (zinc, selenium, magnesium, iron, iodine, copper, manganese, chromium, cobalt, molybdenum), or combinations of the above only. We described a supplement as a standard dose supplement if the trial provided a single micronutrient, or a combination of micronutrients, at the level of the Recommended Daily Intake (RDA). We described any supplement containing a single micronutrient, or a combination of micronutrients in multiples of the RDA, as a high‐dose supplement. We excluded studies that assessed the effect of adding micronutrients to foods (food fortification).

### Types of outcome measures {#CD003650-sec3-0004}

#### Primary outcomes {#CD003650-sec4-0001}

All‐cause mortalityMorbidity (frequency, types, and duration of episodes of opportunistic infections; incidence of AIDS as defined by each trial; hospital admissions; and other types of illnesses related to HIV infection as reported in each study)Disease progression according to either the World Health Organization ([@CD003650-bbs2-0122]), or the Centers for Disease Control and Prevention (CDC) clinical staging system ([@CD003650-bbs2-0113]), as reported in each included trial

#### Secondary outcomes {#CD003650-sec4-0002}

Virological response: proportion of participants who maintained an undetectable viral load and change in HIV‐RNA levels (mean relative change (percent) or mean absolute change, compared with baseline, and standard deviation (SD))Virological failure: proportion of participants who discontinued or switched ART due to virological failure, as defined by each included trialMarkers of immune response, such as change in absolute CD4+ T lymphocyte count (mean relative change (percent) or mean absolute change, compared with baseline, and SD)Nutritional status, including measurements such as bodyweight, Body Mass Index (BMI), and body compositionBiochemical markers, such as serum micronutrient concentrations

We excluded studies that only reported data that related to biochemical markers from this review.

##### Adverse events {#CD003650-sec5-0001}

We extracted data on all adverse events that we judged to be associated with micronutrient supplementation, as reported by each included trial. If the trial authors had classified these events according to the Adverse Event Toxicity Scale, we extracted the data accordingly: grade 1 or 2 (mild to moderate symptoms), grade 3 (serious symptoms), or grade 4 symptoms (denotes life‐threatening events that require a significant clinical intervention) ([@CD003650-bbs2-0096]).

Search methods for identification of studies {#CD003650-sec2-0006}
--------------------------------------------

### Electronic searches {#CD003650-sec3-0005}

We searched the CENTRAL ([Appendix 1](#CD003650-sec2-0016){ref-type="app"}), PubMed ([Appendix 2](#CD003650-sec2-0017){ref-type="app"}), and Embase ([Appendix 3](#CD003650-sec2-0018){ref-type="app"}) databases from January 2010 up to 18 November 2016. We limited the search date from January 2010, since [@CD003650-bbs2-0126] included all trials identified from searches prior to and including January 2010. In addition we checked the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) ([Appendix 4](#CD003650-sec2-0019){ref-type="app"}) and the ClinicalTrials.gov trial register ([Appendix 5](#CD003650-sec2-0020){ref-type="app"}). We also searched the reference lists of the included trials.

### Searching other resources {#CD003650-sec3-0006}

For this update, we searched the reference lists of all the included trials. We also contacted investigators of ongoing studies that have been completed by email to enquire about any new or imminent publications.

Data collection and analysis {#CD003650-sec2-0007}
----------------------------

### Selection of studies {#CD003650-sec3-0007}

Two review authors (MV and SD) independently screened the titles and abstracts identified through the electronic searches for potentially eligible citations for full‐text screening. In the case of uncertainty regarding eligibility, we screened the full‐text article(s). Two review authors (MV and SD) screened full‐text articles using a standardized eligibility form based on the inclusion criteria of the review. In the case of disagreement or uncertainty, a third review author (NS) provided their opinion. We listed all studies that we excluded after full‐text assessment and their reasons for exclusion in a \'[Characteristics of excluded studies](#CD003650-sec2-0026){ref-type="sec"}\' table. We constructed a PRISMA diagram to illustrate the study selection process.

### Data extraction and management {#CD003650-sec3-0008}

Two review authors (MV and SD) independently extracted data from the included trials for the review update using an updated standardized electronic data extraction form. We extracted the following information from each trial.

Administrative details: trial identification number; author(s); published or unpublished; year of publicationDetails of the trial: country and location of trial, trial design, duration and completeness of follow‐up; informed consent and ethics approval, source of fundingDetails of participants: age, gender, disease progression according to clinical staging, relevant baseline characteristics including CD4 count and viral loadDetails of intervention and control group: type, dosage, and frequency of micronutrient(s); additional co‐interventions (such as ART, tuberculosis treatment, or other management of opportunistic infections)Details of outcomes: all prespecified outcomes and any additional outcomes reported in the study; adverse events and toxicityDetails of data analysis: numbers and reported statistics for each reported outcome. Where trial outcomes were reported in more than one reference, we used all the trial reports to extract data as comprehensively as possible

We entered data into the Review Manager 5 (RevMan 5) software ([@CD003650-bbs2-0111]). The trial ID for each included trial consisted of the name of the first trial author followed by the date of publication and the country code where the study was conducted (see [Appendix 6](#CD003650-sec2-0021){ref-type="app"}).

### Assessment of risk of bias in included studies {#CD003650-sec3-0009}

Two review authors (MV and SD) independently assessed the risk of bias of each new included trial using the Cochrane \'Risk of bias\' assessment tool ([@CD003650-bbs2-0102]). Please see [Appendix 7](#CD003650-sec2-0022){ref-type="app"} for the additional assessment of risk of bias in included cluster‐randomized trials.For each trial we assessed the following domains as either at high, low, or unclear risk of bias: sequence generation, allocation concealment, blinding (participants, personnel, and outcome assessor), incomplete outcome data, selective outcome reporting, and other sources of bias.

### Measures of treatment effect {#CD003650-sec3-0010}

For the measures of treatment effect, we used the risk ratio (RR) for dichotomous data, the weighted mean difference (WMD) for continuous data measured on the same scale, and the standardized mean difference (SMD) for continuous data measured on different scales, presented with 95% confidence intervals (CIs). For time‐to‐event data we extracted the hazard ratio (HR). We used RevMan 5 for data analysis ([@CD003650-bbs2-0111]).

### Unit of analysis issues {#CD003650-sec3-0011}

We included two trials with factorial designs ([@CD003650-bbs2-0006]; [@CD003650-bbs2-0026]). For [@CD003650-bbs2-0026], we halved the number of events and participants in the placebo group for dichotomous outcomes and the number of participants for continuous outcomes in our meta‐analysis in order to avoid double counting. Since [@CD003650-bbs2-0006] reported time‐to‐event data we were unable to incorporate the data into a meta‐analysis.

We described the outcome data narratively for the cross‐over trial by [@CD003650-bbs2-0009], since the study authors did not report outcome data before trial cross‐over. For [@CD003650-bbs2-0022] we did not include the data after trial cross‐over as the trial authors did not clearly describe the wash‐out period.

### Dealing with missing data {#CD003650-sec3-0012}

We contacted the authors of three published conference abstracts in order to obtain further information regarding the trial protocol and study outcomes ([@CD003650-bbs2-0005]; Sales 2010; [@CD003650-bbs2-0075]). We also contacted other trial authors in order to clarify data or statistical analysis where needed. Where possible, we conducted a complete‐case analysis. For trial outcomes where this was unclear, we used the number of participants randomized to each trial arm. We documented the attrition rate for each included trial in the \'Risk of bias\' table.

### Assessment of heterogeneity {#CD003650-sec3-0013}

First we assessed trials for clinical heterogeneity by examining variability in the participants, interventions, and outcomes. We assessed statistical heterogeneity visually and by means of the Chi² test for heterogeneity and the I² statistic. We classified heterogeneity according to the I² statistic values as follows ([@CD003650-bbs2-0101]).

0% to 40%: might not be important30% to 60%: may represent moderate heterogeneity50% to 90%: may represent substantial heterogeneity75% to 100%: considerable heterogeneity

### Assessment of reporting biases {#CD003650-sec3-0014}

To prevent reporting biases we searched multiple sources and searched for unpublished studies in trials registers. We did not examine funnel plots to assess the likelihood of publication bias as there were an insufficient number of trials per outcome.

### Data synthesis {#CD003650-sec3-0015}

In view of the anticipated heterogeneity between trial populations and interventions, we used a random‐effects model. When we were unable to pool data due to differences in the statistical methods and measures the study authors used, we presented the data in tables with a narrative summary.

### Subgroup analysis and investigation of heterogeneity {#CD003650-sec3-0016}

We conducted stratified analyses according to whether participants were taking ART or not, and whether they were on concurrent treatment for tuberculosis or not. We stratified outcome data, such as CD4+ cell count and viral load, by time points (baseline and at longest time follow‐up) in order to demonstrate changes over time.

#### Certainty of the evidence {#CD003650-sec4-0003}

Two review authors (MV and SD) independently assessed the certainty of the evidence for the outcomes under each comparison (type of micronutrient intervention) using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. According to this approach the certainty rating of evidence for each outcome is determined by an assessment of the available study data in terms of its risk of bias, inconsistency, indirectness, imprecision, and publication bias. We used GRADEpro Guideline Development Tool (GDT) software to create \'Summary of findings\' tables for each comparison ([@CD003650-bbs2-0099]).

### Sensitivity analysis {#CD003650-sec3-0017}

We could not perform a sensitivity analysis to assess the robustness of the results against the \'Risk of bias\' domains as there were too few studies for each comparison.

Results {#CD003650-sec1-0005}
=======

Description of studies {#CD003650-sec2-0008}
----------------------

### Results of the search {#CD003650-sec3-0018}

The previous version of this review, which included pregnant women and children, included 30 trials ([@CD003650-bbs2-0126]). Only 16 of these were eligible for inclusion in this Cochrane Review.

The PRISMA flow diagram summarizes the results of the searches for this update ([Figure 1](#CD003650-fig-0001){ref-type="fig"}). Electronic database searches identified 1835 records, of which there were 1572 records after we removed duplicates. After we screened these records by title/abstract, we identified 68 articles for full‐text assessment. Handsearching identified three new trials. Seventeen new trials met the inclusion criteria of this review, which gave a total of 33 included trials. Of the new included trials, four reported outcome data in two articles ([@CD003650-bbs2-0002]; [@CD003650-bbs2-0004]; [@CD003650-bbs2-0005]; [@CD003650-bbs2-0006]), and two letters of correspondence were related to one included trial ([@CD003650-bbs2-0018]). Two included trials published their trial protocols ([@CD003650-bbs2-0015]; [@CD003650-bbs2-0020]). We identified one additional trial from our most recent search (18 November 2016), which we included in the \'[Characteristics of studies awaiting classification](#CD003650-sec2-0027){ref-type="sec"}\' section. We identified six ongoing trials from searching trial registries.Figure 1Study flow diagram

### Included studies {#CD003650-sec3-0019}

#### Participants {#CD003650-sec4-0004}

Thirteen trials, which included 4493 participants, were conducted in antiretroviral therapy (ART)‐naive participants ([@CD003650-bbs2-0003]; [@CD003650-bbs2-0006]; [@CD003650-bbs2-0008]; [@CD003650-bbs2-0019]; [@CD003650-bbs2-0020]; [@CD003650-bbs2-0021]; [@CD003650-bbs2-0022]; [@CD003650-bbs2-0023]; [@CD003650-bbs2-0024]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]; [@CD003650-bbs2-0031]; [@CD003650-bbs2-0032]). One small trial did not state whether participants received ART or not ([@CD003650-bbs2-0033]).

The remaining 19 trials included 5730 participants, with most receiving either mono‐ or combination ART ([@CD003650-bbs2-0001]; [@CD003650-bbs2-0009]; [@CD003650-bbs2-0010]; [@CD003650-bbs2-0016]; [@CD003650-bbs2-0027]), or highly active antiretroviral therapy (HAART) ([@CD003650-bbs2-0002]; [@CD003650-bbs2-0004]; [@CD003650-bbs2-0005]; [@CD003650-bbs2-0007]; [@CD003650-bbs2-0011]; [@CD003650-bbs2-0012]; [@CD003650-bbs2-0015]; [@CD003650-bbs2-0013]; [@CD003650-bbs2-0014]; [@CD003650-bbs2-0017]; [@CD003650-bbs2-0018]; [@CD003650-bbs2-0025]; [@CD003650-bbs2-0029]; [@CD003650-bbs2-0030]). Many of these trials were small with fewer than 100 participants, with the exception of [@CD003650-bbs2-0018] which had more than 3000 participants.

In five trials participants were on concurrent treatment for active tuberculosis ([@CD003650-bbs2-0023]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]; [@CD003650-bbs2-0031]; [@CD003650-bbs2-0032]).

#### Trial site {#CD003650-sec4-0005}

Trials were undertaken in the following places.

Africa: Botswana ([@CD003650-bbs2-0006]), Kenya ([@CD003650-bbs2-0003]; [@CD003650-bbs2-0024]), Guinea‐Bissau ([@CD003650-bbs2-0032]), Malawi ([@CD003650-bbs2-0028]), Nigeria ([@CD003650-bbs2-0023]), Rwanda ([@CD003650-bbs2-0020]), Tanzania ([@CD003650-bbs2-0026]; [@CD003650-bbs2-0018]; [@CD003650-bbs2-0031]), Uganda ([@CD003650-bbs2-0015]), and Zambia ([@CD003650-bbs2-0021]; [@CD003650-bbs2-0022])Asia: China ([@CD003650-bbs2-0033]), Singapore ([@CD003650-bbs2-0013]), and Thailand ([@CD003650-bbs2-0002]; [@CD003650-bbs2-0019])North America: Canada ([@CD003650-bbs2-0001]) and USA ([@CD003650-bbs2-0005]; [@CD003650-bbs2-0007]; [@CD003650-bbs2-0009]; [@CD003650-bbs2-0010]; [@CD003650-bbs2-0011]; [@CD003650-bbs2-0016]; [@CD003650-bbs2-0017]; [@CD003650-bbs2-0025]; [@CD003650-bbs2-0027]; [@CD003650-bbs2-0029]; [@CD003650-bbs2-0030])South America: Brazil ([@CD003650-bbs2-0014]) and Peru ([@CD003650-bbs2-0008])Europe: Denmark ([@CD003650-bbs2-0004]) and Italy ([@CD003650-bbs2-0012])

#### Interventions {#CD003650-sec4-0006}

Twenty‐nine placebo‐controlled studies met the inclusion criteria. Of these, two had factorial designs ([@CD003650-bbs2-0006]; [@CD003650-bbs2-0026]). For both of these trials we extracted data for two treatment comparisons. Trials assessed the effectiveness of the supplementation of the following.

Multiple micronutrients (10 trials; 3533 participants: [@CD003650-bbs2-0006]; [@CD003650-bbs2-0015]; [@CD003650-bbs2-0019]; [@CD003650-bbs2-0021]; [@CD003650-bbs2-0022]; [@CD003650-bbs2-0024]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]; [@CD003650-bbs2-0031]; [@CD003650-bbs2-0033])Vitamin A (4 trials; 581 participants: [@CD003650-bbs2-0003]; [@CD003650-bbs2-0009]; [@CD003650-bbs2-0016]; [@CD003650-bbs2-0027])Vitamin D (5 trials; 447 participants: [@CD003650-bbs2-0004]; [@CD003650-bbs2-0012]; [@CD003650-bbs2-0025]; [@CD003650-bbs2-0030]; [@CD003650-bbs2-0032])Vitamin E combined with vitamin C (1 trial, 49 participants: [@CD003650-bbs2-0001])Folinic acid (1 trial, 30 participants: [@CD003650-bbs2-0014])Zinc (6 trials, 826 participants: [@CD003650-bbs2-0002]; [@CD003650-bbs2-0005]; [@CD003650-bbs2-0008]; [@CD003650-bbs2-0013]; [@CD003650-bbs2-0023], [@CD003650-bbs2-0026])Selenium (4 trials, 1308 participants: [@CD003650-bbs2-0006]; [@CD003650-bbs2-0007]; [@CD003650-bbs2-0017]; [@CD003650-bbs2-0020])

In addition, we identified four trials that assessed the effectiveness of the supplementation of the following.

High dose versus standard dose multiple micronutrients ([@CD003650-bbs2-0018])4000 IU vitamin D versus 7000 IU vitamin D ([@CD003650-bbs2-0011])Multiple micronutrients with iron versus multiple micronutrients ([@CD003650-bbs2-0029])β‐carotene with multivitamins versus multivitamins ([@CD003650-bbs2-0010])

The follow‐up periods of these trials ranged from two weeks to 24 months.

#### Sample size {#CD003650-sec4-0007}

Trials were generally underpowered to demonstrate effects on mortality. For example, to demonstrate a 25% reduction in deaths of HIV‐positive participants not on ART 2412 trial participants would be required, and to identify the same reduction for those on ART 7314 trial participants would be required ([Table 11](#CD003650-tbl-0011){ref-type="table"}). This far exceeds the number of participants in the three included trials that reported on this outcome ([@CD003650-bbs2-0018]; [@CD003650-bbs2-0019]; [@CD003650-bbs2-0031]). [@CD003650-bbs2-0018] based their sample calculation of 3000 participants on the basis of a 25% reduction in the composite outcome of death and disease progression (any new or recurrent AIDS‐defining illness). We have provided the optimal information sizes for nutritional outcomes in [Table 12](#CD003650-tbl-0012){ref-type="table"}.Table 1Optimal information size calculations (dichotomous outcomes)**OutcomePowerTwo‐sided significance levelRisk in control groupRelative risk reductionRisk in intervention groupSample size (total)**Death80%95%15.5%^1^25%11.6%2412Death80%95%8.3%^2^25%6.2%4782Death80%95%5.5%^3^25%4.1%7314CD4 cell count ≤ 350 cells/mm^3\ 4^80%95%10%60%55%2312CD4 cell count ≤ 350 cells/mm^3\ 4^80%95%25%60%44%314CD4 cell count ≤ 350 cells/mm^3\ 4^80%95%50%60%29%76[^7]Table 2Optimal information size calculations (continuous outcomes)**OutcomePowerTwo‐sided significance levelRatio of group 1: group 2Mean in control groupSDMean in supplement groupSDMean differenceSample size (total)**Mean blood 25(OH) vitamin D level at 12 months^1^80%95%117 ng/ml928 ng/ml911.522Mean blood 25(OH) vitamin D level at 12 months^1^80%95%117 ng/ml2028 ng/ml2011.5104Mean BMI at 24 months^3^80%95%121 kg/m^2^322 kg/m^2^31 kg/m^2^284Mean BMI at 24 months ^4^80%95%121 kg/m^2^323 kg/m^2^32 kg/m^2^72[^8]

For full details of the included studies refer to the \'[Characteristics of included studies](#CD003650-sec2-0025){ref-type="sec"}\' section.

### Excluded studies {#CD003650-sec3-0020}

We excluded 14 trials that were included in the previous version of this review, [@CD003650-bbs2-0126], from the current version. Eight trials were in HIV‐positive children; four trials were in HIV‐positive pregnant women; and in two trials the study participants received micronutrient supplements that did not contain micronutrients exclusively ([@CD003650-bbs2-0037]; [@CD003650-bbs2-0054]).

We excluded 46 records after full‐text assessment, 13 of which were not RCTs. We excluded the remaining studies because they addressed interventions that were not exclusively micronutrients (n = 10), had a co‐intervention (n = 4), involved trial participants aged less than 15 years (n = 4) or those with HAART co‐morbidity (n = 3), or reported study outcomes not relevant to this review (n = 12) ([Figure 1](#CD003650-fig-0001){ref-type="fig"}).

See the \'[Characteristics of excluded studies](#CD003650-sec2-0026){ref-type="sec"}\' table.

Risk of bias in included studies {#CD003650-sec2-0009}
--------------------------------

We evaluated the risk of bias of included studies for each of the six domains in the [Methods](#CD003650-sec1-0004){ref-type="sec"} section above (see the \'[Characteristics of included studies](#CD003650-sec2-0025){ref-type="sec"}\' table). [Figure 2](#CD003650-fig-0002){ref-type="fig"} and [Figure 3](#CD003650-fig-0003){ref-type="fig"} present a graphical summary of the \'Risk of bias\' assessments.Figure 2\'Risk of bias\' graph: review authors\' judgements about each \'Risk of bias\' item presented as percentages across all included studies.Figure 3\'Risk of bias\' summary: review authors\' judgements about each \'Risk of bias\' item for each included study.

### Allocation {#CD003650-sec3-0021}

Overall 20 trials adequately described a low risk method of random sequence generation. In 13 trials the methods were unclear. Fourteen trials adequately described a method of allocation concealment, and in 19 the methods were unclear.

### Blinding {#CD003650-sec3-0022}

Blinding of participants, treatment providers and outcome assessors was well described in 25 trials, which we judged to be at low risk of detection and performance bias. The remaining trials were at unclear risk except [@CD003650-bbs2-0021], which we considered to be high risk due to the use of a non‐identical placebo. The main reason for trials being at unclear risk was that no information was provided about the blinding of the investigators or outcome assessors.

### Incomplete outcome data {#CD003650-sec3-0023}

We judged 14 trials to be at high risk of attrition bias due to incomplete outcome data. In two trials this risk only applied to the measures of viral load which were only reported on a subset of trial participants ([@CD003650-bbs2-0018]; [@CD003650-bbs2-0019]). Eleven trials had high attrition overall or differential attrition, or both ([@CD003650-bbs2-0001]; [@CD003650-bbs2-0004]; [@CD003650-bbs2-0007]; [@CD003650-bbs2-0008]; [@CD003650-bbs2-0010]; [@CD003650-bbs2-0021]; [@CD003650-bbs2-0022]; [@CD003650-bbs2-0023]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]; [@CD003650-bbs2-0029]), and in [@CD003650-bbs2-0003] participants lost to follow‐up had more advanced HIV disease and vitamin A deficiency. Thus we considered these trials to be at high risk for attrition bias.

### Selective reporting {#CD003650-sec3-0024}

Insufficient information was available to permit judgment about the extent of bias due to selective outcome reporting in all but 11 included studies. We judged 10 of these as at low risk ([@CD003650-bbs2-0005]; [@CD003650-bbs2-0012]; [@CD003650-bbs2-0015]; [@CD003650-bbs2-0018]; [@CD003650-bbs2-0020]; [@CD003650-bbs2-0023]; [@CD003650-bbs2-0025]; [@CD003650-bbs2-0028]; [@CD003650-bbs2-0030]; [@CD003650-bbs2-0032]), and one as at high risk of reporting bias ([@CD003650-bbs2-0017]).

### Other potential sources of bias {#CD003650-sec3-0025}

One trial was stopped early due to evidence of increased alanine transaminase (ALT) levels with the intervention ([@CD003650-bbs2-0018]).

Fourteen trials did not declare potential conflicts of interest ([@CD003650-bbs2-0001]; [@CD003650-bbs2-0002]; [@CD003650-bbs2-0003]; [@CD003650-bbs2-0004]; [@CD003650-bbs2-0007]; [@CD003650-bbs2-0008]; [@CD003650-bbs2-0009]; [@CD003650-bbs2-0010]; [@CD003650-bbs2-0016]; [@CD003650-bbs2-0021]; [@CD003650-bbs2-0023]; [@CD003650-bbs2-0024]; [@CD003650-bbs2-0027]; [@CD003650-bbs2-0028]).

All but 19 trials were funded either fully or partly from government sources ([@CD003650-bbs2-0001]; [@CD003650-bbs2-0002]; [@CD003650-bbs2-0003]; [@CD003650-bbs2-0005]; [@CD003650-bbs2-0006]; [@CD003650-bbs2-0007]; [@CD003650-bbs2-0009]; [@CD003650-bbs2-0010]; [@CD003650-bbs2-0013]; [@CD003650-bbs2-0014]; [@CD003650-bbs2-0016]; [@CD003650-bbs2-0017]; [@CD003650-bbs2-0018]; [@CD003650-bbs2-0019]; [@CD003650-bbs2-0021]; [@CD003650-bbs2-0024]; [@CD003650-bbs2-0027]; [@CD003650-bbs2-0030]; [@CD003650-bbs2-0031]); five were fully or partly funded by pharmaceutical companies ([@CD003650-bbs2-0004]; [@CD003650-bbs2-0009]; [@CD003650-bbs2-0019]; [@CD003650-bbs2-0021]; [@CD003650-bbs2-0025]); and one trial did not provide the source of funding ([@CD003650-bbs2-0033]).

Effects of interventions {#CD003650-sec2-0010}
------------------------

See: [Table 1](#CD003650-tbl-0001){ref-type="table"}; [Table 2](#CD003650-tbl-0002){ref-type="table"}; [Table 3](#CD003650-tbl-0003){ref-type="table"}; [Table 4](#CD003650-tbl-0004){ref-type="table"}; [Table 5](#CD003650-tbl-0005){ref-type="table"}

### Comparison 1: Multiple micronutrients versus placebo {#CD003650-sec3-0026}

Ten trials compared a daily multiple micronutrient supplement to placebo, given for between two weeks and two years (see [Table 13](#CD003650-tbl-0013){ref-type="table"}). Most participants were ART‐naive HIV‐positive adults, and in three trials all participants were on treatment for active pulmonary tuberculosis. Only [@CD003650-bbs2-0015] recruited people already taking ART (49.8% of trial participants), and the remaining participants were commenced on ART at the start of this trial. Trials were conducted in Africa ([@CD003650-bbs2-0006]; [@CD003650-bbs2-0015]; [@CD003650-bbs2-0021]; [@CD003650-bbs2-0022]; [@CD003650-bbs2-0024]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]; [@CD003650-bbs2-0031]), Thailand ([@CD003650-bbs2-0019]), and China ([@CD003650-bbs2-0033]).Table 3Characteristics of trials evaluating multiple micronutrients versus placebo**Trial IDCountryParticipantsBaseline HAART use (%)Mean baseline CD4+ cell count (cells/mm^3^)Mean baseline viral load**\
**(copies/ml or log~10~ copies/mL)MMN dose^1^Duration of supplementation**[@CD003650-bbs2-0006]BotswanaHIV‐positive0423 (median)11,800 (median)High24 months[@CD003650-bbs2-0015]UgandaHIV‐positive49.8^2^145 (median)\
137 (median)N/AStandard18 months[@CD003650-bbs2-0019]ThailandHIV‐positive0244 (median)3.9 (1.0)High48 weeks[@CD003650-bbs2-0021]ZambiaHIV‐positive plus chronic diarrhoea0291 (median)N/AHigh2 weeks[@CD003650-bbs2-0022]ZambiaHIV‐positive0^3^N/AN/AStandard1.9 years^4^[@CD003650-bbs2-0024]KenyaHIV‐positive0294 (209)5.3 (0.9)High6 weeks[@CD003650-bbs2-0033]ChinaHIV‐positiveNot stated417 (69)Not statedStandard6 months[@CD003650-bbs2-0026]TanzaniaHIV‐positive plus active TB0363 (275)4.02 (0.98)High8 months[@CD003650-bbs2-0028]MalawiHIV‐positive plus active TB0Not stated5.4 (median)Standard24 months^5^[@CD003650-bbs2-0031]TanzaniaHIV‐positive plus active TB0305 (227)4.6 (1.0)High24 months[^9]

Four trials evaluated multiple micronutrient supplements in doses consistent with the Recommended Daily Intake (RDA) (standard dose supplements), and six trials used substantially higher doses (high dose supplements). In summary, high dose supplements included: vitamin A (2 to 3 x RDA), B vitamins (6 to 20 x RDA), vitamin C (3 to 5 times x RDA), vitamin D (1 x RDA), Vitamin E (2 to 20 x RDA), selenium (2 to 7 x RDA), and zinc (2 to 4 x RDA) (see [Table 14](#CD003650-tbl-0014){ref-type="table"}).Table 4Composition of multiple micronutrient supplements**MicronutrientRDA male aged 19 to 70 yearsStandard doses^1^High doses^2^Standard doseHigh dose**[@CD003650-bbs2-0022][@CD003650-bbs2-0033][@CD003650-bbs2-0028][@CD003650-bbs2-0015][@CD003650-bbs2-0006][@CD003650-bbs2-0021][@CD003650-bbs2-0019][@CD003650-bbs2-0024][@CD003650-bbs2-0026][@CD003650-bbs2-0031][@CD003650-bbs2-0018]Vitamin A900 µg (3000 IU)---200 µg (660 IU)2424µg (8000 IU)------3182 µg (10500 IU)3027 µg (9990 IU)---1500 µg (5000 IU)1515 µg (5000 IU)------B‐carotene---4.8 mg---------------6 mg---------------Vitamin B1 (Thiamine)1.2 mg1.4 mg1 mg1.5 mg1.4 mg20 mg---24 mg20 mg20 mg20 mg1.2 mg20 mgVitamin B2 (riboflavin)1.3 mg1.4 mg1 mg1.7 mg1.4 mg20mg---15 mg20 mg20 mg20 mg1.2 mg20 mgVitamin B3 (niacin)16 mg18 mg‐20 mg18 mg100 mg---54 mg100mg40 mg100 mg15 mg100 mgVitamin B6 (pyridoxine)1.3 to 1.7 mg1.9 mg1 mg2 mg1.9 mg25 mg---40mg25 mg25 mg25 mg1.3mg25 mgVitamin B9 (folinic acid)400 µg400 µg150 µg400 µg400 µg800 µg5000 µg100 µg800 µg800 µg800 µg400 µg800 µgVitamin B122.4 µg2.6 µg6 µg2.6 µg50 µg---30µg50 µg50 µg50 µg2.4 µg50 µgPanthothenic acid5 mg------------------40 mg---------------Vitamin E15 mg10 mg15 mg133 mg10 mg30 mg300 mg80 mg30 mg60 mg200 mg15 mg30 mgVitamin D5 to 15 µg (200 to 600 IU)5 µg (200 IU)5 µg (200 IU)10 µg (400 IU)---------20 µg (800 IU)---5 µg (200 IU)---------Vitamin K120 µg------------------180 µg---------------Vitamin C90 mg70 mg100 mg500 mg70 mg500 mg300 mg400 mg500 mg200 mg500 mg80 mg500 mgSelenium55 µg65 µg30 µg65 µg---200 µg150 µg400 µg200 µg200 µg100 µg------Iron8 mg6 mg------------10 mg---------------Zinc11 mg15 mg5 mg10 mg------200 mg30 mg---45 mg---------Copper0.9 mg------------------3 mg---5 mg---------Iodine150 µg------175 µg---------300 µg---------------Chromium35 µg------------------150 µg---------------Manganese2.3 mg------------------8 mg---------------Calcium1000 mg---400 mg------------------------------[^10]

Of the ten trials, we judged four to be at low risk of selection bias ([@CD003650-bbs2-0006]; [@CD003650-bbs2-0015], [@CD003650-bbs2-0018]; [@CD003650-bbs2-0019]), and we considered seven to be at low risk of performance and detection bias as they adequately described blinding ([@CD003650-bbs2-0006]; [@CD003650-bbs2-0015]; [@CD003650-bbs2-0019]; [@CD003650-bbs2-0022]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]; [@CD003650-bbs2-0031]).

#### Mortality {#CD003650-sec4-0008}

Overall, statistically significant differences on mortality were not demonstrated, but the trials were substantially underpowered to confidently detect or exclude small but clinically important effects (risk ratio (RR) 0.91, 95% confidence interval (CI) 0.72 to 1.15; 7 trials, 2897 participants, [Analysis 1.1](#CD003650-fig-00101){ref-type="fig"}).

In three trials in ART‐naive adults, although the proportion of deaths was lower with supplementation, the 95% confidence interval (CI) was wide and included the possibility of both clinically important effects and no effect (RR 0.60, 95% CI 0.31 to 1.15; 3 trials, 1068 participants; I² statistic = 0%). One additional small trial from Zambia, with only four weeks follow‐up, also reported no difference in mortality but did not present data that we could include in the meta‐analysis ([@CD003650-bbs2-0021]).In the only trial in adults on ART, [@CD003650-bbs2-0015], the proportion of deaths was similar in both treatment arms, and the 95% CI was very wide (RR 1.25, 95% CI 0.50 to 3.10; 1 trial, 400 participants).In three trials in adults on treatment for active tuberculosis (and also not on ART), although the CI was narrower, there was no effect of supplementation on mortality (RR 0.92, 95% CI 0.69 to 1.23; 3 trials, 1429 participants; I² statistic = 54%). One small factorial trial from Tanzania, [@CD003650-bbs2-0026], found a statistically significant effect in a subgroup of HIV‐positive participants who received multiple micronutrients plus zinc, but the CI was wide and the trial was underpowered (RR 0.29, 95% CI 0.09 to 0.87; 1 trial, 84 participants). A positive result in an underpowered study is not likely to reflect a true result (low positive predictive value (PPV)) and the magnitude of the effect estimate may also be exaggerated ([@CD003650-bbs2-0093]). Furthermore, the trial authors reported differential attrition between treatment groups.

#### Morbidity and clinical disease progression {#CD003650-sec4-0009}

Two trials reported the risk of hospital admission, and although this was lower with multiple micronutrient supplementation, the CIs were wide and included both clinically important benefits and harms (RR 0.86, 95% CI 0.61 to 1.22; 2 trials, 881 participants, [Analysis 1.2](#CD003650-fig-00102){ref-type="fig"}). In one trial, [@CD003650-bbs2-0015], participants commenced ART at the start of the trial and in the second trial, [@CD003650-bbs2-0019], participants were not on ART.

One additional trial in people on treatment for tuberculosis reported no difference in the risk of clinical disease progression (hazard ratio (HR) 1.08 95% CI 0.72 to 1.62; 1 trial, 313 participants, [Analysis 1.3](#CD003650-fig-00103){ref-type="fig"}).

#### Virological and immunological outcomes {#CD003650-sec4-0010}

Nine trials reported changes in CD4+ count over periods from four weeks to two years (see [Table 15](#CD003650-tbl-0015){ref-type="table"}). We could not incorporate one additional trial from Botswana that reported time‐to‐event analyses (time to reach CD4+ count \< 250 cells/mm³) into the meta‐analyses ([@CD003650-bbs2-0006]).Table 5Change in CD4 cell count (cells/mm^3^): multiple micronutrients versus placebo**Trial IDStatistical measureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0015]Median (IQR)145 (86 to 215)Not reported200137 (68 to 192)Not reported20018 monthsMD ‐ 6.17 (95% CI ‐29.3 to 16.9)^2^[@CD003650-bbs2-0019]Median (IQR)244 (52 to 544)200 (66 to 358)192261 (50 to 550)232 (73 to 377)18448 weeks\"Did not differ\"[@CD003650-bbs2-0021]Median (IQR)292Not reported66282Not reported694 weeks\"Not different\"^3^[@CD003650-bbs2-0022]Mean (SD)370 (190)415 (242)41365 (212)409 (192)431.9 years^3^P = 0.55[@CD003650-bbs2-0024]Mean (SD)294 (209)300 (205)179262 (202)265 (189)1786 weeksAdjusted regression co‐efficient 23 (95% CI 3 to 43); P = 0.03[@CD003650-bbs2-0033]Mean (SD)417 (69)589 (85)50466 (72)483 (59)496 monthsP \< 0.05[@CD003650-bbs2-0026]Mean (SD)460 (391)423 (373)48460 (385)403 (460)488 weeksP = 0.18[@CD003650-bbs2-0031]Mean (SD)305 (277)Not reported200339 (256)340 (240)2042 years^5^MD ‐5 (−37 to 26); P = 0.74[@CD003650-bbs2-0006]Median (IQR)428 (336 to 555)Not reported220411 (327 to 545)Not reported2172 yearsNot reported^7^[^11]

Six trials reported data as means with standard deviation (SD) and the pooled effect had a wide 95% CI including modest benefits and harms (mean difference (MD) 24.79, 95% CI −23.54 to 73.12; 6 trials, 1581 participants; [Analysis 1.4](#CD003650-fig-00104){ref-type="fig"}, [Analysis 1.5](#CD003650-fig-00105){ref-type="fig"}). Only one small trial from China administering multiple micronutrients at around the daily recommended intake, reported a statistically significant effect with supplementation after six months (1 trial, 99 participants, [@CD003650-bbs2-0033]). The other much larger trials that administered higher doses of multiple micronutrients found no suggestion of effects; including 808 participants with HIV alone, and 674 participants with HIV plus active tuberculosisThree trials reported data as medians and interquartile range (IQR), and neither found a statistically significant result (3 trials, 911 participants, data not pooled, [Table 15](#CD003650-tbl-0015){ref-type="table"})One additional trial from Botswana reported data as the HR of reaching a CD4+ count of less than 250 cells/mm³. The hazard was lower with high dose supplements of multivitamins plus selenium for two years (HR 0.48, 95% CI 0.26 to 0.88; 1 trial, 439 participants) and with multivitamins alone (HR 0.54; 95% CI 0.3 to 0.98; 1 trial, 436 participants) However, the trial authors reported that this effect was only apparent with supplementation of both multivitamins and selenium after adjustment for multiple confounders (HR 0.46, 95% CI 0.25 to 0.85; 1 trial, 439 participants) ([@CD003650-bbs2-0006])

Five trials of high dose multiple micronutrients reported changes in viral load at time points from six weeks to two years (see [Table 16](#CD003650-tbl-0016){ref-type="table"}).Table 6Change in viral load (log~10~ copies/mL): multiple micronutrients versus placebo**Trial IDStatistical measureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0006]Median (IQR)4.0 (3.3‐4.7)Not reported^2^2204.3 (3.6 to 4.8)Not reported^2^21724 monthsP = 0.4^3^[@CD003650-bbs2-0019]Mean (SD)3.94.4 (1.4)71^4^4.24.5 (1.54)6948 weeksP = 0.4[@CD003650-bbs2-0024]Mean (SD)5.3 (0.9)5.3 (0.9)1795.4 (0.9)5.4 (0.9)1786 weeksP = 0.4[@CD003650-bbs2-0026]Mean (SD)3.72 (1.18)3.85 (1.4)483.9 (1.33)4.1 (1.54)488 weeks\"Not significant\"^5^[@CD003650-bbs2-0031]Mean (SD)4.6 (1.0)Not reported714.6 (0.9)4.74 (1.54)692 years^6^MD −0.08 (−0.22 to 0.05); P = 0.23[^12]

Four trials reported data as means with SDs and the pooled estimate was close to no effect with a CI which included a modest benefit and no effect (MD −0.10, 95% CI −0.25 to 0.05; 4 trials, 1064 participants; [Analysis 1.6](#CD003650-fig-00106){ref-type="fig"},[Analysis 1.7](#CD003650-fig-00107){ref-type="fig"})The fifth trial reported no effect on viral load in a multivariable random‐effects regression model (1 trial, 437 participants, P = 0.4) ([@CD003650-bbs2-0006])

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0011}

Three trials reported changes in measures of body composition (BMI, weight, mid‐upper arm circumference (MUAC), fat mass or lean body mass) with no statistically significant differences between groups (see [Table 17](#CD003650-tbl-0017){ref-type="table"}).Table 7Change in nutritional status parameters: multiple micronutrients versus placebo**Trial IDNutritional parameterStatistical measureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0031]BMI (kg/m^2^)Mean (SD)19.3 (2.8)Not reported23319.6 (2.9)21.2\
(3.3)2382 years^2^MD ‐0.1\
(−0.4 to 0.2); P = 0.37[@CD003650-bbs2-0015]Weight (kg)\
Haemoglobin (g/dL)Not reported\
Median (IQR)Not reported\
12.2 (11.2 to 13.2)Not reported\
Not reported200\
200Not reported\
12.3 (11.3 to 13.5)Not reported\
Not reported200\
20018 months\
18 monthsMD 0.54 (−0.40 to 1.48); P = 0.691\
MD 0.16 (−0.21 to 0.16);\
P = 0.977[@CD003650-bbs2-0019]^12^Blood vitamin E (µmol/L)^3^Mean (SD)22 (9)Not reportedNot reported19 (7)Not reportedNot reported48 weeksMD 10.7 (7.0 to 14.3)^4^; P \< 0.001Blood selenium (µmol/L)^5^Mean (SD)1.6 (0.2)Not reportedNot reported1.6 (0.2)Not reportedNot reported48 weeksMD 0.16 (0.0 to 0.34)^6^; P = 0.04[@CD003650-bbs2-0021]^12^Blood vitamin A (µmol/L)^7,8^Mean0.63Not reported660.65Not reported694 weeksP = 0.21Blood vitamin E (µmol/L)^3,8^Mean11.4Not reported6611.7Not reported694 weeks\"No difference\"[@CD003650-bbs2-0022]BMI (kg/m^2^)\
MUAC (cm)\
Fat mass (kg)\
Lean body mass (kg)\
Grip strength (kg)Not reportedNot reportedNot reportedNot reportedNot reportedNot reportedNot reported1.9 years ^9^\"No significant differences at any time point\"[@CD003650-bbs2-0028]^12^Blood vitamin A (µmol/L)^7,11^Geometric mean0.59Reported in a graph3830.59Reported in a graph3978 months\"Significantly higher\"Blood selenium (µmol/L)^10,11^Geometric mean0.66Reported in a graph3920.64Reported in graph4058 months[^13]

Three trials reported changes in blood concentrations of vitamin A, vitamin E, or selenium (see [Table 17](#CD003650-tbl-0017){ref-type="table"}), with statistically significant increases after 48 weeks supplementation in Thailand ([@CD003650-bbs2-0019]), and eight months supplementation in Malawi ([@CD003650-bbs2-0028]). The third small trial from Zambia reported no change in serum vitamin A or vitamin E concentrations after four weeks supplementation, despite many being deficient in one or both at baseline (1 trial, 135 participants, [@CD003650-bbs2-0021]).

#### Adverse events associated with supplementation {#CD003650-sec4-0012}

One trial with high dose micronutrient supplements reported no differences in serious adverse events such as acute diarrhoea, vomiting, or severely elevated ALT levels ([@CD003650-bbs2-0006]). Genital HIV‐shedding was increased after six weeks, following high dose supplements in another trial ([@CD003650-bbs2-0024]). A third trial of high dose supplementation reported discolouration of urine more frequently in the intervention group, but no differences for other minor adverse events such as nausea, headache, dizziness, drowsiness, or rash ([@CD003650-bbs2-0019]). Three trials that involved high dose supplementation did not report any adverse events ([@CD003650-bbs2-0021]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0031]).

High dose supplements was associated with a decrease in peripheral neuropathy in one trial, although this was not reported for just the subgroup with HIV (RR 57%, 95% CI 41% to 69%; 1 trial, 887 participants) ([@CD003650-bbs2-0031]). Participants in this trial were taking isoniazid for active tuberculosis which is a known vitamin B6 antagonist and may cause neuropathy without supplementation.

One trial with standard dose supplements reported no differences in adverse events such as nausea and vomiting ([@CD003650-bbs2-0015]). A cluster‐randomized trial with standard dose supplements reported four cases of pellagra in the placebo group (three were associated with high ethanol intakes) ([@CD003650-bbs2-0022]). Two trials that involved standard dose supplementation did not report any adverse events ([@CD003650-bbs2-0028]; [@CD003650-bbs2-0033]).

#### Certainty of the evidence {#CD003650-sec4-0013}

For a critical appraisal of the summary of evidence, see the \'Summary of findings for the main comparison\' table ([Table 1](#CD003650-tbl-0001){ref-type="table"}) and Additional tables 8, 9, and 10 for the stratified analyses (participants taking ART or not, and whether they were on concurrent treatment for tuberculosis or not) ([Table 18](#CD003650-tbl-0018){ref-type="table"}; [Table 19](#CD003650-tbl-0019){ref-type="table"}; [Table 20](#CD003650-tbl-0020){ref-type="table"}).Table 8Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ART**Multiple micronutrients compared to placebo for adults with HIV infection not currently taking ARTParticipant or population:** adults with HIV infection not currently taking ART **Settings:** all settings **Intervention:** multiple micronutrient supplementation (standard or high dose daily) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboMicronutrientsMortality**\
Follow‐up: 12 to 24 months**45 per 100026 per 1000** (14 to 52)**RR 0.60**\
(0.31 to 1.15)1068 (3 trials)⊕⊕⊝⊝ **low**^1,2,3,4^\
due to indirectness and imprecisionMultiple micronutrients may reduce mortality**Hospital admissions**\
Follow‐up: 48 weeks**84 per 100066 per 1000**\
(35 to 125)**RR 0.79**\
(0.42 to 1.49)481\
(1 trial)⊕⊝⊝⊝ **very low**^1,4,5^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on hospital admissions**CD4 cell count**\
Follow‐up: 6 weeks to 2 yearsThe mean in the placebo groups ranged from\
**265 to 409 cells/mm**³The mean in the multiple micronutrient group was\
**30.36 cells/mm**³ **higher**\
(7.13 lower to 67.84 higher)---441 (2 trials)⊕⊕⊝⊝\
**low**^1,6,7^\
due to indirectness and inconsistencyMultiple micronutrients may have little or no effect on CD4+ cell count**Viral load**\
Follow‐up: 6 to 48 weeksThe mean in the placebo groups ranged from\
**4.4 to 5.3 log~10~copies/mL**The mean in the multiple micronutrient groups was\
**0.10 log~10~copies/mL lower**\
(0.27 lower to 0.07 higher)---497\
(2 trials)⊕⊕⊕⊝ **moderate**^1,8^\
due to indirectnessMultiple micronutrients probably have little or no effect on viral load**BMI** (kg/m²)\
Follow‐up: 1.9 years---------84 (1 trial)⊕⊝⊝⊝ **very low**^1,9,10^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on BMIThe basis for the assumed risk is the median control group risk across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** ART: antiretroviral therapy; BMI: body mass index; CI: confidence interval; MUAC: mid‐upper arm circumference; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^14]Table 9Multiple micronutrients compared to placebo for adults with HIV infection currently taking ART**Multiple micronutrients compared to placebo for adults with HIV infection currently taking ARTParticipant or population:** adults with HIV infection currently taking ART **Settings:** any setting **Intervention:** multiple micronutrient supplementation (standard dose daily) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboMicronutrientsMortality**\
Follow‐up: 12 to 24 months**40 per 100050 per 1000** (20 to 124)**RR 1,25**\
(0.50 to 3.10)400 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on mortality**Hospital admissions**\
Follow‐up: 48 weeks**195 per 1000176 per 1000** (115 to 265)**RR 0.90**\
(0.59 to 1.36)400 (1 trial)⊕⊝⊝⊝ **very low**^1,2,3^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on mortality**CD4 cell count**\
Follow‐up: 18 monthsThe mean change in the placebo group was **147 cells/mm**³The mean change in the multiple micronutrient group was **6.17 cells/mm**³**lower**\
(29.3 lower to 16.9 higher)\_367 (1 trial)⊕⊝⊝⊝ **very low**^1,2,4^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on CD4 cell count**Viral load**------------------**Weight** (kg)\
Follow‐up: 18 monthsThe mean change in the placebo group was **3.3 kg**The mean change in the multiple micronutrient group was **0.54 kg higher**\
(0.40 lower to 1.48 higher)400 (1 trial)⊕⊝⊝⊝ **very low**^1,2,4^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on weight\*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** CI: confidence interval; HR: hazard ratio; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^15]Table 10Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis**Multiple micronutrients compared to placebo for adults with HIV infection and concurrent active tuberculosis not currently taking ARTParticipant or population:** adults with HIV infection and concurrent active tuberculosis not currently taking ART **Settings:** any setting **Intervention:** multiple micronutrient supplementation (standard or high dose daily) **Comparison:** placebo**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)Number of participants (trials)Certainty of the evidence (GRADE)CommentsAssumed riskCorresponding riskPlaceboMicronutrientsMortality**\
Follow‐up: 8 to 24 months**357 per 1000328 per 1000** (246 to 439)**RR 0.92**\
(0.69 to 1.23)1429 (3 trials)⊕⊕⊝⊝ **low**^1,2.3,4^\
due to indirectness and imprecisionMultiple micronutrients may have little or no effect on mortality**Clinical disease progression from stage 3 to stage 4**\
Follow‐up: 24 months------**HR 1.08** (0.72 to 1.62313\
(1 trial)⊕⊝⊝⊝\
**very low**^1,4,5^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on clinical disease progression**CD4 cell count**\
Follow‐up: 2 to 24 monthsThe mean in the placebo groups ranged from\
**340 to 403 cells/mm**³The mean in the multiple micronutrient group was\
**5.77 cells/mm**³ **lower**\
(55.8 lower to 44.25 higher)---674 (2 trials)⊕⊕⊝⊝\
**low**^1,3,4^\
due to indirectness and imprecisionMultiple micronutrients may have no effect on CD4 cell count**Viral load**\
Follow‐up: 2 to 24 monthsThe mean in the placebo groups ranged from\
**4.1 to 4.7 log~10~copies/mL**The mean in the multiple micronutrient groups was\
**0.09 log~10~copies/mL lower**\
(0.45 lower to 0.26 higher)---343\
(2 trials)⊕⊕⊝⊝\
**low**^1,3,4^\
due to indirectness and imprecisionMultiple micronutrients may have no effect on viral load**BMI**\
Follow‐up: 24 monthsThe mean BMI in the placebo group was **21.2 kg/m^2^**The mean BMI in the micronutrient group was\
**0.1 lower**\
(0.4 lower to 0.2 higher)---471 (1 trial)⊕⊝⊝⊝\
**very low**^1,4,5^\
due to indirectness and imprecisionWe don\'t know if multiple micronutrients have any effect on BMI\*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). **Abbreviations:** ART: antiretroviral therapy; CI: confidence interval; HR: hazard ratio; RR: risk ratio.**GRADE Working Group grades of evidence** **High certainty:** further research is very unlikely to change our confidence in the estimate of effect. **Moderate certainty:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low certainty:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low certainty:** we are very uncertain about the estimate.[^16]

### Comparison 2: High‐dose versus standard dose multivitamins {#CD003650-sec3-0027}

One large Tanzanian trial, [@CD003650-bbs2-0018], investigated the effects of a standard versus a high‐dose daily multivitamin supplement for 24 months among participants starting HAART (see [Table 14](#CD003650-tbl-0014){ref-type="table"}).

#### Mortality {#CD003650-sec4-0014}

There were no statistically significant differences in all‐cause mortality (RR 1.06, 95% CI 0.89 to 1.26; 1 trial, 3418 participants; [Analysis 2.1](#CD003650-fig-00201){ref-type="fig"}), or AIDS‐related mortality (RR 1.14, 95% CI 0.82 to 1.58; 1 trial, 3418 participants; [@CD003650-bbs2-0018]).

#### Morbidity and clinical disease progression {#CD003650-sec4-0015}

There was no difference in clinical disease progression events combined with death from any cause (RR 1.00, 95% CI 0.96 to 1.04; 1 trial, 3418 participants).

#### Immunological and virological outcomes {#CD003650-sec4-0016}

There was a small difference between groups in mean CD4+ cell count at baseline (MD −7.00 cells/mm³, 95% CI −13.74 to −0.26), and a similar difference at 15 months (MD −12.00 cells/mm³, 95% CI −24.00 to −0.00; 1 trial, 3418 participants, [Analysis 2.2](#CD003650-fig-00202){ref-type="fig"}). No differences were demonstrated in mean viral load at baseline or end of follow‐up (MD −0.20 log~10~copies/mL, 95% CI −0.51 to 0.11; 1 trial, 236 participants, [Analysis 2.3](#CD003650-fig-00203){ref-type="fig"}; [@CD003650-bbs2-0018]).

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0017}

There was no difference in BMI between the two groups (MD 0 kg/m^2^; 95% CI −0.2 to 0.2; 1 trial, 3418 participants). Blood concentrations of micronutrients were not reported.

#### Adverse events associated with supplementation {#CD003650-sec4-0018}

This trial was stopped early with a median length of follow‐up of 15 months due to an increased risk of elevated ALT levels (greater than 40 IU/L) among trial participants who received high dose multivitamin supplements (incidence rate ratio (IRR) 1.44, 95% CI 1.11 to 1.87; one trial, 2921 participants). No differences were observed for other adverse events such as fatigue, nausea or vomiting, diarrhoea, severe anaemia, and rashes or lesions. The incidence of peripheral neuropathy was lower with high dose supplements (IRR 0.81, 95% CI 0.7 to 0.94; 1 trial, 3418 participants).

### Comparison 3: Vitamin A versus placebo {#CD003650-sec3-0028}

Four trials compared a vitamin A supplement to placebo (see [Table 21](#CD003650-tbl-0021){ref-type="table"}). Participants from two trials in the USA received a single high dose of vitamin A (200,000 IU to 300,000 IU) and were followed up for four to eight weeks ([@CD003650-bbs2-0016]; [@CD003650-bbs2-0027]). ART‐naive women in one trial from Kenya received a daily dose of vitamin A (10,000 IU) for six weeks ([@CD003650-bbs2-0003]). The trial authors of a small cross‐over trial of daily supplements containing a vitamin A precursor (β‐carotene) did not report data before cross‐over ([@CD003650-bbs2-0009]).Table 11Characteristics of trials evaluating vitamin A supplements versus placebo**Trial IDCountryParticipantsBaseline ART useMean baseline blood vitamin A concentration (µmol/L)^1^Mean baseline CD4+ cell count (cells/mm^3^)Mean baseline viral load (log~10~ copies/mL)Dose^2^Duration of supplementation**[@CD003650-bbs2-0003]KeniaHIV‐positive women0%0.097 (median)\
0.095 (median)240 (median)\
203 (median)5.34 (median)\
5.54 (median)10,000 IU retinol daily6 weeks[@CD003650-bbs2-0016]USAHIV‐positive women49%1.52 (0.42)\
1.41 (0.31)Not reportedNot reported300,000 IU retinolSingle dose[@CD003650-bbs2-0029]USAHIV‐positive IDUs46%1.61\
1.37296 (median)\
259 (median)9.49 (median)\
9.67 (median)200,000 IU retinolSingle dose[@CD003650-bbs2-0009]^3^USAHIV‐positive94%---------180 mg β‐carotene4 weeks[^17]

Of the four trials, we judged one to be at low risk of selection bias ([@CD003650-bbs2-0027]), and all four that adequately described blinding and were at low risk of performance and detection bias.

#### Mortality, morbidity, and clinical disease progression {#CD003650-sec4-0019}

The trials did not report these outcomes.

#### Immunological and virological outcomes {#CD003650-sec4-0020}

Two trials reported changes in CD4+ count at four and six weeks follow‐up, and neither reported statistically significant changes (2 trials, 464 participants, data not pooled, see [Table 22](#CD003650-tbl-0022){ref-type="table"}). One trial did report that mean CD4+ count was higher in the supplemented group after six weeks (P = 0.04), but the difference was no longer statistically significant after multivariate linear regression analysis ([@CD003650-bbs2-0003]).Table 12Change in CD4 cell count (cells/mm^3^): vitamin A versus placebo**Trial IDStatistical measureInterventionControlTiming of end‐pointDifference between groups at end‐point (as reported by trial authors)BaselineEnd‐pointN^1^BaselineEnd‐pointN^1^**[@CD003650-bbs2-0027]Median296Reported in a graphNot reported^2^259Reported in a graphNot reported^2^4 weeksP = 0.17[@CD003650-bbs2-0003]Median2402721762032251786 weeksP = 0.04\
Adjusted regression coefficient 0.34 −0.22 to 0.90); P = 0.90[^18]

Three trials reported changes in viral load, with no statistically significant differences at four to eight weeks (3 trials, 495 participants, data not pooled, see [Table 23](#CD003650-tbl-0023){ref-type="table"}).Table 13Change in viral load (log~10~ copies/mL) : Vitamin A versus placebo**Trial IDStatistical measureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0027]Median9.49Reported in a graphNot reported^2^9.67Not reportedNot reported^2^4 weeksP = 0.17[@CD003650-bbs2-0016]Geometric meanReported in a graphReported in a graph19Reported in a graphReported in a graph128 weeksP = 0.56[@CD003650-bbs2-0003]Median5.345.341765.545.491786 weeksP = 0.1[^19]

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0021}

Three trials reported changes in blood retinol concentrations (data not pooled, see [Table 24](#CD003650-tbl-0024){ref-type="table"}). In the only trial with a significant proportion of participants with vitamin A deficiency at baseline (59% \< 1.05 µmol/L), median serum concentrations were higher after six weeks of supplementation compared to placebo (P = 0.03) ([@CD003650-bbs2-0003]). In the other two trials, in which most participants were not deficient, average blood retinol concentrations remained unchanged after follow‐up periods of four and eight weeks, respectively ([@CD003650-bbs2-0016]; [@CD003650-bbs2-0027]).Table 14Change in nutritional status parameters: vitamin A versus placebo**Trial IDNutritional parameterStatistical MeasureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0003]^3^Vitamin A (µmol/L)^2^Median0.971.03Not reported0.950.94Not reported6 weeksP = 0.03. \"No effect\" reported for those who were severely deficient at baseline[@CD003650-bbs2-0027]^3^Vitamin A (µmol/L)^3^Median1.61Presented in a graphNot reported1.37Presented in a graphNot reported4 weeks\"Not different\"[@CD003650-bbs2-0016]^3^Vitamin A (µmol/L)^3^Median1.561.54201.371.30154 weeks\"No change\"[^20]

Note: one further trial from the USA evaluated supplementation with a vitamin A precursor, β‐carotene (60 mg) three times daily ([@CD003650-bbs2-0010]). This trial reported an increase in blood concentrations of β‐carotene at three months but no statistically significant effects on CD4+ cell count.

#### Adverse events associated with supplementation {#CD003650-sec4-0022}

Signs or symptoms of toxicity (headache, nausea, vomiting, diarrhoea, fever) were similar in the intervention and control groups at 24 hours and one week after administration in one trial ([@CD003650-bbs2-0016]). No adverse events were reported in the other two trials of vitamin A supplementation ([@CD003650-bbs2-0003]; [@CD003650-bbs2-0029]). Slight skin discolouration was reported by the participants in the intervention group of a one small trial of β‐carotene supplementation ([@CD003650-bbs2-0009]).

#### Certainty of the evidence {#CD003650-sec4-0023}

For a critical appraisal of the summary of evidence, see \'Summary of findings\' table 2 ([Table 2](#CD003650-tbl-0002){ref-type="table"}).

### Comparison 4: Vitamin D versus placebo {#CD003650-sec3-0029}

Five trials compared a vitamin D supplement, with or without a calcium supplement, to placebo (see [Table 25](#CD003650-tbl-0025){ref-type="table"}). Participants in two trials received a total of three or four doses of vitamin D (100,000 IU), given every three to five months ([@CD003650-bbs2-0012]; [@CD003650-bbs2-0032]). Two trials from the USA used a daily supplement containing 7000 IU vitamin D or 4000 IU vitamin D plus calcium (1000 mg), respectively, for 12 months ([@CD003650-bbs2-0025]; [@CD003650-bbs2-0030]). A fifth trial from Denmark combined a single dose of vitamin D (100,000 IU) at study entry with a daily vitamin D supplement (1200 IU) plus calcium (1200 mg) for 16 weeks ([@CD003650-bbs2-0004]).Table 15Characteristics of trials evaluating Vitamin D supplements versus placebo**Trial IDCountryParticipantsBaseline ART useMean baseline blood 25(OH)~2~ vitamin D concentration (ng/mL)^1^Mean baseline CD4+ cell count (cells/mm^3^)Mean baseline viral load (log~10~ copies/mL)Dose^2^Duration of supplementation**[@CD003650-bbs2-0004]DenmarkHIV‐positive men100%27.2 (11.5)\
29.2 (12.4)507 (268)\
463 (197)Not reported100,000 IU then 1200 IUSingle dose at baseline then daily for 16 weeks (plus 1200 mg calcium daily)[@CD003650-bbs2-0012]ItalyHIV‐positive; ≤ 30 years86%15 (median)^3^663 (median)\
673 (median)Not reported100,000 IUSingle dose at baseline and at 3, 6, and 9 months[@CD003650-bbs2-0025]USAHIV‐positive men and women0%^4^26.7 (median)\
25.1 (median)346 (median)\
337 (median)4.54000 IUDaily for 48 weeks (plus 100 mg calcium)[@CD003650-bbs2-0030]USAHIV‐positive; ≤ 25 years76%18.2 (8.4)\
17.7 (9)Not reported^5^3.17 (0.96)^6^7000 IUDaily for 12 months[@CD003650-bbs2-0032]Guinea‐BissauHIV‐positive plus active TB0%Not reported for HIV‐positive participantsNot reported for HIV‐positive participantsNot reported100,000 IUSingle dose at baseline, 5, 8 months[^21]

In one trial from Guinnea‐Bissau participants did not receive ART and were on treatment for active pulmonary tuberculosis ([@CD003650-bbs2-0032]). In the other trials most participants were on ART (see [Table 25](#CD003650-tbl-0025){ref-type="table"}).

We considered only one of the five trials to be at low risk of selection bias ([@CD003650-bbs2-0032]), but three trials adequately described blinding and we considered them to be at low risk of detection and performance bias ([@CD003650-bbs2-0004]; [@CD003650-bbs2-0012]; [@CD003650-bbs2-0032]).

#### Mortality, morbidity, and clinical disease progression {#CD003650-sec4-0024}

Only a single trial reported mortality in people with active tuberculosis, which was significantly underpowered to evaluate mortality (RR 1.15, 95% CI 0.65 to 2.02; 1 trial, 131 participants, [Analysis 3.1](#CD003650-fig-00301){ref-type="fig"}). The effect estimate has wide CIs which include both important effects and no effect.

#### Immunological and virological outcomes {#CD003650-sec4-0025}

Four trials reported changes in the mean or median CD4+ cell counts, over periods from four to 12 months and found no statistically significant effects (4 trials, 288 participants, data not pooled; see [Table 26](#CD003650-tbl-0026){ref-type="table"}).Table 16Change in CD4 cell count (cells/mm^3^): vitamin D versus placebo**Trial IDStatistical measureBaselineEndpointTiming of endpointDifference between groups at endpoint (as reported by trial authors)InterventionControlN^1^InterventionControlN^1^**[@CD003650-bbs2-0004]Mean (SD)507 (268)463 (197)17Not reportedNot reported1516 weeks\"No changes\" in naïve or activated CD4+ cell counts[@CD003650-bbs2-0012]Median151525Not reportedNot reported2512 monthsMD 58.1 (−114.5 to 230.7)^2^[@CD003650-bbs2-0025]Median34634279551^3^526^3^8648 weeksP = 0.90[@CD003650-bbs2-0032]MeanNot reportedNot reportedNot reportedNot reportedNot reportedNot reported8 monthsMD −22 (P = 0.17)^4^[^22]

One very small study from the USA reported a reduction in viral load over time in those participants with a detectable viral load, using a multi‐level regression model (1 trial, 28 participants, P \< 0.05) ([@CD003650-bbs2-0030]).

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0026}

Four trials reported changes in serum concentrations of 25‐hydroxy vitamin D for periods that ranged from four to 12 months. Both single dose supplements and daily supplements resulted in a significant increase in mean or median blood concentrations (ng/mL) (4 trials, 305 participants, data not pooled; see [Table 27](#CD003650-tbl-0027){ref-type="table"}).Table 17Change in nutritional status parameters: vitamin D versus placebo**Trial IDNutritional parameterStatistical MeasureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0004]^2^25(OH) vitamin D (ng/mL)^2^Mean (SD)27.2 (11.5)31.6 (9.9)1729.2 (12.4)19.2 (13.9)1516 weeksP \< 0.001[@CD003650-bbs2-0012]^2^25(OH) vitamin D (ng/mL)^2^Median15Not reported2515Not reported2512 monthsMD 12.5 (5.9 to 19) P \< 0.001[@CD003650-bbs2-0025]^2^25(OH) vitamin D (ng/mL)^2^Median26.756.47925.126.28648 weeksP \< 0.001[@CD003650-bbs2-0030]^2^25(OH) vitamin D (ng/mL)^2^Mean (SD)10.3 (6.4)17 (13.1)3011.3 (7.6)10.5 (6.2)2812 monthsP \< 0.001[^23]

Note: one further trial from the USA compared supplementation with 4000 IU vitamin D to 7000 IU vitamin D daily in participants on ART ([@CD003650-bbs2-0011]). This trial reported an increase in blood concentrations of 25‐hydroxy vitamin D with both doses at three months, but no statistically significant effects on viral load.

#### Adverse events associated with supplementation {#CD003650-sec4-0027}

One trial reported one case of hypercalcaemia in a trial participant who received a single high dose of vitamin D, followed by daily administration ([@CD003650-bbs2-0004]). The other four trials of vitamin D supplementation did not report any cases of hypercalcaemia ([@CD003650-bbs2-0012]; [@CD003650-bbs2-0025]; [@CD003650-bbs2-0030]; [@CD003650-bbs2-0032]).

#### Certainty of the evidence {#CD003650-sec4-0028}

For a critical appraisal of the summary of evidence, see \'Summary of findings\' table 3 ([Table 3](#CD003650-tbl-0003){ref-type="table"}).

### Comparison 5: Zinc versus placebo {#CD003650-sec3-0030}

Six trials compared a zinc supplement to placebo, given for between two weeks and 18 months (see [Table 28](#CD003650-tbl-0028){ref-type="table"}). Two trials provided daily supplements at the level of the RDA ([@CD003650-bbs2-0002]; [@CD003650-bbs2-0005]), with one being a small trial from Thailand in participants with immunological discordance on ART ([@CD003650-bbs2-0002]).Table 18Characteristics of trials evaluating zinc supplements versus placebo**Trial IDCountryParticipantsBaseline ART useMean baseline blood zinc concentration (µg/L)^1^Mean baseline CD4+ cell count (cells/mm^3^)Mean baseline viral load (copies/mL or log~10~ copies/mL)Dose^2^Duration of supplementation**[@CD003650-bbs2-0002]^3^ThailandHIV‐positive100% with immunological discordance80 (median)\
76 (median)183 (median)\
162 (median)Not reported15 mg daily6 months[@CD003650-bbs2-0005]USAHIV‐positive62%^4^60 (10)^5^373 (280)4.0 (1.0)12 mg (women)\
15 mg (men)18 months[@CD003650-bbs2-0008]PeruHIV‐positive plus persistent diarrhoea0%66 (median)\
65 (median)65 (median)\
55 (median)Not reported50 mg twice daily14 days[@CD003650-bbs2-0013]SingaporeHIV‐positive95%86.9 (15.0)\
92.2 (18.3)112 (62)\
131 (65)26 338 (38 335)\
28 093 (41 05650 mg daily28 days[@CD003650-bbs2-0023]NigeriaHIV‐positive plus active TB0%Not reportedNot reportedNot reported90 mg weekly^6^6 months[@CD003650-bbs2-0026]TanzaniaHIV‐positive plus active TB0%Not reported406 (median)\
460 (median)3.83 (median)\
3.90 (median)45 mg daily8 months[^24]

Higher doses of zinc (50 mg to 100 mg) were given to ARV‐naive participants with persistent diarrhoea for 14 days in one trial in Peru ([@CD003650-bbs2-0008]) and to participants on ART from Singapore for four weeks ([@CD003650-bbs2-0013]). In another two trials, participants were on treatment for active pulmonary tuberculosis, and received either a high daily dose of zinc (45 mg) or a weekly dose (90 mg) for six to eight months ([@CD003650-bbs2-0023]; [@CD003650-bbs2-0026]).

We considered only one of the six trials to be at low risk of selection bias ([@CD003650-bbs2-0008]), but five trials adequately described blinding and we judged them to be at low risk of performance or detection bias.

#### Mortality {#CD003650-sec4-0029}

All three trials that reported deaths were substantially underpowered to confidently detect or exclude effects. None of the trials found statistically significant results and the 95% CI for the overall effect was wide, including both important effects and no effect (RR 1.24, 95% CI 0.53 to 2.86; 3 trials, 433 participants, [Analysis 4.1](#CD003650-fig-00401){ref-type="fig"}).

#### Morbidity and clinical disease progression {#CD003650-sec4-0030}

One trial from Peru in ART‐naive adults with persistent diarrhoea reported that a high daily dose of zinc (100 mg) had no effect on the persistence of diarrhoea after two weeks (HR 0.91, 95% CI 0.5 to 1.66; 1 trial, 104 participants, [Analysis 4.2](#CD003650-fig-00402){ref-type="fig"}; [@CD003650-bbs2-0008]).

One trial from the USA reported that daily zinc supplementation at the level of the DRI for 18 months significantly reduced the proportion of participants with diarrhoea over time (odds ratio (OR) 0.4, 95% CI 0.18 to 0.87; 1 trial, 231 participants, [Analysis 4.3](#CD003650-fig-00403){ref-type="fig"}; [@CD003650-bbs2-0005]). However, the 95% CI was wide and the trial was also underpowered to have confidence in this result.

#### Immunological and virological outcomes {#CD003650-sec4-0031}

Three trials reported changes in CD4+ cell count over periods from 28 days to six months (3 trials, 192 participants, data not pooled, see [Table 29](#CD003650-tbl-0029){ref-type="table"}) . One trial reported a statistically significant difference in one small subgroup ([@CD003650-bbs2-0002]). This subgroup is substantially underpowered and therefore a positive result is not likely to reflect a true result (low PPV) ([@CD003650-bbs2-0093]). However, one additional trial from the USA in adults on ART reported a statistically significant reduction in the risk of reaching a CD4+ count less than 200 cells/mm³ after supplementation for 18 months (RR 0.24, 95% CI 0.10 to 0.56; 1 trial, 231 participants; [Table 29](#CD003650-tbl-0029){ref-type="table"}; [@CD003650-bbs2-0005]).Table 19Change in CD4 count (cells/mm^3^) : zinc versus placebo**Trial IDStatistical measureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0002]Median\
(IQR)183\
(151 to 213)250\
(190 to 286)13162\
(139 to 182)192\
(162 to 254)^17^6 monthsSupplementation increased median CD4+ in those with low zinc at baseline (P = 0.042) but not those with normal zinc (P \> 0.05)[@CD003650-bbs2-0005]Mean\
(SD)385\
(285)Not reported104361\
(275)Not reported9618 monthsReduced risk of CD4+ \< 200 cells/µL^2^ with intervention (RR 0.24, 95% CI 0.10 to 0.56)[@CD003650-bbs2-0008]Median66Not reported---65Not reported------Not reported[@CD003650-bbs2-0013]Mean\
(SD)113\
(61)127\
(73)30134\
(63)156\
(75)3328 daysP = 0.91[@CD003650-bbs2-0026]Mean\
(95% CI)406\
(327 to 485)422\
(331 to 512)58460 (351 to 569)403\
(309 to 569)482 months\"Not significant\"[^25]

Three trials reported changes in viral load over periods from 28 days to 18 months, and all three trials (including [@CD003650-bbs2-0005]) reported no statistically significant differences with supplementation (3 trials, 400 participants, data not pooled, see [Table 30](#CD003650-tbl-0030){ref-type="table"}).Table 20Change in viral load (copies/mL or log~10~ copies/mL): zinc versus placebo**Trial IDStatistical measureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0005]Mean\
(SD)4.0\
(1.0)Not reported1154.0\
(1.1)Not reported11618 months\"Not affected by supplementation\"[@CD003650-bbs2-0013]Mean\
(SD)24,740\
(36,856)27,652\
(39,418)3026,286\
(40,297)24,551\
(39,013)3328 daysP = 0.26[@CD003650-bbs2-0026]Mean (95% CI)3.83 (3.52 to 4.15)4.28 (3.86 to 4.71)583.9 (3.53 to 4.27)4.1 (3.67 to 4.54)482 months\"Not significant\"[^26]

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0032}

Two trials reported blood zinc concentrations at the trial endpoints of 28 days and 6 months, respectively (two trials, data not pooled, see [Table 31](#CD003650-tbl-0031){ref-type="table"}) ([@CD003650-bbs2-0002]; [@CD003650-bbs2-0013]). No difference in zinc concentrations were reported, except for a small number of participants from one trial in Thailand who were deficient in zinc at baseline ([@CD003650-bbs2-0002]).Table 21Changes in nutritional status parameters: zinc versus placebo**Trial IDNutritional parameterStatistical MeasureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by trial authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0002]^2,3^Blood zinc (µg/L)Median\
(IQR)80\
(66 to 87)82\
(71 to 100)1376\
(66 to 88)74\
(69 to 82)176 months\"higher after zinc supplementation, particularly in patients with low plasma zinc levels at baseline\"[@CD003650-bbs2-0005]Blood zinc (µg/L)Mean\
(SD)40\
(10)Not reportedNot reported40\
(11)Not reportedNot reported18 monthsAdjusted^4^ regression coefficient ß = 0.04; P = 0.0472[@CD003650-bbs2-0008]^5^Blood zinc (µg/L)Median66Not reportedNot reported65Not reportedNot reported14 daysNot reported^5^[@CD003650-bbs2-0013]^5^Blood zinc (µg/L)Mean (SD)92.2 (18.3)120.3 (68.0)3086.9 (15)111.8 (37.9)3328 daysP = 0.67[^27]

In addition, the authors of one trial from Peru in adults with persistent diarrhoea reported a smaller proportion of supplemented participants with low blood zinc levels after 14 days (1 trial, 159 participants, P = 0.01, see [Table 31](#CD003650-tbl-0031){ref-type="table"}) ([@CD003650-bbs2-0008]). Another trial from the USA reported significantly higher blood zinc concentrations in the supplemented group at the study endpoint of 18 months, adjusted for C‐reactive protein levels (1 trial, 231 participants, ß = 0.04; P = 0.047) ([@CD003650-bbs2-0005]).

#### Adverse events associated with supplementation {#CD003650-sec4-0033}

In one trial one participant in the intervention group developed an erythematous rash after taking a standard dose supplement for one month, which resolved when the supplement was discontinued ([@CD003650-bbs2-0002]). Two trials of high dose supplementation reported similar numbers of participants in the intervention and control groups with gastrointestinal symptoms such as vomiting, diarrhoea or abdominal pain ([@CD003650-bbs2-0008]; [@CD003650-bbs2-0013]).

#### Certainty of the evidence {#CD003650-sec4-0034}

For a critical appraisal of the summary of evidence, see \'Summary of findings\' table 4 ([Table 4](#CD003650-tbl-0004){ref-type="table"}).

### Comparison 6: Selenium versus placebo {#CD003650-sec3-0031}

Four trials compared a daily selenium supplement (200 µg) to placebo, given for between nine and 24 months (see [Table 32](#CD003650-tbl-0032){ref-type="table"}). Two trials recruited only ART‐naive participants ([@CD003650-bbs2-0006]; [@CD003650-bbs2-0020]), and two recruited both ART‐naive people and people on ART ([@CD003650-bbs2-0007]; [@CD003650-bbs2-0017]).Table 22Characteristics of trials evaluating selenium supplements versus placebo**Trial IDCountryParticipantsBaseline ART useMean baseline blood selenium concentration (µg/l)^1^Mean baseline CD4+ cell count (cells/mm^3^)Mean baseline viral load (copies/mL or log~10~ copies/mL)Dose^2^Duration of supplementation (months)**[@CD003650-bbs2-0006]BotswanaHIV‐positive0 %65 (10)\
70 (24)^3^423 (median)18 500 (median)200 µg daily24 months[@CD003650-bbs2-0007]USAHIV‐positive IDUsCombination therapy 21%\
HAART 46%^3^Not reported^5^427 (421)\
378 (295)55,257 (147, 152)\
60,905 (144, 292)200 µg daily12 months[@CD003650-bbs2-0017]USAHIV‐positive73%Not reported^6^417 (264)\
441 (266)24,558 (87,051)\
10,491 (20,251)200 µg daily9 months[@CD003650-bbs2-0020]RwandaHIV‐positive0%^7^Not reported552 (median)\
527 (median)3.8 (median)\
3.9 (median)200 µg daily24 months[^28]

Of the four trials, we only judged one to be at low risk of selection bias ([@CD003650-bbs2-0006]), and three to be at low risk of performance and detection bias as they adequately described blinding ([@CD003650-bbs2-0006]; [@CD003650-bbs2-0007]; [@CD003650-bbs2-0017]).

#### Mortality {#CD003650-sec4-0035}

Not reported.

#### Morbidity and clinical disease progression {#CD003650-sec4-0036}

One trial in HIV‐positive injection drug users in the USA reported a statistically significant reduction in the risk of hospital admissions for opportunistic infections and HIV‐related conditions after supplementation for 12 months (RR 0.40, 95% CI 0.21 to 0.75; 1 trial, 186 participants, [Analysis 5.1](#CD003650-fig-00501){ref-type="fig"}). However, the trial authors stated that fewer participants in the placebo group compared to the selenium group were on ART at baseline (P \< 0.05) which may have influenced this result ([@CD003650-bbs2-0007]).

#### Immunological and virological outcomes {#CD003650-sec4-0037}

All four trials reported measures of change in CD4+ cell count with mixed findings and poor reporting of baseline and end values (see [Table 33](#CD003650-tbl-0033){ref-type="table"}). In people not taking ART we observed the following.Table 23Change in CD4 cell count (cells/mm^3^): selenium versus placebo**Trial IDStatistical measureInterventionControlTiming of endpointDifference between groups at endpoint (as reported by study authors)BaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0006]Median\
(IQR)423\
(347 to 539)Not reported220411\
(327 to 545)Not reported2172 yearsNot reported^2^[@CD003650-bbs2-0007]Mean (SD)427(421)Not reportedNot reported376(295)Not reportedNot reported12 monthsNot reported^3^[@CD003650-bbs2-0017]Mean (SD)417 (264)Not reportedNot reported441 (266)Not reportedNot reported9 monthsNot reported^4^[@CD003650-bbs2-0020]Median (IQR)552 (470 to 636)Not reported149527 (465 to 610)Not reported15124 monthsNot reported^5^[^29]

[@CD003650-bbs2-0006] reported no significant reduction in the risk of reaching a CD4+ count \< 250 cells/mm³ with selenium supplements for two years in people not on ART (HR 0.83 95% CI: 0.48 to 1.42; 1 trial, 437 participants), and [@CD003650-bbs2-0020] reported no significant reduction in the risk of reaching a CD4+ count of less than 350 cells/mm³ (RR 0.81 95% CI 0.61 to 1.09; 1 trial, 300 participants)However, [@CD003650-bbs2-0020] reported a reduction in the monthly rate of CD4 cell depletion (MD 1.74, 95% CI 0.31 to 3.17; 1 trial, 300 participants)

In populations with mixed exposure to ART, we observed the following.

[@CD003650-bbs2-0007] reported that fewer trial participants in the supplemented group experienced a CD4 cell decline of greater than 50 cells/mm³ (P = 0.01; authors\' own figures)[@CD003650-bbs2-0017] reported a multiple regression model that found higher selenium levels predicted a greater increase in CD4+ cell counts at 9 months (P \< 0.04; authors\' own figures). However, this trial is at high risk of selective reporting as the statistically significant results are only for a subgroup of participants classified as \'selenium responders\'. It is unclear if this classification or analysis was planned a priori

Only three trials reported effects on viral load and statistically significant benefits were only reported from the multiple regression model used by [@CD003650-bbs2-0017].

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0038}

Three trials reported statistically significant increases in blood selenium concentrations of participants after supplementation for 6 to 12 months (527 participants, data not pooled, see [Table 34](#CD003650-tbl-0034){ref-type="table"})Table 24Change in nutritional status parameters: selenium versus placebo**Trial IDNutritional parameterStatistical measureInterventionControlTiming of endpointCommentBaselineEndpointN^1^BaselineEndpointN^1^**[@CD003650-bbs2-0007]^2^Blood selenium (µg/L)---Not reportedNot reported‐Not reportedNot reportedNot reported12 monthsNot reported ^3^[@CD003650-bbs2-0017]^2^Blood selenium (µg/L)---Not reportedNot reported83Not reportedNot reported919 monthsMD 31.7 (27.4 to 36); P\<0.001[@CD003650-bbs2-0020]Blood selenium (µg/L)---Not reportedNot reported‐Not reportedNot reported---24 months---Sales 2010^2^Blood selenium (µg/L)^4^Mean (SD)65 (10)147 (15.3)3370 (24)69 (12.1)466 monthsP\<0.001[^30]

#### Adverse events associated with supplementation {#CD003650-sec4-0039}

One trial reported no differences in symptoms such as nausea, vomiting and skin and hair changes of participants, but those in the intervention group were more likely to report anxiety (P = 0.04) and sleep symptoms (P = 0.01). ([@CD003650-bbs2-0020]). Another trial stated that all serious adverse events reported (which included acute diarrhoea, vomiting, or severely elevated ALT levels) were adjudicated as having a remote relationship to the intervention ([@CD003650-bbs2-0006]). Two other selenium supplementation trials reported no adverse events ([@CD003650-bbs2-0007]; [@CD003650-bbs2-0017]).

#### Certainty of the evidence {#CD003650-sec4-0040}

For a critical appraisal of the summary of evidence, see \'Summary of findings\' table 5 ([Table 5](#CD003650-tbl-0005){ref-type="table"}).

### Comparison 7: Vitamin E plus vitamin C versus placebo {#CD003650-sec3-0032}

One small Canadian trial compared high daily doses of vitamins E (800 IU) and C (1000 mg) to placebo in adults on combination ART for three months. Participants were followed up for six months because of a possible carry‐over effect of the intervention ([@CD003650-bbs2-0001]).

Allocation concealment was not well described and so the risk of selection bias was unclear, but the trial was adequately blinded.

#### Mortality {#CD003650-sec4-0041}

Not reported.

#### Morbidity and clinical disease progression {#CD003650-sec4-0042}

[@CD003650-bbs2-0001] reported that high daily doses of vitamin E and C for three months had no effect on the risk of new AIDS defining infections after six months (RR 3.54, 95% CI 0.43 to 29.43; 1 trial, 49 participants).

#### Immunological and virological outcomes {#CD003650-sec4-0043}

[@CD003650-bbs2-0001] reported no effect on viral load (log~10~copies/mL) after three months supplementation of high daily doses of vitamin E and C (MD 0.95 log ~10~ copies/mL, 95% CI 0.14 to 2.04; 1 trial, 49 participants).

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0044}

This trial reported that high daily doses of vitamins E and C for three months increased blood concentrations of vitamin E (µmol/L) (MD 28.70, 95% CI 20.01 to 37.39; one trial, 49 participants) and vitamin C (µmol/L) (MD 27.30, 95% CI 12.88 to 41.72; 1 trial, 49 participants) of adults on ART ([@CD003650-bbs2-0001]).

#### Adverse events associated with supplementation {#CD003650-sec4-0045}

Two participants in the intervention group reported epigastric discomfort ([@CD003650-bbs2-0001]).

### Comparison 8: Folinic acid versus placebo {#CD003650-sec3-0033}

One small Brazilian trial compared the effect of a daily folinic acid supplement (5 mg) to placebo on the vascular response of 30 HIV‐positive adults on ART ([@CD003650-bbs2-0014]). This trial was at low risk of selection bias, and detection and performance bias.

#### Mortality {#CD003650-sec4-0046}

Not reported.

#### Morbidity and clinical disease progression {#CD003650-sec4-0047}

Not reported.

#### Immunological and virological outcomes {#CD003650-sec4-0048}

This trial reported no difference in median CD4 cell counts after daily supplementation of folinic acid for four weeks (1 trial, 30 participants, P = 0.994) ([@CD003650-bbs2-0014]).

#### Nutritional status and blood micronutrient concentrations {#CD003650-sec4-0049}

This trial reported increases in blood concentrations of folate and vitamin B12 after supplementation of folinic acid for four weeks (1 trial, 30 participants, P \< 0.001) ([@CD003650-bbs2-0014]).

#### Adverse events associated with supplementation {#CD003650-sec4-0050}

No adverse events were reported ([@CD003650-bbs2-0014]).

### Comparison 9: Iron versus no iron {#CD003650-sec3-0034}

One trial in the USA compared the effect of a daily micronutrient supplement containing iron to a supplement without iron in female injection drug users for 12 months. Of the trial participants who were HIV‐positive, approximately one‐third were on HAART at baseline and during the study ([@CD003650-bbs2-0029]).

#### Mortality {#CD003650-sec4-0051}

Not reported.

#### Morbidity and clinical disease progression {#CD003650-sec4-0052}

Not reported.

#### Immunological and virological outcomes {#CD003650-sec4-0053}

This trial reported no difference in CD4 cell counts or viral load measurements in participants who received the micronutrient plus iron supplement compared to those who received the supplement without iron for 12 months (CD4 cell count (cells/mm³): MD 35, 95% CI −83.5 to 153.5; viral load (log~10~copies/mL): MD −0.4, 95% CI −0.99 to 0.19; 1 trial, 103 participants; [@CD003650-bbs2-0029]).

#### Adverse events associated with supplementation {#CD003650-sec4-0054}

No adverse events were reported ([@CD003650-bbs2-0029]).

Discussion {#CD003650-sec1-0006}
==========

Summary of main results {#CD003650-sec2-0011}
-----------------------

### Multiple micronutrients {#CD003650-sec3-0035}

Routine multiple micronutrient supplementation may have little or no effect on mortality in adults living with HIV, but the pooled analysis remains underpowered to confidently exclude small effects (*low certainty evidence*). Trials were conducted in antiretroviral therapy (ART)‐naïve adults (3 trials, 1068 participants, *low certainty evidence*), adults on ART (1 trial, 400 participants, *very low certainty evidence*), and adults with concurrent active tuberculosis (3 trials, 1429 participants, *low certainty evidence*).

Routine supplementation for up to two years, has also not been shown to have consistent benefits on either mean CD4+ cell count (*low certainty evidence*) or mean viral load (*moderate certainty evidence*). One recent trial in ART‐naïve adults reported a reduction in the risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation in Botswana. However, this effect was only robust in the trial arm receiving multiple micronutrients plus selenium (not either supplementation alone) and is inconsistent with the findings of other trials using similar combinations of micronutrients and selenium.

In one additional trial that compared high dose multiple micronutrient supplementation with standard doses in people on antiretroviral therapy (ART), peripheral neuropathy was reduced with high dose supplements compared to standard dose, but the trial was stopped early due to increased adverse events in the high dose group.

### Single or dual micronutrients {#CD003650-sec3-0036}

None of the trials of single or dual micronutrient supplements were adequately powered to assess for effects on mortality or morbidity outcomes such as hospital admissions and persistence or rate of diarrhoea. Clinically important effects on CD4+ cell count or viral load were not reported. Supplementation probably does increase blood concentrations of vitamin D and zinc, and may also increase blood concentrations of vitamin A, especially in those who are deficient at baseline.

Overall completeness and applicability of evidence {#CD003650-sec2-0012}
--------------------------------------------------

The included trials of multiple micronutrient supplements were predominantly conducted in people who either were not taking ART or were on concurrent treatment for tuberculosis. In these populations, routine supplementation has not been shown to consistently improve disease progression as measured by average CD4+ cell count. One recent well‐conducted trial, from Botswana detected a benefit in the group receiving multivitamins with selenium but not with multivitamins alone. However, the lack of demonstrable benefit in other trials with similar selenium content, suggest that this effect should be repeated before reliable conclusions can be drawn.

The trials of single or dual micronutrient supplements included more participants on ART, and several were conducted in populations with proven micronutrient deficiencies. Despite this the only demonstrable benefits were improvements in serum levels of some micronutrients. However, these effects may be enough for some to recommend routine supplementation in similar populations.

There are several possible explanations for the lack of benefit seen in many of these trials.

The period of supplementation may have been insufficient to demonstrate effects, with benefits only accruing over prolonged periods of supplementation. Supplementation ranged from as little as four weeks up to two years.The prevalence of micronutrient deficiencies may have been too low in some of these populations to demonstrate an effect. Baseline micronutrient status was poorly assessed in many of the included trials, particularly those evaluating multiple micronutrients, so it is difficult to determine which populations these negative results should be applied to. Only one trial reported adjustment of their analysis of blood micronutrient concentrations for the effect of inflammation, an important confounder.The doses supplemented varied considerably. Many trials evaluated doses significantly higher than the daily recommended intake, and one trial of multiple micronutrients directly compared high doses with standard doses to investigate this. However, it should be noted that the high doses were not well‐tolerated in this trial.The trials may simply be too small to demonstrate effects. Certainly there is insufficient evidence to say that micronutrients could never have effects.

Given the lack of benefit in those not on ART, it seems unlikely that large effects would be seen in those who are taking ART, but adequately powered trials may still be justifiable to explore this. There may be a number of ways by which specific micronutrients may impact on or interact with ART, including aspects of drug pharmacokinetics. However, the clinical significance of these interactions remains to be determined ([@CD003650-bbs2-0109]).

Quality of the evidence {#CD003650-sec2-0013}
-----------------------

We considered the certainty of the evidence for most of the outcomes in this review to be low or very low, meaning that we can have only minimal confidence in these effects. We downgraded the certainty of the evidence mainly for the following reasons.

Indirectness: since micronutrient deficiencies differ widely among populations it is difficult to generalize the findings of a single trial, or even a few trials, to all settings, and all populations.Imprecision: most included trials were small and well below the optimal information size for the outcomes that were being measured and therefore not able to reliably detect or exclude an effect.

Potential biases in the review process {#CD003650-sec2-0014}
--------------------------------------

We tried to minimize any biases in the review process by performing a comprehensive search of the literature, and by independently selecting studies, appraising studies, and extracting data. Two review authors, MV and SD, assessed the risk of bias of the new included studies using the updated \'Risk of bias\' tool ([@CD003650-bbs2-0102]).

This review included outcome data for HIV participants from four RCTs that included both HIV‐positive and HIV‐negative participants without stratified randomization ([@CD003650-bbs2-0022]; [@CD003650-bbs2-0023]; [@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]).

Agreements and disagreements with other studies or reviews {#CD003650-sec2-0015}
----------------------------------------------------------

In the previous version of this Cochrane Review, [@CD003650-bbs2-0126] concluded that further trials of single supplements (vitamin D, zinc, and selenium) were required to build the evidence base for adults and that the long‐term clinical benefits, adverse effects, and optimal formulation of multiple micronutrient supplements required further investigation.

[@CD003650-bbs2-0097] conducted a narrative review to investigate whether the 2003 WHO recommendations for micronutrient intake in HIV‐positive adults should change. This review focused primarily on the results of nine trials of multiple micronutrient supplementation; seven trials in non‐pregnant HIV‐positive adults, and two in pregnant HIV‐positive women. The authors noted that \"five of the six trials that used high‐dose multiple micronutrients showed benefits in terms of either improved CD4 cell counts or survival\", but also that \"many of these trials were small and of short duration, and the long‐term risks and benefits of high‐dose multiple micronutrients are not established\". Our analysis and appraisal of the evidence agrees that there is currently insufficient evidence to make firm conclusions about the effects of supplementation.

For the effects of micronutrient supplementation in pregnant women and children with HIV, see the separate Cochrane reviews by [@CD003650-bbs2-0116] and [@CD003650-bbs2-0104].

Authors\' conclusions {#CD003650-sec1-0007}
=====================

To date trials of routine multiple micronutrient supplementation have not demonstrated consistent clinically important benefits on HIV disease progression or mortality. However, the trials are generally too small to confidently exclude the possibility of important effects.These findings should not be interpreted as a reason to deny supplementation where specific deficiencies have been demonstrated (such as vitamin D, zinc, and selenium), or where the person\'s diet is unlikely to meet the recommended daily allowance of vitamins and minerals.Furthermore, adequately powered studies with sufficient follow‐up periods are still required to confidently prove or exclude any long‐term clinical benefit of routine supplementation.Such research should not be to the detriment of ART, as this remains the one intervention to date that has consistently been shown to reduce morbidity and mortality, and improve the nutritional status of adults living with HIV/AIDS.
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**SearchQuery**[\#7](#7)Search ((\#1 AND \#2 AND \#5)) AND (\"2010/01/01\"\[Date ‐ Publication\] : \"2013/07/05\"\[Date ‐ Publication\])[\#6](#6)Search (\#1 AND \#2 AND \#5)[\#5](#5)Search (\#3 OR \#4)[\#4](#4)Search ("24,25‐dihydroxyvitamin D 3" OR "25‐hydroxyvitamin D 2" OR "4‐aminobenzoic acid" OR acetylcarnitine OR alpha‐tocopherol OR aminobenzoic acids OR ascorbic acid OR beta carotene OR beta‐tocopherol OR biotin OR boron OR cadmium OR calcifediol OR calcitriol OR carnitine OR cholecalciferol OR chromium OR cobalt OR cobamides OR cod liver oil OR copper OR dehydroascorbic acid OR dihydrotachysterol OR dihydroxycholecalciferols OR ergocalciferols OR flavin mononucleotide OR folic acid OR formyltetrahydrofolates OR fursultiamin OR gamma‐tocopherol OR hydroxocobalamin OR hydroxycholecalciferols OR inositol OR iodine OR iron OR leucovorin OR manganese OR magnesium OR molybdenum OR niacin OR niacinamide OR nickel OR nicorandil OR nicotinic acids OR palmitoylcarnitine OR pantothenic acid OR pteroylpolyglutamic acids OR pyridoxal OR pyridoxal phosphate OR pyridoxamine OR pyridoxine OR riboflavin OR selenium OR silicon OR tetrahydrofolates OR thiamine OR thiamine monophosphate OR thiamine pyrophosphate OR thiamine triphosphate OR thioctic acid OR tin OR tocopherols OR tocotrienols OR ubiquinone OR vanadium OR zinc)[\#3](#3)Search (micronutrients OR micronutrient OR "trace element" OR "trace elements" OR vitamins OR vitamin OR carotenoids OR carotenoid OR carotenes OR carotene)[\#2](#2)Search (randomized controlled trial \[pt\] OR controlled clinical trial \[pt\] OR randomized \[tiab\] OR placebo \[tiab\] OR drug therapy \[sh\] OR randomly \[tiab\] OR trial \[tiab\] OR groups \[tiab\]) NOT (animals \[mh\] NOT humans \[mh\])[\#1](#1)Search (HIV Infections\[MeSH\] OR HIV\[MeSH\] OR hiv\[tiab\] OR hiv‐1\*\[tiab\] OR hiv‐2\*\[tiab\] OR hiv1\[tiab\] OR hiv2\[tiab\] OR hiv infect\*\[tiab\] OR human immunodeficiency virus\[tiab\] OR human immunedeficiency virus\[tiab\] OR human immuno‐deficiency virus\[tiab\] OR human immune‐deficiency virus\[tiab\] OR ((human immun\*\[tiab\]) AND (deficiency virus\[tiab\])) OR acquired immunodeficiency syndrome\[tiab\] OR acquired immunedeficiency syndrome\[tiab\] OR acquired immuno‐deficiency syndrome\[tiab\] OR acquired immune‐deficiency syndrome\[tiab\] OR ((acquired immun\*\[tiab\]) AND (deficiency syndrome\[tiab\])) OR \"sexually transmitted diseases, Viral\"\[MeSH:NoExp\])

**SearchQuery\#12**\#1 AND \#7 AND \#10 AND \[embase\]/lim AND \[1‐1‐2010\]/sd NOT \[5‐7‐2013\]/sd**\#11**\#1 AND \#7 AND \#10**\#10**\#8 OR \#9**\#9**\'24,25‐dihydroxyvitamin d 3\'/de OR \'24,25‐dihydroxyvitamin d 3\' OR \'25‐hydroxyvitamin d 2\'/de OR \'25‐hydroxyvitamin d 2\' OR \'4‐aminobenzoic acid\'/de OR \'4‐aminobenzoic acid\' OR \'acetylcarnitine\' OR \'acetylcarnitine\'/de OR acetylcarnitine OR \'alpha‐tocopherol\'/de OR \'alpha‐tocopherol\' OR \'aminobenzoic acids\'/de OR \'aminobenzoic acids\' OR \'ascorbic acid\'/de OR \'ascorbic acid\' OR \'beta carotene\'/de OR \'beta carotene\' OR \'beta‐tocopherol\'/de OR \'beta‐tocopherol\' OR \'biotin\' OR \'biotin\'/de OR biotin OR \'boron\' OR \'boron\'/de OR boron OR \'cadmium\' OR \'cadmium\'/de OR cadmium OR \'calcifediol\' OR \'calcifediol\'/de OR calcifediol OR \'calcitriol\' OR \'calcitriol\'/de OR calcitriol OR \'carnitine\' OR \'carnitine\'/de OR carnitine OR \'cholecalciferol\' OR \'cholecalciferol\'/de OR cholecalciferol OR \'chromium\' OR \'chromium\'/de OR chromium OR \'cobalt\' OR \'cobalt\'/de OR cobalt OR \'cobamides\' OR \'cobamides\'/de OR cobamides OR \'cod liver oil\'/de OR \'cod liver oil\' OR \'copper\' OR \'copper\'/de OR copper OR \'dehydroascorbic acid\'/de OR \'dehydroascorbic acid\' OR \'dihydrotachysterol\' OR \'dihydrotachysterol\'/de OR dihydrotachysterol OR \'dihydroxycholecalciferols\' OR \'dihydroxycholecalciferols\'/de OR dihydroxycholecalciferols OR \'ergocalciferols\' OR \'ergocalciferols\'/de OR ergocalciferols OR \'flavin mononucleotide\'/de OR \'flavin mononucleotide\' OR \'folic acid\'/de OR \'folic acid\' OR \'formyltetrahydrofolates\'/de OR \'formyltetrahydrofolates\' OR \'fursultiamin\' OR \'fursultiamin\'/de OR fursultiamin OR \'gamma‐tocopherol\'/de OR \'gamma‐tocopherol\' OR \'hydroxocobalamin\' OR \'hydroxocobalamin\'/de OR hydroxocobalamin OR \'hydroxycholecalciferols\' OR \'hydroxycholecalciferols\'/de OR hydroxycholecalciferols OR \'inositol\' OR \'inositol\'/de OR inositol OR \'iodine\' OR \'iodine\'/de OR iodine OR \'iron\' OR \'iron\'/de OR iron OR \'leucovorin\' OR \'leucovorin\'/de OR leucovorin OR \'manganese\' OR \'manganese\'/de OR manganese OR \'magnesium\' OR \'magnesium\'/de OR magnesium OR \'molybdenum\' OR \'molybdenum\'/de OR molybdenum OR \'niacin\' OR \'niacin\'/de OR niacin OR \'niacinamide\' OR \'niacinamide\'/de OR niacinamide OR \'nickel\' OR \'nickel\'/de OR nickel OR \'nicorandil\' OR \'nicorandil\'/de OR nicorandil OR \'nicotinic acids\'/de OR \'nicotinic acids\' OR \'palmitoylcarnitine\' OR \'palmitoylcarnitine\'/de OR palmitoylcarnitine OR \'pantothenic acid\'/de OR \'pantothenic acid\' OR \'pteroylpolyglutamic acids\'/de OR \'pteroylpolyglutamic acids\' OR \'pyridoxal\' OR \'pyridoxal\'/de OR pyridoxal OR \'pyridoxal phosphate\'/de OR \'pyridoxal phosphate\' OR \'pyridoxamine\' OR \'pyridoxamine\'/de OR pyridoxamine OR \'pyridoxine\' OR \'pyridoxine\'/de OR pyridoxine OR \'riboflavin\' OR \'riboflavin\'/de OR riboflavin OR \'selenium\' OR \'selenium\'/de OR selenium OR \'silicon\' OR \'silicon\'/de OR silicon OR \'tetrahydrofolates\' OR \'tetrahydrofolates\'/de OR tetrahydrofolates OR \'thiamine\' OR \'thiamine\'/de OR thiamine OR \'thiamine monophosphate\'/de OR \'thiamine monophosphate\' OR \'thiamine pyrophosphate\'/de OR \'thiamine pyrophosphate\' OR \'thiamine triphosphate\'/de OR \'thiamine triphosphate\' OR \'thioctic acid\'/de OR \'thioctic acid\' OR \'tin\' OR \'tin\'/de OR tin OR \'tocopherols\' OR \'tocopherols\'/de OR tocopherols OR \'tocotrienols\' OR \'tocotrienols\'/de OR tocotrienols OR \'ubiquinone\' OR \'ubiquinone\'/de OR ubiquinone OR \'vanadium\' OR \'vanadium\'/de OR vanadium OR \'zinc\' OR \'zinc\'/de OR zinc**\#8**\'micronutrient\'/de OR micronutrient OR \'micronutrients\'/de OR micronutrients OR \'trace element\'/de OR \'trace element\' OR \'trace elements\'/de OR \'trace elements\' OR \'trace mineral\'/de OR \'trace mineral\' OR \'vitamin\'/de OR vitamin OR \'vitamins\'/de OR vitamins OR \'carotenoid\'/de OR carotenoid OR \'carotenoids\'/de OR carotenoids OR \'carotene\'/de OR carotene OR carotenes**\#7**\#2 NOT \#6**\#6**\#3 NOT \#5**\#5**\#3 AND \#4**\#4**\'human\'/de OR \'normal human\'/de OR \'human cell\'/de**\#3**\'animal\'/de OR \'animal experiment\'/de OR \'invertebrate\'/de OR \'animal tissue\'/de OR \'animal cell\'/de OR \'nonhuman\'/de**\#2**\'randomized controlled trial\'/de OR \'randomized controlled trial\' OR random\*:ab,ti OR trial:ti OR allocat\*:ab,ti OR factorial\*:ab,ti OR placebo\*:ab,ti OR assign\*:ab,ti OR volunteer\*:ab,ti OR \'crossover procedure\'/de OR \'crossover procedure\' OR \'double‐blind procedure\'/de OR \'double‐blind procedure\' OR \'single‐blind procedure\'/de OR \'single‐blind procedure\' OR (doubl\* NEAR/3 blind\*):ab,ti OR (singl\*:ab,ti AND blind\*:ab,ti) OR crossover\*:ab,ti OR cross+over\*:ab,ti OR (cross NEXT/1 over\*):ab,ti**\#1**\'human immunodeficiency virus infection\'/exp OR \'human immunodeficiency virus\'/exp OR \'human immunodeficiency virus\':ab,ti OR \'human immuno+deficiency virus\':ab,ti OR \'human immunedeficiency virus\':ab,ti OR \'human immune+deficiency virus\':ab,ti OR hiv:ab,ti OR \'hiv‐1\':ab,ti OR \'hiv‐2\':ab,ti OR \'acquired immunodeficiency syndrome\':ab,ti OR \'acquired immuno+deficiency syndrome\':ab,ti OR \'acquired immunedeficiency syndrome\':ab,ti OR \'acquired immune+deficiency syndrome\':ab,ti

hiv \| vitamin OR micronutrient OR trace element OR carotenoid

Interventional Studies \| HIV \| micronutrient OR \"trace element\" OR vitamin OR carotenoid OR carotene

**ISO 3166‐1 alpha‐3 CODECountry**BRABrazilBWABotswanaCANCanadaCHNChinaDENDenmarkGNBGuinnea‐BissauITAItalyKENKeniaMWIMalawiNIGNigeriaPERPeruRWARwandaSGPSingaporeTHAThailandTZATanzaniaUGAUgandaUSAUnited StatesZMBZambia

**Source:** International organization for Standardization ([@CD003650-bbs2-0105])

Domain 1: recruitment bias {#CD003650-sec3-0037}
==========================

Recruitment bias can occur when individuals are recruited to the trial after the clusters have been randomized ([@CD003650-bbs2-0102]). The types of participants recruited can be influenced by the knowledge of whether the specific cluster is an intervention or a control cluster.

Adequate: when no recruiting was done after randomization.Inadequate: when additional recruiting was done after randomization.Unclear: when no reporting was done regarding the timing of recruiting all participants.

Domain 2: baseline imbalance {#CD003650-sec3-0038}
============================

Cluster‐randomized trials often randomize all clusters at once, therefore, a lack of allocation concealment should not usually be a problem ([@CD003650-bbs2-0102]). However, when there is only a small number of clusters, there is a possibility of chance baseline imbalances between the randomized groups. This may affect either the clusters or the individuals.

Adequate: when the baseline comparability of clusters is sufficient, or when statistical adjustment for baseline characteristics occurred ([@CD003650-bbs2-0102]).Inadequate: when there are significant differences between clusters and no statistical adjustments for baseline characteristics were made accordingly.Unclear: when no reporting was done regarding baseline characteristics, or when it is not clear whether the differences between the clusters were significant.

Domain 3: loss of clusters {#CD003650-sec3-0039}
==========================

It is possible that complete clusters may be lost from a trial, and have to be omitted from the analysis ([@CD003650-bbs2-0102]). In the same way as for missing outcome data in individually randomized trials, this may lead to bias in cluster‐randomized trials. In addition, missing outcomes for individuals within clusters may also lead to a risk of bias in cluster‐randomized trials.

Adequate: there were no missing data, or the missing data were addressed in the correct manner.Inadequate: there were missing data and it was dealt with in a way that could have introduced bias.Unclear: when no reporting was done regarding missing data (either complete clusters or individuals within clusters), or when it is unclear whether the authors of the primary study have dealt with the missing data adequately (for example, acceptable statistical adjustments).

Comparison 1Multiple micronutrients versus placeboOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality](#CD003650-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Multiple micronutrients versus placebo, Outcome 1 Mortality.72897Risk Ratio (M‐H, Random, 95% CI)0.91 \[0.72, 1.15\]1.1 People with HIV not on ART31068Risk Ratio (M‐H, Random, 95% CI)0.60 \[0.31, 1.15\]1.2 People with HIV on ART or initiating ART1400Risk Ratio (M‐H, Random, 95% CI)1.25 \[0.50, 3.10\]1.3 People with HIV not on ART and on treatment for active tuberculosis31429Risk Ratio (M‐H, Random, 95% CI)0.92 \[0.69, 1.23\][2 Hospital admissions](#CD003650-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Multiple micronutrients versus placebo, Outcome 2 Hospital admissions.2881Risk Ratio (M‐H, Random, 95% CI)0.86 \[0.61, 1.22\]2.1 People with HIV not on ART1481Risk Ratio (M‐H, Random, 95% CI)0.79 \[0.42, 1.49\]2.2 People with HIV on ART1400Risk Ratio (M‐H, Random, 95% CI)0.90 \[0.59, 1.36\][3 Clinical disease progression](#CD003650-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Multiple micronutrients versus placebo, Outcome 3 Clinical disease progression.1Hazard Ratio (Random, 95% CI)1.08 \[0.72, 1.62\]3.1 People with HIV not on ART and on treatment for active tuberculosis1Hazard Ratio (Random, 95% CI)1.08 \[0.72, 1.62\][4 CD4+ cell count](#CD003650-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Multiple micronutrients versus placebo, Outcome 4 CD4+ cell count.6Mean Difference (IV, Random, 95% CI)Subtotals only4.1 At baseline51209Mean Difference (IV, Random, 95% CI)‐18.27 \[‐55.97, 19.42\]4.2 At longest follow‐up61533Mean Difference (IV, Random, 95% CI)26.40 \[‐22.91, 75.70\][5 CD4+ cell count at longest follow‐up; subgrouped by participant characteristics](#CD003650-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Multiple micronutrients versus placebo, Outcome 5 CD4+ cell count at longest follow‐up; subgrouped by participant characteristics.6Mean Difference (IV, Random, 95% CI)Subtotals only5.1 People with HIV not on ART2441Mean Difference (IV, Random, 95% CI)30.36 \[‐7.13, 67.84\]5.2 People with HIV on ART or initiating ART1367Mean Difference (IV, Random, 95% CI)‐6.0 \[‐35.87, 23.87\]5.3 People with HIV not on ART and on treatment for active tuberculosis2626Mean Difference (IV, Random, 95% CI)‐5.77 \[‐55.80, 44.25\]5.4 People with HIV ‐ Not stated if they are taking ART199Mean Difference (IV, Random, 95% CI)106.0 \[77.23, 134.77\][6 Viral load](#CD003650-fig-00106){ref-type="fig"}Analysis 1.6Comparison 1 Multiple micronutrients versus placebo, Outcome 6 Viral load.4Mean Difference (IV, Random, 95% CI)Subtotals only6.1 At baseline41166Mean Difference (IV, Random, 95% CI)‐0.05 \[‐0.16, 0.07\]6.2 At longest follow‐up4792Mean Difference (IV, Random, 95% CI)‐0.10 \[‐0.26, 0.06\][7 Viral load at longest follow‐up; sub‐grouped by participant characteristics](#CD003650-fig-00107){ref-type="fig"}Analysis 1.7Comparison 1 Multiple micronutrients versus placebo, Outcome 7 Viral load at longest follow‐up; sub‐grouped by participant characteristics.4Mean Difference (IV, Random, 95% CI)Subtotals only7.1 People with HIV not on ART2497Mean Difference (IV, Random, 95% CI)‐0.10 \[‐0.27, 0.07\]7.2 People with HIV not on ART but in treatment for active tuberculosis2295Mean Difference (IV, Random, 95% CI)‐0.09 \[‐0.45, 0.26\]

Comparison 2High dose multivitamins versus standard doseOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality](#CD003650-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 High dose multivitamins versus standard dose, Outcome 1 Mortality.13418Risk Ratio (M‐H, Fixed, 95% CI)1.06 \[0.89, 1.26\]1.1 People with HIV on ART or initiating ART13418Risk Ratio (M‐H, Fixed, 95% CI)1.06 \[0.89, 1.26\][2 CD4+ cell count](#CD003650-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 High dose multivitamins versus standard dose, Outcome 2 CD4+ cell count.16186Mean Difference (IV, Fixed, 95% CI)‐8.20 \[‐14.08, ‐2.32\]2.1 At baseline13418Mean Difference (IV, Fixed, 95% CI)‐7.0 \[‐13.74, ‐0.26\]2.2 At follow‐up12768Mean Difference (IV, Fixed, 95% CI)‐12.0 \[‐22.00, ‐0.00\][3 Viral load](#CD003650-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 High dose multivitamins versus standard dose, Outcome 3 Viral load.1Mean Difference (IV, Fixed, 95% CI)Subtotals only3.1 Baseline13418Mean Difference (IV, Fixed, 95% CI)0.0 \[‐0.05, 0.05\]3.2 At follow‐up1236Mean Difference (IV, Fixed, 95% CI)‐0.20 \[‐0.51, 0.11\]

Comparison 3Vitamin D versus placeboOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality](#CD003650-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Vitamin D versus placebo, Outcome 1 Mortality.1Risk Ratio (M‐H, Random, 95% CI)Subtotals only1.1 People with HIV not on ART and on treatment for active tuberculosis1131Risk Ratio (M‐H, Random, 95% CI)1.15 \[0.65, 2.02\]

Comparison 4Zinc versus placeboOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality](#CD003650-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Zinc versus placebo, Outcome 1 Mortality.3433Risk Ratio (M‐H, Random, 95% CI)1.24 \[0.53, 2.86\]1.1 People with HIV on ART1231Risk Ratio (M‐H, Random, 95% CI)1.39 \[0.58, 3.32\]1.2 People with HIV not on ART and on treatment for active tuberculosis2202Risk Ratio (M‐H, Random, 95% CI)1.62 \[0.22, 11.89\][2 Persistence of diarrhoea](#CD003650-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Zinc versus placebo, Outcome 2 Persistence of diarrhoea.1104Hazard Ratio (Random, 95% CI)0.91 \[0.50, 1.66\]2.1 People with HIV not on ART1104Hazard Ratio (Random, 95% CI)0.91 \[0.50, 1.66\][3 Rate of diarrhoea](#CD003650-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Zinc versus placebo, Outcome 3 Rate of diarrhoea.1231Odds Ratio (Random, 95% CI)0.40 \[0.18, 0.87\]3.1 People with HIV on ART1231Odds Ratio (Random, 95% CI)0.40 \[0.18, 0.87\]

Comparison 5Selenium versus placeboOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Hospital admissions](#CD003650-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Selenium versus placebo, Outcome 1 Hospital admissions.1186Risk Ratio (M‐H, Random, 95% CI)0.40 \[0.21, 0.75\]1.1 People with HIV on ART1186Risk Ratio (M‐H, Random, 95% CI)0.40 \[0.21, 0.75\]

**DateEventDescription**16 May 2017New search has been performedWe included 17 new trials in this review update, and assessed the certainty of the evidence using the GRADE approach. Nigel Rollins stepped down from the review author team. Solange Durao and David Sinclair joined as review authors.16 May 2017New citation required and conclusions have changedThe original protocol for this review included studies in both HIV‐positive children and pregnant women ([@CD003650-bbs2-0124]). Two separate reviews on the role of micronutrient supplementation for HIV‐positive pregnant women, [@CD003650-bbs2-0116], and children, [@CD003650-bbs2-0104], have been published. The primary focus of this review update was therefore on the role of micronutrient supplementation in HIV‐positive men and women who were not pregnant.

Protocol first published: Issue 4, 2003 Review first published: Issue 4, 2005

**DateEventDescription**3 June 2011AmendedParagraph added about the review being split into three reviews.19 January 2011AmendedExternal source of support added.9 November 2010New citation required and conclusions have changedSubstantial update of the review.9 November 2010New search has been performedSubstantial update.9 November 2010Feedback has been incorporatedExternal reviewers\' feedback incorporated into update30 September 2010New search has been performedInclusion of 16 additional trials, assessment of Risk of Bias using new ROB tool, and extensive updating of text.

The original protocol for this review included studies in both HIV‐positive children and pregnant women ([@CD003650-bbs2-0124]). Two separate reviews on the role of micronutrient supplementation for HIV‐positive pregnant women, [@CD003650-bbs2-0116], and children, [@CD003650-bbs2-0104], have been published. The primary focus of this review update was therefore on the role of micronutrient supplementation in HIV‐positive men and women who were not pregnant.

Characteristics of included studies \[ordered by study ID\] {#CD003650-sec2-0025}
===========================================================

[@CD003650-bbs2-0001]MethodsCountry: Canada\
Setting: primary care physicians\
Duration of recruitment: April 1995 to August 1996\
Duration of follow‐up: 6 months\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria: patients of participating physicians with stable HIV‐infection.\
Exclusion criteria: active opportunistic infection, smoking, prior antioxidant therapy, hyperlipidaemia, kidney/liver dysfunction, intractable diarrhoea (≥ 6 liquid stools/day), vomiting, gastrointestinal (GI) bleeding\
Participants randomized: 49; 47 males and 2 females; mean age = 39 years\
Loss to follow‐up/withdrawal: 0\
Exclusions postrandomization: 0InterventionsIntervention: 800 IU vitamin E and 1000 mg vitamin C\
Control: placebo\
Duration: daily for 3 monthsOutcomesPrimary outcomes\
Viral load, oxidative stress (lipid peroxides, malondialdehyde, breath pentane)\
Secondary outcomes\
Plasma micronutrients (vitamin E, C, A carotenoids, zinc, selenium); new and recurrent infections (AIDS‐defining, HIV‐associated, and other)Adverse eventsTwo participants in the intervention group reported epigastric discomfortNotesNumber of participants on antiretroviral therapy (ART)\
Supplement group: 22/23 (85%).Control group: 18/26(78%).\
Controlled diet 2 weeks prior to randomization and throughout study period, and dietary counselling.\
Source of funding: Canadian Foundation for AIDS Research***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used a random number table to perform randomization.Allocation concealment (selection bias)Unclear riskThe trial authors did not adequately describe allocation concealment.Blinding (performance bias and detection bias) All outcomesLow riskThe trial authors blinded the participants and investigators to treatment.Incomplete outcome data (attrition bias) All outcomesHigh riskThere were high and unequal proportions of missing outcomes (3/23 intervention group versus 6/26 control group).Selective reporting (reporting bias)Unclear riskThere was insufficient information; the trial protocol was unavailable.Other biasUnclear riskThe trial authors did not declare their conflicts of interest, if any.[@CD003650-bbs2-0002]MethodsCountry: Bangkok, Thailand\
Setting: HIV Clinic, Ramathibodi Hospital, Mahidol University\
Duration of recruitment: May 2011 to April 2012\
Duration of trial: 6 months\
Duration of follow‐up: 6 months\
Design: randomized placebo‐controlled trial, stratified according to baseline blood zinc levels\
Follow‐up: monitoring of clinical condition, adverse events, and adherence every 3 monthsParticipantsInclusion criteria: HIV‐positive people aged ≥ 18 years who were on ART for at least 12 months, with complete viral suppression (HIV RNA 40 copies/mL), and having CD4＋ cell count \< 200 cells/mm³ that increased \< 30% from baseline after achieving undetectable HIV RNA after 12 months of ART.\
Exclusion criteria: pregnancy or women planning to become pregnant, and participants who previously received zinc supplements (duration not stated).\
Participants screened: 70\
Participants eligible for randomization: 31\
Participants randomized: 31 (low blood zinc levels (N = 12); normal blood zinc levels (N = 19))\
Mean age at randomization: 45 ± 11 years\
21 female/10 male\
62.3% (144/231) of participants were receiving ART at baseline.\
The trial authors reported that the distribution of the ART regimens was similar between the 2 groups at baseline.InterventionsInterventionS: 15 mg chelated zinc daily\
Control: placebo daily\
Duration: 6 months\
Compliance: participants were asked to return any unused study medication every 3 months and pill counts were conducted. The trial authors did not report compliance rates.OutcomesPrimary\
Blood zinc levels\
Secondary\
CD4 count, CD4 %Adverse eventsOne participant in the zinc group developed an erythematous rash after supplementation for 1 month, which resolved when the participants discontinued taking the zinc supplement.NotesLinks to other studies (study ID): Asdamongkol 2012 under [@CD003650-bbs2-0002]\
Source of funding: research grant of Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand\
Conflict of interest: None\
Ethics: Ramathibodi Hospital, Mahidol University Institutional Ethics committee but type of consent not stated\
Trial registration: not stated***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial randomized participants to receive zinc supplements or placebo in a 1:1 ratio in blocks of 4. However, the trial authors did not clearly describe the process of selecting the blocks.Allocation concealment (selection bias)Unclear riskAlthough the trial authors stated that the pharmacy bottled the supplements, they did not provide any information on whether the bottles were prelabelled in a sequential order.Blinding (performance bias and detection bias) All outcomesLow riskThe trial authors stated that the zinc or placebo pills were indistinguishable in shape, size, and colour. Outcome measures (laboratory assays) were unlikely to have been affected by detection bias.Incomplete outcome data (attrition bias) All outcomesLow riskOnly 1 participant in the zinc group was withdrawn from the trial during the follow‐up period.Selective reporting (reporting bias)Unclear riskThe trial protocol was unavailable.Other biasLow riskThe trial authors declared that they had no conflicts of interest.[@CD003650-bbs2-0003]MethodsCountry: Kenya\
Setting: hospital outpatient clinic\
Duration of recruitment: September 1998 to June 2000\
Median duration of follow‐up: 42 days (32 to 445 days)\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria: HIV‐1 seropositive women attending Coast Provincial General Hospital outpatient clinics in Mombasa, Kenya\
Exclusion criteria: age \< 18 or \> 45; pregnancy, or use of vitamin supplements or oral contraceptive pills\
Participants randomized: 400; 400 females; median age = 28 years\
Loss to follow‐up/withdrawal: 46\
Exclusions postrandomization: 0InterventionsIntervention: vitamin A (10,000 IU retinyl palmitate)\
Control: placebo\
Duration: daily for 6 weeksOutcomesPrimary outcomes:\
Vaginal HIV DNA and RNA\
Secondary outcomes\
Plasma viral load\
CD4 and CD8 countsAdverse eventsNone reportedNotesSource of funding: research grants from NIH, University of Washington, and Fogarty International Center; International AIDS Research and Training Program scholarships; Gen‐Probe (reagents)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used computer‐generated block randomization.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe how they performed allocation concealment.Blinding (performance bias and detection bias) All outcomesLow riskThe participants and investigators were blinded to treatment.Incomplete outcome data (attrition bias) All outcomesHigh riskHigh attrition in both treatment groups (vitamin A group: 12%; placebo group: 11%). The trial authors stated that those lost to follow‐up had more advanced HIV disease and were more likely to be vitamin A‐deficient.Selective reporting (reporting bias)Unclear riskThere was insufficient information regarding selective reporting; the trial protocol was not available.Other biasUnclear riskThe trial authors did not declare whether or not they had conflicts of interest.[@CD003650-bbs2-0004]MethodsCountry: Denmark\
Setting: outpatient clinic, Department of Infectious Diseases, Hvidovre Hospital\
Duration of recruitment: July 2008 to September 2009\
Duration of trial: 15 months\
Duration of follow‐up: 16 weeks\
Design: randomized placebo‐controlled trial with 3 intervention arms\
Follow‐up: at baseline, a medical history and assessment of total calcium intake was performed for each participant.\
At baseline and at 16 weeks, bloods were taken to measure immunological parameters, HIV‐viral load, parathyroid hormone, calcium, vitamin D, and biochemical bone markers. The trial assessed quality of life of each participant at baseline and at 16 weeks (Medical Outcomes Study (MOS) 36‐item Short Form Health Survey (SF‐36) questionnaire)ParticipantsInclusion criteria: HIV‐positive males aged ≥ 18 years who were receiving highly active antiretroviral therapy (HAART)\
Exclusion criteria: previous bone disease, tuberculosis, sarcoidosis, active malignancy with bone metastasis, elevated serum calcium\
Participants randomized: 61\
Mean age at randomization: 48 ± 9 years\
No reported baseline differences between treatment groups in terms of time since HIV diagnosis, type of HAART, CD4 and CD8 cell counts, HIV viral load, calcium intake\
Treatment assignment of 2 participants who used vitamin D supplementation prior to the study not reportedInterventionsInterventionS: calcitriol and vitamin D: 100,000 IU vitamin D at study entry; tablets containing 1200 mg calcium plus 1200 IU vitamin D and 0.5 µg to 1.0 µg calcitriol daily\
Vitamin D: 100,000 IU vitamin D at study entry; tablets containing 1200 mg calcium plus 1200 IU vitamin D and placebo daily\
Control: placebo at trial entry; tablets containing 1200 mg calcium and placebo daily\
Duration: 16 weeks\
Compliance: participants were asked to return any unused trial medication after 16 weeks. Compliance rates with the daily study tablets were not reported for each treatment group. According to the trial authors, 77% and 67% of participants achieved a satisfactory compliance (defined by the trial authors as ≥ 80% of the number of tablets dispensed) for the calcitriol/placebo tablet and cholecalciferol/placebo tablet, respectively.OutcomesPrimary outcome\
Changes in absolute CD4 and CD8 count, changes in % CD4 and % CD8\
Secondary outcome:\
Changes in HIV viral load and blood concentrations of parathyroid hormone (PTH), calcium, 25 hydroxyvitamin D (25‐OHD), and 1,25 hydroxyvitamin D 1,25(OH)D2Changes in quality of lifeChanges in biochemical bone markers of bone formation (P1NP) and bone resorption (CTx)Adverse eventsHypercalcaemia (calcitriol + vitamin D group (2 events); vitamin D group (1 event), constipation (8 events))\
11 adverse events were only reported as unrelated to the study medication (calcitriol + vitamin D group (6 events); vitamin D group (3 events); control group (2 events))NotesSource of funding: Pharma‐Vinci, Roche (sponsorship of trial supplements)\
Conflict of interest: nothing declared\
Ethics: regional ethics committee and the National Board of Health.\
Trial registered at clinicaltrials.gov (NCT00990678)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskIt is unclear how the trial generated randomization codes.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide any information regarding allocation concealment.Blinding (performance bias and detection bias) All outcomesLow riskThe trial authors reported that participants and investigators were blinded throughout the trial. For the outcomes of CD4/CD8 cell counts and viral loads, lack of blinding of outcome assessors was unimportant.Incomplete outcome data (attrition bias) All outcomesHigh riskAttrition was not similar across treatment groups: (19/20 (95%) for calcitriol and vitamin D group; 17/19 (89%) for vitamin D group, and 15/22 (68%) for control group). The reasons for attrition in each group were unclear.Selective reporting (reporting bias)Unclear riskThe trial protocol from clinicaltrials.gov states the measurement of all outcomes at baseline and at 2, 4, 8, 12, and 16 weeks. However, the trial authors reported data for baseline and 16 weeks only. Although the trial authors reported T lymphocyte subsets (CD4, CD8) as the primary outcome, the trial protocol describes blood vitamin D concentrations as the primary outcome.Other biasUnclear riskThe trial authors did not include any statement on conflicts of interest. It was unclear whether study sponsors played any role in the study design or reporting of study findings.[@CD003650-bbs2-0005]MethodsCountry: USA\
Setting: primary health care clinic, Miami\
Duration of recruitment:March 2002 to December 2005\
Duration of trial: 46 months\
Duration of follow‐up: 18 months\
Design: randomized placebo‐controlled trial\
Follow‐up: a nurse practitioner performed a physical examination, medical history, urine toxicology, and took bloods (CD4 count, HIV viral load, C‐Reactive protein, zinc) from participants at baseline and every 6 months. The trial assessed participants\' morbidity during monthly visits to clinic by means of a questionnaire, which was confirmed by information recorded in medical charts. Cause of death was determined by means of authorized contacts, medical records, and death certificates.ParticipantsInclusion criteria: HIV‐positive people aged ≥ 18 years with low plasma zinc levels (\< 0.75 mg/L) and no history of endocrine or psychiatric disorders\
Exclusion criteria: premenopausal women who were pregnant or had an intention to become pregnant; plasma zinc levels ≤ 0.35 mg/L at any time during the trial\
Participants screened: 557\
Participants eligible for randomization: 246\
Participants randomized: 231; 62 female and 169 male\
Mean age at randomization: 42.7 ± 7 years\
62.3% (144/231) of participants were receiving ART at baseline.\
There were no reported baseline differences in demographic characteristics, clinical disease stage, CD4 cell count, HIV viral load, adherence to ART, drug or alcohol use, cigarette use, or plasma zinc levelsInterventionsIntervention: 12 mg of elemental zinc for women; 15 mg for men daily\
Control: placebo daily\
Duration: 18 months\
Compliance: assessed monthly with questionnaires and pill counts. 3.65 ± 0.31 pills returned out of a possible 4 pills per month\
After completion of the trial it is reported that participants who received zinc had higher blood zinc concentrations over time compared to those who received placebo, after controlling for C‐Reactive protein concentrations (data not provided).OutcomesPrimary outcomes:\
Immunological failure (CD4 count \< 200 cells/mm³)\
Secondary outcomes:\
HIV viral loadMorbidity (incidence of diarrhoea, upper and lower respiratory infections, and other health events (not specified))Prevalence of hypertensionMortalityAdverse eventsNoneNotesSource of funding: National Institute on Drug Abuse\
Conflict of interest: none\
Ethics: Florida International University Institutional Review Board\
Trial registered at clinicaltrials.gov (NCT00149552)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskIt was unclear how the trial generated randomization codes.Allocation concealment (selection bias)Low riskA pharmacist bottled and precoded the trial supplements for each participant for the entire trial period according to the randomization code.Blinding (performance bias and detection bias) All outcomesLow riskThe trial authors reported that the clinical and study personnel and participants were blinded. Only the pharmacist and statistician were aware of treatment assignments during the trial.Incomplete outcome data (attrition bias) All outcomesLow riskThere was low attrition. However, the uneven numbers, deaths, plasma zinc, and dropouts may be related to main outcome.Selective reporting (reporting bias)Low riskThe primary and secondary outcomes as reported are consistent with the trial protocol from [www.clinicaltrials.gov](www.clinicaltrials.gov).Other biasLow riskThe trial authors declared that they had no conflicts of interest. An independent company that was not involved in the design or implementation of the study, or the analysis and reporting of the findings. manufactured the trial supplements.[@CD003650-bbs2-0006]MethodsCountry: Botswana\
Setting:Princess Marina Hospital, Gaborone, Botswana\
Duration of recruitment:\
Duration of trial: 4 years and 7 months (December 2004 to July 2009)\
Duration of follow‐up: 24 months\
Design: randomized placebo‐controlled factorial trial with 3 intervention arms\
Follow‐up: a monthly questionnaire was administered about acceptability of the supplement, adherence, adverse effects, and intercurrent morbidity (health events occurring between the trial visits; confirmed by documentation in medical record)\
Every 3 months: physical examination and medical history performed by a nurse or physician, blood sample taken for CD4 cell count\
Every 6 months: HIV viral load, plasma micronutrient levels (20% subsample), and blood chemistriesParticipantsInclusion criteria: HIV‐positive participants aged 18 years and older, ART‐naive and CD4 cell count \> 350 /µL\
Exclusion criteria: pregnancy\
Participants screened: 1003\
Participants eligible for randomization: 922\
Participants randomized: 878\
Median age at randomization: 31 to 33 years\
The trial authors reported no statistically differences in baseline CD4 cell count, HIV viral load, Body Mass Index (BMI), haemoglobin, albumin, total cholesterol, and HDL‐cholesterol levels.InterventionsIntervention (multivitamins group): thiamin 20 mg, riboflavin 20 mg, vitamin B6 25 mg, niacin 100 mg, vitamin B12 50 µg, folic acid 0.8 mg, vitamin C 500 mg, vitamin E 30 mg\
Intervention (selenium group): 200 µg daily\
Intervention (multivitamins plus selenium group): as above\
Control: placebo daily\
Administered as 1 pill daily. Pills were indistinguishable in shape, size, and colour.\
Duration: 24 months\
Compliance: pill counts at each follow‐up visit, Adherence reported as 96% (no standard deviation (SD) stated)\
The trial measured plasma micronutrient levels (subsample of participants) but the trial authors did not report this information\
All participants received isoniazid (INH) prophylaxisOutcomesPrimary outcome\
Time from randomization to reaching CD4 cell count of 200 cells/µL or less. In March 2008, this outcome was changed to reaching a CD4 cell count of 250/µL or less due to change in ART policy\
Secondary outcomes:\
HIV viral loadComposite of time from randomization to reaching CD4 cell count of 200/ µL or less or AIDS defining conditions or AIDS‐defining deathTime from randomization to reaching CD4 cell count of 350/ µL or lessComposite of time from randomization to reaching CD4 cell count of 350/ µL or less or AIDS defining conditions or AIDS‐defining deathAdverse eventsThe trial authors reported a total of 79 adverse events which they judged as having a remote relationship with the trial intervention.\
Acute diarrhoea/vomiting: 5 events (3 in multivitamins plus selenium group; 2 placebo group)\
Severely elevated alanine transaminase (ALT) (\> 5 times normal range): 3 events (1 in multivitamins group; 2 in placebo group)NotesLinks to other trials (trial ID): Sales 2010\
Source of funding: National Institute on Drug Abuse\
Conflict of interest: none\
Ethics: Florida International University Institutional Review Board, Harvard School of Public Health IRB, Botswana Health Research Unit of the National Ministry of Health\
Trial registration: not reported***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskA statistician generated block randomization in blocks of 20.Allocation concealment (selection bias)Low riskParticipants were assigned into one of the trial groups using the next sequential number from the randomization list generated by the data centre. The pharmacist prelabelled the pills for the entire trial with the identification number according to the assignment list.Blinding (performance bias and detection bias) All outcomesLow riskPills were indistinguishable in shape, size, and colour; also the trial authors stated that trial personnel and participants were blinded. Outcome measures (laboratory assays) were unlikely to be affected by detection bias.Incomplete outcome data (attrition bias) All outcomesUnclear riskThe trial authors reported the number of participants who withdrew from the trial due to pregnancy; however, other reasons for lost‐to follow‐up were not stated. There were similar levels of attrition across treatment groups (selenium group: 17% (38/220); multivitamins plus selenium group: 19% (42/220); placebo group: 15% (21/219))\
For the measures of viral load, the trial authors performed multiple imputation, but did not provide any details in terms of the proportion of data that was missing.Selective reporting (reporting bias)Unclear riskThe trial protocol was unavailable.Other biasLow riskThe trial authors declared no conflicts of interest. The trial was funded by a non‐conflicting funding source.[@CD003650-bbs2-0007]MethodsCountry: USA\
Setting: community‐based clinic\
Duration of recruitment: 1998 to 2000\
Duration of follow‐up: 12 months\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria: confirmed HIV, past or present use of illegal drugs, ≥ 18 years, adequate selenium status (\> 85 µg/L)\
Exclusion criteria: selenium deficient (\< 85 µg/L)\
Participants randomized: 259\
112 female\
Median age = 40 years (range 24 to 54)\
Loss to follow‐up/withdrawal: 73 at 12 months\
Exclusions postrandomization: 0Interventions200 microgram selenium or placebo daily for 12 months.OutcomesPrimary outcomes\
Number of hospital admissionsType of hospital admissionsRisk of hospitalization\
Secondary outcomes\
CD4 countHospitalization costPlasma seleniumAdverse eventsNone reportedNotesNumber of participants on ART: Selenium group: 64 (76%) Control group: 60 (53%)\
Number, type, and duration of hospital admissions recorded 2 years prior and during study period. Medical records reviewed by team of physicians.\
Source of funding: research grant and commercial (materials)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe how they performed sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe how they performed allocation concealment.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskExclusions from the analysis (73/259 (28%)) not reported by treatment group.Selective reporting (reporting bias)Unclear riskInsufficient information; the trial protocol was unavailableOther biasUnclear riskThe trial authors did not declare on any conflicts of interest, if any.[@CD003650-bbs2-0009]MethodsCountry: USA\
Setting: hospital outpatient clinics\
Duration of recruitment: not stated\
Duration of follow‐up: 8 weeks\
Design: randomized cross‐over trial; no washout periodParticipantsInclusion criteria: HIV‐seropositive\
Exclusion criteria: on other forms of vitamin A supplementation; significant hepatic or renal dysfunction; active opportunistic infection or fever\
Participants randomized: 21\
20 male and 1 female\
Median age: not stated\
Loss to follow‐up/withdrawal: 4\
Exclusions postrandomization: 0InterventionsIntervention: 60 mg beta‐carotene\
Control: placebo\
Duration: 3 times daily for 4 weeksOutcomesPrimary outcomes\
CD4 counts\
Secondary outcomes\
White blood cell countLymphocyte countB‐lymphocytesSerum beta‐caroteneAdverse eventsNo toxicity; skin discolouration in treatment groupNotesCD4 count data reported as means and ranges\
16 participants received ART.\
Source of funding: Hoffman La Roche Inc.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of random sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesLow riskLow attrition at 1 month; the trial authors provided reasons.Selective reporting (reporting bias)Unclear riskThere was insufficient information; the trial protocol was unavailable.Other biasUnclear riskThe trial authors did not declare on conflict of interest, if any.[@CD003650-bbs2-0010]MethodsCountry: USA\
Setting: hospital outpatient clinic and private practice\
Duration of recruitment: not stated\
Duration of follow‐up: 3 months\
Design: randomized controlled trial (RCT)ParticipantsInclusion criteria: HIV‐seropositive; \> 21 years\
Exclusion criteria: other forms of vitamin A supplementation 30 days prior to study; ART 60 days prior to study; significant hepatic or renal dysfunction; CD4 \< 50 or \> 600\
Participants randomized: 72\
63 male and 9 female\
Median age: not stated\
Loss to follow‐up/withdrawal: 4 at 1 month; 22 at 3 months\
Exclusions postrandomization: 0InterventionsIntervention: 60 mg beta‐carotene + multivitamins\
Control: placebo + multivitamins\
Duration: 3 times daily for 3 monthsOutcomesPrimary outcomes\
CD4 counts\
Secondary outcomes\
T‐cell countsWhite blood cell countsNatural killer cellsHIV p‐24 antigenSerum beta‐caroteneBody weightKarnofsky scoresAdverse eventsNone reportedNotesNumber of participants on ART: treatment group: 10 (28%); control group: 17 (47%)\
Source of funding: research grant and commercial (materials)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of random sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskHigh attrition at 3 months (22/72 participants were lost to follow‐up); the trial authors did not provide reasons.Selective reporting (reporting bias)Unclear riskInsufficient information; the trial protocol was unavailable.Other biasUnclear riskThe trial authors did not declare on conflict of interest, if any.[@CD003650-bbs2-0008]MethodsCountry: Peru\
Setting: tertiary hospitals\
Duration of recruitment: June 1998 to Jan 2000\
Duration of follow‐up: 2 weeks\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria:\
HIV‐seropositive, persistent diarrhoea (≥ 7 days) without prior treatment\
Exclusion criteria: none stated\
Participants randomized: 159\
49 female and 110 male\
Median age = 30 years (range 19 to 57) in zinc group\
Median age = 31 years (range 19 to 64) in placebo group\
Loss to follow‐up/withdrawal: 51\
Exclusions postrandomization: 0InterventionsIntervention: zinc sulphate (100 mg)\
Control: placebo\
Duration: daily for 14 daysOutcomesPrimary outcomes\
Persistence of diarrhoeaTime until cessation of diarrhoea\
Secondary outcomes:\
Plasma zinc and copper levelsAdverse eventsGastrointestinal symptoms attributable to the medication (nausea, vomiting, abdominal pain) similar in both treatment groupsNotesSulfamethoxazole‐trimethoprim prescribed for participants with enteric bacterial pathogens (23 in zinc group and 12 in placebo)\
Source of funding: Fogarty IARTP grant; University of Washington Center for AIDS Research; Centers for Disease Control and Prevention (CDC)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used computer‐generated blocked randomization.Allocation concealment (selection bias)Low riskThe trial authors stated that the treatment allocators were unable to access the assignment roll.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskThere were high losses to follow‐up in both groups (34.6% intervention group versus 29.5% control group).Selective reporting (reporting bias)Unclear riskThere was insufficient information; the trial protocol was unavailable.Other biasUnclear riskThe trial authors did not declare on conflict of interest, if any.[@CD003650-bbs2-0011]MethodsCountry: USA\
Setting: 2 outpatient clinics, Philadelphia\
Design: RCT (safety trial)\
Duration of recruitment: January 2010 to January 2011\
Duration of follow‐up: 12 weeks\
Follow‐up: participants were followed up at 6 and 12 weeks.\
Blood and urine measurements were also performed for vitamin D (25‐hydroxy vitamin D, 1,25‐dihydroxy vitamin D), calcium, metabolic parameters, and immunological parameters.ParticipantsInclusion criteria: participants with perinatally acquired HIV (PHIV) and behaviorally‐acquired HIV (BHIV)\
Exclusion criteria: participation in another study impacting 25(OH) vitamin D, pregnant or lactating females, and other conditions affecting growth, dietary intake, or nutritional status. People who were taking supplements that contained vitamin D were not eligible. Those willing to discontinue supplementation with approval of their medical provider were eligible after a 2‐month washout period.\
Participants screened: 240\
Participants eligible for randomization: 146\
Randomization was stratified by HIV acquisition (PHIV/BHIV) and season of the year\
Participants randomized: 44\
Mean age at randomization: 18.4 ± 4.7 years (4000 IU vitamin D group) and 19.1 ± 5.0 yrs (7000 IU vitamin D group)\
30 male and 14 female\
Clinical characteristics, growth status, ART regimen similar at baselineInterventionsIntervention: 7000 IU vitamin D group\
One gelatin capsule containing one 2000 IU capsule and one 5000 IU softgel (over‐encapsulated) daily\
Control: 4000 IU vitamin D group\
One gelatin capsule containing two 2000 IU capsules (over‐encapsulated) daily\
Duration: 12 weeks\
Compliance: residual tablets or volumes recorded at the 12‐week visit. Adherence also assessed by questionnaire at 6,12 weeks and telephonically at weeks 1, 3, 5, 8, and 10. The trial authors did not report the mean adherence during the trial period.OutcomesPrimary outcomes\
Serum 25 (OH) vitamin D and calcium concentrations\
Secondary outcomes\
Immunological and virological parametersAdverse eventsNo evidence of any adverse biochemical, haematological, immunological, or virological eventNotesSource of funding: National Institutes of Health\
Conflict of interest: none\
Ethics: Children\'s Hospital of Philadelphia IRB\
Trial registration: NCT01092338***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskIt was unclear how the randomization codes were generated.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide any information regarding the method of allocation concealment.Blinding (performance bias and detection bias) All outcomesUnclear riskBlinding not specified except for participants who received a single capsule which was identical in size, shape, and colour.Incomplete outcome data (attrition bias) All outcomesLow riskAttrition was due to migration (n = 1) and loss to follow‐up (n = 1).Selective reporting (reporting bias)Unclear riskThe trial protocol was not available.Other biasLow riskThe trial authors declared no conflicts of interest. A non‐conflicting funding source funded the trial.[@CD003650-bbs2-0012]MethodsCountry: Italy\
Setting: outpatient clinic, Milan\
Duration of recruitment: April 2011‐\
Duration of trial: 15 months\
Duration of follow‐up: 12 months\
Design: randomized placebo‐controlled trial\
Follow‐up: blood samples were taken from each participant (vitamin D, immunological parameters) at baseline and at 3, 6, 9, 12 monthsParticipantsInclusion criteria: HIV‐positive people aged ≤ 30 years, low blood vitamin D concentrations (25(OH)D \< 30 ng/mL)\
Exclusion criteria: participants of African descent, hyperparathyroidism, vitamin D supplementation during the 12 month period prior to study entry, use of any medication known to alter vitamin D (excluding ARV) in the previous 6 months, concomitant severe illness\
Participants screened: 90\
Participants eligible for randomization: 57\
Participants randomized: 52\
Median age at randomization: vitamin D group: 20 (interquartile range (IQR) 18 to 23) yrs; placebo group: 18 (15 to 23) years\
86% (43/50) of participants on HAART\
No reported baseline differences in clinical disease stage, type of antiretroviral therapy (ART), CD4 cell count, blood vitamin D, calcium, Parathyroid hormone (PTH) concentrations. Undetectable viral load (\< 37 copies/mL) was recorded for 72% (18/25) and 84% (21/25) of participants in the vitamin D and placebo group, respectively at baseline.InterventionsIntervention: single dose of 100,000 IU vitamin D (oral dose in oil suspension) at baseline and at 3, 6, and 9 months\
Control: single dose of placebo (oral dose in oil suspension) at baseline and at 3, 6, and 9 months\
Compliance: directly observedOutcomesPrimary outcomes\
Serial mean changes in 25(OH)D; 1,25 (OH)2D concentrations\
Secondary outcomes\
Serial mean changes in absolute CD4 cell count, % CD4Adverse eventsReported no adverse events during the trial periodNotesSource of funding: Italian Ministry of Health\
Conflict of interest: none\
Ethics: Luigi Sacco Hospital Ethical Committee\
Trial registered at clinicaltrialsregister.eu (2011‐00059354)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used block randomization in blocks of 4.Allocation concealment (selection bias)Unclear riskThe trial used matching sealed plastic syringes labelled with unique identification numbers, but it is unclear if these numbers were sequentially labelled or not.Blinding (performance bias and detection bias) All outcomesLow riskAll the trial participants, outcome assessors (laboratory technicians and immunologists) and personnel, except the paediatrician who administered the treatment, were blinded to it.Incomplete outcome data (attrition bias) All outcomesLow riskThe trial authors did not provide any reasons for lost to follow‐up of 2 participants in the placebo group at 3 and 6 months. The trial authors performed ITT analyses.Selective reporting (reporting bias)Low riskThe primary and secondary outcomes as reported are consistent with the trial protocol from www.clinicaltrialsregister.euOther biasLow riskThe trial authors declared that they had no conflicts of interest.[@CD003650-bbs2-0013]MethodsCountry: Singapore\
Setting: outpatient clinic at national HIV referral centre, Tan Tock Seng Hospital\
Duration of trial: January 2003 to July 2003 (7 months)\
Duration of follow‐up: 28 days\
Design: randomized placebo‐controlled trial\
Follow‐up: medical history, physical examination, adverse events at 14 and 28 days. Bloods taken in fasted state at baseline and after 28 days for immunological parameters and zinc levelsParticipantsInclusion criteria: HIV‐positive participants \> 18 years with CD4 count \< 200 cells/mm³, no opportunistic infections 6 months prior and stable ART for 3 months prior to study entry\
Exclusion criteria: pregnancy, intravenous drug users, on immunomodulatory therapy, oral zinc supplementation\
Participants screened: 420\
Participants eligible for randomization:189\
Participants randomized: 66\
Mean age at randomization: 40 ± 7.8 yrs (zinc group) versus 40 ± 8.3 yrs (placebo group)\
61 male and 5 female\
77% of participants were on HAART. Demographic, clinical characteristics, and antiretroviral drug regimes were similar in both treatment groups at baseline.InterventionsIntervention: 220 mg zinc sulphate (50 mg elemental zinc) administered as a capsule daily along with ART\
Control: placebo\
Supplement and placebo capsules were identical in appearance\
Duration: 28 days\
Compliance: adherence was reported as the proportion of participants in each treatment group who took ≥ 90% of scheduled doses (zinc group: 93.5% (30/32); control group: 94% (32/34)).OutcomesPrimary outcome: immune response to tuberculosis\
Secondary outcomes: CD4, CD8 cell counts, naive T cells, blood zinc levelsAdverse eventsNausea or vomiting (3 participants in both groups), diarrhoea (4 participants in intervention group versus 1 participant in control group)\
One participant from the zinc group developed Indinavir‐related renal colic on day 7.\
One participant from the placebo group developed fever on day 28 and was diagnosed with *M. fortuitum* infection.\
One participant from the placebo group developed a *Staphylococcus aureus* soft tissue abscess on day 23.NotesConflict of interest: none\
Source of funding: National Health Group Singapore\
Ethics:Tan Tock Seng Hospital***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a computer‐generated randomization sequence in blocks of 6.Allocation concealment (selection bias)Unclear riskIt was unclear how the trial organized the process of treatment allocation.Blinding (performance bias and detection bias) All outcomesUnclear riskBlinding was not specified, except for participants who received identical capsules.Incomplete outcome data (attrition bias) All outcomesLow riskThe trial withdrew one participant due to an adverse event. This was unlikely to have influenced the results.Selective reporting (reporting bias)Unclear riskThe trial protocol was not available.Other biasLow riskThe trial authors included a statement regarding no conflicts of interest.[@CD003650-bbs2-0014]MethodsCountry: Brazil\
Setting: outpatient clinic, Hospital de Clínicas de Porto Alegre, Porto Alegre\
Duration of recruitment: August 2009 to September 2011\
Duration of trial: 25 months\
Duration of follow‐up: 4 weeks\
Design: randomized placebo‐controlled trial\
Follow‐up: blood samples and vascular measurements taken at baseline and again at 4 weeksParticipantsInclusion criteria: HIV‐positive adults on HAART (at least 6 months) with undetectable HIV viral load (\<50 copies/mL) and CD4 count \> 200 cells/mm³\
Exclusion criteria: diabetes mellitus, active infection, liver or renal disease, history of cardiovascular disease, uncontrolled hypertension, pregnancy, use of illicit drugs, mental illness, current tobacco use, women on hormone replacement therapy and current intake of dietary supplements (such folic acid, antioxidants)\
Participants screened: 1332\
Participants eligible for randomization: 175\
Participants randomized: 30 participants stratified according to sex\
Mean age at randomization: 45 ± 2 years\
14 male and 16 female\
All participants were on HAART. Clinical characteristics and antiretroviral drug regimes were similar at baseline.InterventionsIntervention: 1 capsule containing 5 mg folinic acid daily (in the morning)\
Control: 1 placebo capsule, indistinguishable in appearance, daily (in the morning).\
Duration: 4 weeks\
Compliance: no details provided, but an increase in blood folic acid concentrations was demonstrated in the intervention group.OutcomesPrimary outcome\
Brachial artery vascular response\
Secondary outcomes\
CD4 cell counts, blood concentrations of folate, vitamin B12, lipid profiles, homocysteineAdverse eventsNo adverse events were reportedNotesConflict of interest: none\
Source of funding: research grants and scholarship (Hospital de Clınicas de Porto Alegre Fund for Research (FIPE‐ HCPA), Coordination for the Development of Higher Education (CAPES), Brazil)\
Ethics: Hospital de Clínicas de Porto Alegre Ethics review board***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used computer‐generated randomization in blocks of 10.Allocation concealment (selection bias)Low riskA person not affiliated to the trial precoded and sequentially numbered bottles.Blinding (performance bias and detection bias) All outcomesLow riskThe trial authors reported blinding of participants and investigators.Incomplete outcome data (attrition bias) All outcomesLow riskNo loss to follow‐up occurred.Selective reporting (reporting bias)Unclear riskThere was insufficient information, and the trial protocol was not availableOther biasLow riskThe trial authors declared that they had no conflicts of interest[@CD003650-bbs2-0015]MethodsCountry: Uganda\
Setting: outpatient clinic, Mackerere University College, Kampala\
Design: placebo‐controlled trial\
Duration of recruitment: April 2010 to June 2012\
Duration of follow‐up: 18 months\
Follow‐up: at baseline and at 3, 6, 12, and 18 months participants underwent a full clinical examination. In addition, assessments of the following was performed: complete blood counts, CD4 cell count, presence of syphilis, malaria, intestinal parasites, and nutritional status.ParticipantsInclusion criteria: HIV‐positive adults ≥ 18 yrs, initiation of ART at the time of randomization or on HAART for at least 6 months, intention to stay within 20 km of study site\
Exclusion criteria:Pregnancy, participants who were very ill\
Participants screened: 1134\
Participants eligible for randomization: 421\
Participants randomized: 400\
Mean age at randomization: 36.9 ± 9.6 years (intervention group) 34.7 ± 8.1 years (control group)\
123 male and 277 female\
Clinical characteristics, duration of ART, and multivitamin use similar at baseline.InterventionsIntervention (multivitamin group): daily tablet providing the following vitamins at the RDA level\
1.4 mg vitamin B1, 1.4 mg vitamin B2, 1.9 mg vitamin B6, 2.6 µg vitamin B12, 18 mg niacin, 0.4 mg folic acid, 70 mg vitamin C, 10 mg vitamin E\
Control: daily tablet consisting of placebo\
Duration: 18 months\
Compliance: assessed by research staff every month by recording participant self reported compliance and conducting pill counts. The trial authors did not report mean compliance.OutcomesPrimary: changes in CD4 cell count and weight, quality of life\
Secondary: changes in haemoglobin, blood ALT concentrations, development of a new or recurrent disease progression event including all‐cause mortality, hospitalization events, changes in ART from first‐ to second‐line therapyAdverse eventsA total of 550 adverse events were reported mostly related to nausea and vomiting, with no differences between treatment arms.\
The trial authors also reported 1 event of severe anaemia (Hb \< 7 g/dL) in the multivitamin group and 3 events of high ALT concentrations (\> 200 IU/L) (1 in multivitamin arm, 2 in placebo arm).NotesConflict of interest: none\
Source of funding: Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health research grant\
Ethics: Scientific Review Committee of the Infectious Diseases Institute at Makerere University College of Health Sciences and Institutional Review Boards of Harvard School of Public Health and Makerere University School of Public Health\
Trial registered at clinicaltrials.gov (NCT 1228578)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskPrior to initiation of the trial, a staff member at Harvard School of Public Health (HSPH) who was not associated with trial implementation generated serial numbers from 1 to 400 and randomly assigned participants to intervention or placebo groups, in blocks of 10.Allocation concealment (selection bias)Low riskTrial regimen bottles were labelled with serial numbers only. The trial pharmacist at the trial site dispensed the assigned regimen bottles to participants in sequential order of enrolment. The list that showed the trial arm linked to each serial number remained with the trial statistician at HSPH and was not accessible to trial staff in Uganda.Blinding (performance bias and detection bias) All outcomesLow riskTrial participants, staff, and investigators were blinded. The size, colouring, and packaging of the placebo was identical to the multivitamin tablet.Incomplete outcome data (attrition bias) All outcomesLow riskOverall attrition was low (8%) and was due to death (18/400), migration (7/400), withdrawal of consent (2/400), and loss to follow‐up (6/400).Selective reporting (reporting bias)Low riskThe primary and secondary outcomes were as reported, and were consistent with the trial protocol ([@CD003650-bbs2-0015]).Other biasLow riskThe trial authors declared they had no conflicts of interest. A non‐conflicting funding source funded the trial.[@CD003650-bbs2-0016]MethodsCountry: USA\
Setting: HIV clinic\
Duration of recruitment: January to July 1996\
Duration of follow‐up: 8 weeks\
Design: randomized placebo‐controlled safety trialParticipantsInclusion criteria: 18 to 45 years, CD4 \> 200 cells/mm³\
Exclusion criteria: pregnant or breastfeeding\
Participants randomized: 40 women\
Mean age (SD) in years = 36.2 (5.6) in vitamin A group and 33.2 (5.6) in placebo group\
Loss to follow‐up/withdrawal: 1\
Exclusions postrandomization: 0InterventionsIntervention: 300,000 IU vitamin A\
Control: placebo\
Duration: single doseOutcomesPrimary outcomes\
Viral loadT‐cell subsets (%CD4; % CD8 which are CD38+)\
Secondary outcomes:\
Vitamin A statusAdverse eventsSigns or symptoms of toxicity (headache, nausea, vomiting, diarrhoea, fever) similar in the intervention and control groups at 24 hours and 1 week after administration.NotesNumber of participants on ART\
Vitamin A group: 12 (60%)Control group: 7 (35%)\
Source of funding: Paediatric AIDS Foundation grant***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of random sequence generation used.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment used.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesLow riskOne participant was lost to follow‐up.Selective reporting (reporting bias)Unclear riskInsufficient information; the trial protocol was not available.Other biasUnclear riskThe trial authors did not declare on conflicts of interest, if any[@CD003650-bbs2-0017]MethodsCountry: USA\
Setting: university clinic\
Duration of recruitment: June 2001 to July 2005\
Duration of follow‐up: 9 months\
Design: randomized placebo controlled trialParticipantsInclusion criteria: aged 18 to 55 years; no history of major systemic disorders related to HIV; premenopausal and not pregnant\
Exclusion criteria: on treatment for chronic conditions; selenium deficient\
Participants randomized: 310\
Mean age = 40.5 years\
179 male and 86 female\
Loss to follow‐up/withdrawal: 88\
Exclusions postrandomization: 48 pretreatmentInterventionsIntervention: selenium (200 µg)\
Control: placebo\
Duration: daily for 9 monthsOutcomesPrimary outcomes\
Viral loadCD4 countSerum seleniumAdverse eventsNoneNotesParticipants on ART: 105/141 (74%) in selenium group; 87/121 (72%) in placebo group\
Preliminary analysis at 9 months of an 18‐month trial\
Source of funding: National Institutes of Health***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used computerized block randomization.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment used.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesUnclear riskThere were high unexplained losses to follow‐up, which were balanced between groups. The trial authors performed imputational analyses.Selective reporting (reporting bias)High riskThe trial only reported data on main study outcomes for subgroups of participants (selenium responding versus non‐responding participants).Other biasLow riskThe trial authors declared they had no conflicts of interest.[@CD003650-bbs2-0018]MethodsCountry: Tanzania\
Setting: outpatient HAART clinics\
Duration of recruitment: November 2006 to November 2008\
Median duration of follow‐up: 15 months (IQR 6 to 19)\
Design: RCT\
Follow‐up: full clinical examination and HIV disease staging (WHO staging criteria) of participants conducted at baseline and thereafter monthly by trial physicians. Occurrence of any illness in the previous month recorded by trial nurses at baseline and thereafter monthly. They also performed anthropometric measurements (height, weight, waist, hip, mid‐thigh, mid‐arm circumference) at baseline and monthly thereafter. Bloods were taken from participants at baseline and every 4 months for T cell counts, full blood count, and ALT. HIV viral load was determined at the same time intervals, but was subject to the availability of reagents. Dietary intake was assessed at baseline and every 12 months.\
Participants were followed up monthly until the date of death, loss to follow‐up, or early study closure (refer to section on adverse events). Cause of death was determined by the use of medical records and standard verbal autopsy techniques by 2 HIV clinicians who had to reach consensus.ParticipantsInclusion criteria: men and women with HIV‐infection initiating ART (WHO Stage 4 HIV disease and CD4 count \< 200; WHO Stage HIV infection and CD4 count \< 350), intention to stay in Dar es Salaam for at least 2 years\
Exclusion criteria: pregnant or lactating women\
Participants randomized: 3418\
Mean age at randomization: 37.8 ± 8.6 years (high‐dose group) versus 38.4 ± 8.6 years (standard‐dose group)\
1141 female, 569 male (high‐dose group) versus 1181 female, 527 male (standard‐dose group)InterventionsIntervention (high‐dose group): micronutrient tablet daily containing 8 different micronutrients at multiple levels of the Recommended Daily Allowance (RDA): thiamine 20 mg, riboflavin 20 mg, vitamin B6 25 mg, niacin 100 mg, vitamin B12 50 µg, folic acid 0.8 mg, vitamin C 500 mg, vitamin E 30 mg\
Control (standard‐dose group): micronutrient tablet daily containing 8 different micronutrients at single level of the RDA: thiamin 1.2 mg, riboflavin 1.2 mg, vitamin B6 1.3 mg, niacin 15 mg, vitamin B12 2.4 µg, folic acid 0.4 mg, vitamin C 80 mg, vitamin E 15 mg\
The intervention and control tablets were indistinguishable in terms of appearance and taste.\
Duration: minimum of 24 months\
Compliance: determined by the number of tablets absent from the returned bottles every month divided by the number of the tablets the participant should have taken. Mean compliance was reported as 90% for both treatment groups (no variance reported).\
Co‐intervention: cotrimoxazole prophylaxis if CD4 count \< 200 in all participantsOutcomesPrimary: all‐cause mortality, HIV disease progression (new or recurrent episode of HIV disease according to the WHO Clinical Staging system)\
Secondary: AIDS‐related mortality (due to *Pjiroveci* pneumonia, pulmonary tuberculosis, extrapulmonary tuberculosis, Kaposi sarcoma, wasting, HIV/AIDS with opportunistic infection, invasive cervical carcinoma), changes in CD4 count, HIV viral load, BMI, haemoglobinAdverse eventsPreliminary data analysis after 1 year after the start of the trial (November 2008) indicated an increased mortality risk with high‐dose supplementation. Subsequently, all participants received standard dose supplements up to March 2008 when it was determined that the increased mortality risk was restricted to severely malnourished participants (BMI \< 16).\
These participants were subsequently excluded from enrolment and those who had been enrolled received standard dose supplementation. Since 612 participants enrolled in this period did not fulfil the eligibility criteria of the trial protocol, the sample size was increased.\
However, the trial was terminated prematurely in March 2009 because of evidence of increased ALT levels among participants receiving the high‐dose supplement.\
Other adverse events reported include during the trial included fatigue, nausea or vomiting, diarrhoea, severe anaemia, peripheral neuropathy, rashes or lesions and genital discharge or sores.NotesSource of funding: National Institute of Child Health\
Conflict of interest: none\
Ethics: Harvard School of Public Health, Muhimbili University of Health and Allied Sciences, Tanzania Food and Drugs Authority, and National Institute of Medical Research\
Trial registered at clinicaltrials.gov (NCT00383669)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a computer‐generated randomization sequence in blocks of 20.Allocation concealment (selection bias)Low riskIndependent pharmacists performed sequential numbering of trial supplements. At each research site participants were allocated to the next numbered bottle at that site.Blinding (performance bias and detection bias) All outcomesLow riskThe trial authors reported the participants and research staff as blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskOverall loss to follow‐up was not reported. The trial authors only analysed viral load for a subset (7%) of trial participants and therefore this outcome was judged to be at high risk of attrition bias.Selective reporting (reporting bias)Low riskThe primary and secondary outcomes as reported, as well as the reported changes to the trial protocol, are consistent with the trial protocol at [www.clinicaltrials.gov](www.clinicaltrials.gov).Other biasHigh riskTrial was stopped early due to evidence of increased levels of ALT in the high‐dose group.[@CD003650-bbs2-0019]MethodsCountry: Thailand\
Setting: outpatient clinic\
Duration of recruitment: March 2000 to January 2001\
Duration of follow‐up; 48 weeks\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria: older than 18 years; 50 \< CD4 \< 550\
Exclusion criteria: taking ARV or micronutrients for during month prior to enrolment\
Participants randomized: 481 (stratified according to CD4 cell count \< 200 cells/mm³ and ≥ 200 cells/mm³)\
189 male and 292 female\
Mean age = 32 years\
Loss to follow‐up/withdrawal: 79 at 48 weeks\
Exclusions postrandomization: 0InterventionsIntervention: micronutrient supplement (3000 µg vitamin A, 6 mg beta‐carotene, 20 µg vitamin D, 80 mg vitamin E, 180 µg vitamin K, 400 mg vitamin C, 24 mg vitamin B1, 15 mg vitamin B2, 40 mg vitamin B6, 30 µg vitamin B12, 0.1 mg folic acid, 40 mg pantothenic acid, 10 mg iron, 200 mg magnesium, 8 mg manganese, 30 mg zinc, 300 µg iodine, 3 mg copper, 400 µg selenium, 150 µg chromium, 60 mg cysteine)\
Control: placebo\
Duration: twice daily for 48 weeks.OutcomesPrimary outcomes\
MortalityHospital admissions\
Secondary outcomes\
CD4 countsViral loadAdverse eventsA total of 137 minor adverse events such as dizziness, drowsiness, nausea, and rash reported, with more participants in the intervention arm who reported urine discolouration (P \< 0.001)NotesSource of funding: Nestle Foundation; Vitabiotics***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used centralized randomization in blocks of 10.Allocation concealment (selection bias)Low riskInterventions were packaged in identical coded bottles.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskAttrition was low overall (12/242 in the treatment group and 3/239 in the placebo group). Similar baseline median CD4 cell counts among participants from both treatment groups who were lost to follow‐up. The trial authors used survival analysis to address missing outcome data. However, the trial authors only analysed viral load for a subset (29%) of trial participants and so we judged this trials to be at high risk of attrition bias for this outcome.Selective reporting (reporting bias)Unclear riskInsufficient information; the trial protocol was not available.Other biasLow riskThe trial authors provide a declaration on no conflicts of interest.[@CD003650-bbs2-0020]MethodsCountry: Rwanda\
Setting: 2 outpatient facilities\
Design: placebo‐controlled trial\
Duration of recruitment: not stated\
Duration of follow‐up: 24 months\
Follow‐up: trained nursing practitioners will collect clinical, nutritional, and psychosocial data at baseline and at 6, 12, 18, and 24 months. Blood samples will also be taken for CD4 cell count and viral load measurements at these time intervals.ParticipantsInclusion criteria: HIV‐positive adults aged ≥ 21 years, ART‐naive with CD4 cell counts 400 to 650 cells/mm³, HIV‐positive women willing to practice barrier method of birth control, intention to remain in clinic catchment area for study period\
Exclusion criteria: pregnancy\
Participants screened: 2680\
Participants eligible for randomization: 300\
Participants randomized: 300\
Mean age at randomization: 33 years (median) IQR 28 to 39 years (intervention group); 35 years (median) IQR 28 to 41 years (control group)\
98 male and 202 female\
Sociodemographic characteristics, CD4 cell count, HIV viral load, BMI similar at baseline.InterventionsIntervention: 1 tablet containing 200 µg selenium (in the form of selenomethionine) daily\
Control: 1 placebo tablet daily\
Duration: 24 months\
Compliance: adherence counselling provided at baseline and every month. The trial authors did not report mean compliance data.OutcomesPrimary: composite of the following: reduction in CD4 cell count \< 350 cells/mm³ or start of ART or development of AIDS‐defining illness\
Secondary: viral load at 6, 12, 18, and 24 months, quality of life, weight gain, presence of opportunistic infections, mortalityAdverse eventsMost participants did not report any symptoms. Self‐reported symptoms included nausea, vomiting, skin or hair changes or both, and changes in emotional status. Participants in the selenium group were more likely to report anxiety (41 events versus 16 events in the placebo group; P = 0.04) and sleep symptoms (36 events versus 15 events in the placebo group, P = 0.01).NotesSource of funding: Global Benefit, Canada. Micronutrient supplement supplied by a nutraceutical company (CanAlt labs and Seroyal)\
Conflict of interest: none\
Ethics: institutional review boards of the Canadian College of Naturopathic Medicine and Wilfred Laurier University in Canada, and the National Ethics Committee (NEC) in Rwanda.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe research department of the manufacturing company prepared the randomization schedule using a simple randomization block design, but the trial authors did not specify the method of sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors stated that each participant was assigned to a unique study identification number. Sequential numbering and allocation was not explicitly stated. They also stated that an unblinded allocation list was provided to the treatment provider and an independent statistician for the purpose of conducting an interim analyses.Blinding (performance bias and detection bias) All outcomesUnclear riskThe trial authors did not specify whether blinding was performed, except for participants who received identical supplements.Incomplete outcome data (attrition bias) All outcomesLow riskAttrition was 6% in both treatment groups (9/151 in the selenium group and 9/149 in the placebo group). Reasons for attrition included death (n = 2), migration (n = 9) and loss to follow‐up (n = 7). The trial authors stated that 10 participants (4 in the selenium group and 6 in the placebo group) were not included in their primary analyses.Selective reporting (reporting bias)Low riskPrimary and secondary outcomes are consistent with the trial protocol ([@CD003650-bbs2-0020]).Other biasLow riskAlthough the pharmaceutical industry provided the trial supplements, the trial authors included a statement of no conflicts of interest.[@CD003650-bbs2-0021]MethodsCountry: Zambia\
Setting: home care service of tertiary hospital\
Duration of recruitment: not stated\
Duration of follow‐up: 4 weeks\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria: adults with persistent diarrhoea for more than 1month\
Exclusion criteria: \< 18 years, pregnancy, administration of antibiotics in the week prior to recruitment, Karnofsky scores \> 80 or \< 50.\
Participants randomized: 135\
79 male and 56 female\
Median age = 32.5 years (micronutrient); 34 (placebo)\
Loss to follow‐up/withdrawal: 29\
Exclusions postrandomization: 0InterventionsIntervention: micronutrient supplement (10,500 IU vitamin A, 300 mg vitamin C, 300 mg vitamin E, 150 µg selenium and 200 mg zinc sulphate) Both treatment groups also received 5 mg folic acid and 800 mg albendazole twice daily.\
Control: placebo\
Duration: daily for 2 weeksOutcomesPrimary outcomes\
Recovery from diarrhoeaPatient weeks with and without diarrhoea during 12 weeks\' follow‐upRemission at 4 weeksAll‐cause mortality during first 4 weeksChange in BMI and mid‐upper arm circumference (MUAC)Change in Karnofsky score\
Secondary outcomes\
Changes in CD4 and CD8 counts at 4 weeksChanges in serum vitamin A and E after 4 weeksAdverse eventsNoneNotesSource of funding: Smithkline Beecham***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of random sequence generation used.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment used.Blinding (performance bias and detection bias) All outcomesHigh riskMicronutrient and placebo capsules were not identical; it was unclear whether providers and assessors were blinded to treatment.Incomplete outcome data (attrition bias) All outcomesHigh risk25% of participants were lost to follow‐up due to death and the tradition of going back to the family home when terminally ill.Selective reporting (reporting bias)Unclear riskThere was insufficient information; the trial protocol was not availableOther biasUnclear riskThe trial authors did not provide a declaration on conflicts of interest.[@CD003650-bbs2-0022]MethodsCountry: Zambia\
Setting: Misisi township, Lusaka, Zambia\
Duration of trial: August 2003 to December 2006 (41 months)\
Duration of follow‐up: 38 months\
Design: cluster randomized cross‐over trial (cluster randomization by household)\
Follow‐up: trained nurses recorded episodes of diarrhoea and cough every 2 weeks. Nutritional status (height, weight, MUAC, body impedance) and household hygiene (score) were assessed at 6, 14, 22, and 38 monthsParticipantsInclusion criteria: all adult (≥ 18 years) residents\
HIV status: HIV‐positive (n = 136); HIV negative (n = 224), and unknown HIV‐status (n = 140)InterventionsMembers of the same household received the same treatment allocation\
Intervention: multiple micronutrient tablet once daily (β‐carotene 4.8 mg; 1.4 mg vitamin B1, 1.4 mg vitamin B2, 1.9 mg vitamin B6, 2.6 µg vitamin B12; 18 mg niacin; 70 mg vitamin C; 10 mg vitamin E; 0.4 mg folic acid; 30 mg iron; 15 mg zinc; 2 mg copper; 65 µg selenium and 150 µg iodine)\
Control: placebo tablet once daily (supplement and placebo tablets identical in appearance and taste\
Duration: 1.9 years to trial cross‐over; thereafter 1.5 years\
Adherence: unused trial supplements were retrieved monthly. Median compliance reported as \> 95% (variance not reported) at the crossover point.OutcomesPrimary outcome\
Incidence of diarrhoea\
Secondary outcomes\
Incidence of severe diarrhoeal episodesIncidence of respiratory infection (cough)Changes in CD4 count of HIV‐positive participantsChanges in nutritional statusMortalityAdverse eventsFour cases of pellagra occurred in the placebo group; 3 of whom were associated with high ethanol intakesNotesSource of funding: Wellcome trust\
Ethics: University of Zambia Research Ethics Committee; London School of Hygiene and Tropical Medicine Research Ethics Committee\
Trial registration: ISRCTN 31173864\
Conflict of interest: declared no conflict of interest. None of the authors had any financial interest in manufacturing or licensing of any micronutrient formulation.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial statistician generated the random number sequence for the selection of households.Allocation concealment (selection bias)Low riskOnly the statistician and manufacturers had access to the trial code. The supplements were supplied in precoded, sealed plastic bottles.Blinding (performance bias and detection bias) All outcomesLow riskParticipants, investigators, and assessors were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskThere were high rates of attrition (30% before cross‐over; 42% at trial completion); the trial authors did not state the attrition rates for each treatment group.Selective reporting (reporting bias)Low riskAll the outcomes as reported are consistent with the trial protocol from [www.controlled‐trials.com](www.controlled‐trials.com), except for all‐cause mortality.Other biasLow riskThe trial authors declared that they had no conflicts of interest.\
Recruitment bias: households were randomized, all participating members of each household received the same treatment allocation.\
Baseline imbalance: randomization was stratified by household size\
Loss of clusters: attrition of clusters was not reported.[@CD003650-bbs2-0023]MethodsCountry: Nigeria\
Setting: 8 district hospitals, Abuja, Nigeria\
Duration of recruitment: September 2003 to June 2005\
Duration of trial:Not stated\
Duration of follow‐up: 6 months\
Design: randomized placebo‐controlled factorial trial with three intervention arms\
Follow‐up :Blood samples (complete blood count, erythrocyte sedimentation rate (ESR) and biochemical tests) and three sputum samples and a chest X‐ray, were conducted at enrolment. Sputum specimens were collected weekly for the first 8 weeks of therapy and again at 12, 16, 20 and 24 weeks. Blood samples and chest X‐rays were repeated at 2 and 6 month follow‐up.ParticipantsInclusion criteria: HIV‐positive and HIV‐negative adults aged \> 15 years with sputum positive pulmonary tuberculosis\
Exclusion criteria: previous antituberculous therapy, pregnancy, lactation, use of corticosteroids or zinc in the previous month, major surgery in the previous month, diabetes, severe cardiovascular or hepatic disease, currently taking oral contraceptives, unable to return\
Participants screened: 1321 (399 smear‐positive)\
Participants eligible for randomization: 350\
Participants randomized: 350 (155 HIV‐positive participants not stratified)\
Mean age at randomization: 29 to 34 years\
The mean BMI was greater in the zinc group at baseline:21.3 ± 4.7 versus 19.6 ± 3.5 (zinc and vitamin A group) versus 19.8 ± 3.3 (placebo group)InterventionsIntervention: 90 mg elemental zinc plus retinol (5000 IU) weekly or 90 mg elemental zinc plus placebo weekly\
Control: duel placebo (similar in appearance) weekly\
Duration: 6 months\
Adherence: all participants received their supplements under direct observation for the first 2 months together with standard antituberculous treatment (2RHZE/4HE). Monthly supplies were then given for the following 4 months.OutcomesPrimary outcomes: sputum conversion, CXR scores\
Secondary outcomes: clinical symptoms, BMI, Karnofsky score, deaths, ESR, haemoglobinAdverse eventsTwo major adverse events (participants withdrawn from trial)NotesSource of funding: none stated\
Conflict of interest: no statement included\
Ethics: Liverpool School of Tropical Medicine Research Ethics Committee, Zankli Medical Centre Institutional Review Board\
Trial registration: ISRCTN36636609***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskTreatment allocation into three supplement groups was performed at the Liverpool School of Tropical Medicine using permuted block randomization with 4 different block sizes. Random numbers generated by Minitab with block randomization using 4 different block sizes.Allocation concealment (selection bias)Low riskAn investigator who was not on site prepared the allocation sequence. Treatment assignments were prepared in serially numbered sealed envelopes. Sequentially numbered packets were assigned consecutively to participants according to allocation sequence.Blinding (performance bias and detection bias) All outcomesLow riskInvestigators, participants, and the laboratory staff were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskLoss to follow‐up of HIV‐positive participants at 6 months was not balanced between treatment groups: zinc group 16 % (8/56); zinc and vitamin A group 23% (11/47); and placebo group: 30% (16/52).Selective reporting (reporting bias)Low riskPrimary outcomes reported were consistent with the trial protocol (ISRCTN36636609).Other biasUnclear riskThe trial authors did not provide any conflict of interest statement.[@CD003650-bbs2-0024]MethodsCountry: Kenya\
Setting: outpatient clinics at Coast Provincial General Hospital, Mombasa\
Duration of recruitment: September 1998 to June 2000\
Duration of trial: 22 months\
Duration of follow‐up: 6 weeks\
Design: randomized placebo‐controlled trial\
Follow‐up: at the 6 week follow‐up visit participants underwent a physical examination and bloods and genital tract specimens were collected (as before at baseline)ParticipantsInclusion criteria: women (18 to 45 years) with HIV‐1 infection\
Exclusion criteria: women who were pregnant or the use of vitamin supplements or oral contraceptives during 3‐month period before study entry\
Participants screened: 2021\
Participants eligible for randomization: 650\
Number randomized: 400 (plus 200 participants in vitamin A arm)\
Mean age: 29 ± 7 years (micronutrient group) versus 29 ± 6 years (placebo group)\
No participant received ART. It is reported that CD4 cell count and vaginal HIV shedding were higher in the micronutrient group (statistical significance not shown).InterventionsIntervention: micronutrient supplement (20 mg vitamin B1, 20 mg vitamin B2, 25 mg vitamin B6, 50 µg vitamin B12; 100 mg niacin; 500 mg vitamin C; 30 mg vitamin E; 0.8 mg folic acid; 200 µg selenium) administered as a hard gel capsule daily.\
Control: placebo (supplement and placebo capsules identical in appearance)\
Duration: daily for 6 weeks\
Compliance: reported as the proportion of participants in each treatment group who took 95% of scheduled doses (micronutrient group: 93.7% (168/179); control group: 92.1% (164/178). Supplements were dispensed with an electronic alarm vial.OutcomesPrimary outcomes: vaginal and cervical HIV‐1 shedding\
Secondary outcomes: CD4, CD8 cell count, viral loadAdverse eventsMultivitamin supplementation increased cervical and vaginal shedding of HIV‐positive cellsNotesSource of funding: National Institutes of Health and University of Washington Clinical Nutrition Research Unit\
Conflict of interest: statement not included\
Ethics: University of Nairobi, University of Washington\
Trial registration: not specified***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used computer‐generated randomization sequence in blocks.Allocation concealment (selection bias)Unclear riskIt was unclear who was responsible for the allocation of treatment (sequential numbering of medication bottles not specified).Blinding (performance bias and detection bias) All outcomesUnclear riskBlinding was not specified except for participants who received identical capsules.Incomplete outcome data (attrition bias) All outcomesUnclear riskTwenty‐one(10.5%) and 22(11%) participants were lost to follow‐up from the multivitamin and placebo groups respectively. However, the trial authors did not state the reasons for loss to follow‐up. Participants who were lost to follow‐up had lower CD4 cell counts compared to those who completed the trial, but cell counts were not reported for each treatment group.Selective reporting (reporting bias)Unclear riskThe trial protocol was not availableOther biasUnclear riskThe trial authors did not provide any statement regarding conflicts of interest.[@CD003650-bbs2-0025]MethodsCountry: USA\
Setting:39 AIDS Clinical trials network research units\
Duration of recruitment: September 2011 to February 2012\
Duration of trial: 48 weeks\
Duration of follow‐up: 48 weeks\
Design: randomized placebo‐controlled trial\
Follow‐up: blood samples at enrolment, 24 and 48 weeks; DXA scan at enrolment and again at 48 weeksParticipantsInclusion criteria: HIV‐positive people who were not on ART with viral load \> 1000 copies/mL and blood 25 (OH) vitamin D level ≥ 10 and \< 75 ng/mL, creatinine clearance ≥ 60 mL/min and serum calcium \< 10.5 mg/dL.\
Exclusion criteria: participants taking daily supplements containing calcium and vitamin D exceeding 500 mg and 800 IU respectively, any biphosphonate therapy, recent steroid or chemotherapy treatment, thyroid disease, substance or alcohol abuse, a history of fragility fracture, osteoporosis or nephrolithiasis or weight \> 300 lb. Pregnant and lactating women were also excluded.\
Participants screened: 218\
Participants eligible for randomization: 183\
Number randomized: 167\
Mean age: 36 years (IQR 28 to 47) (vitamin D/calcium group) versus 31 years (IQR 25 to 44) (placebo group)\
Two participants from the vitamin D/calcium group had protocol violations due to the incorrect screening vitamin D assay being performed. The trial authors did not include this data in the analyses.InterventionsIntervention: 4000 IU vitamin D3 daily plus 500 mg calcium carbonate twice daily with food\
Control: placebo daily plus placebo twice daily with food (identical in appearance)\
Duration: daily for 48 weeks\
Compliance: all participants were initiated on first line ART (EFV/FTC/TDF)OutcomesPrimary: change in total hip bone mineral density (BMD)\
Secondary: changes in lumbar spine BMD, 25(OH) vitamin D levels, parathyroid hormone (PTH), markers of bone turnover, and other inflammatory biomarkers and CD4 cell counts at 24 and 48 weeksAdverse eventsNo differences were observed between the treatment groups in terms of reported adverse events during the study period. Vitamin D/calcium group (33 Grade 1‐2 events, 15 Grade 3 events, and 2 Grade 4 events) and placebo group (33 Grade 1‐2 events, 15 Grade 3 events, and 5 Grade 4 events). No cases of hypercalcaemia were reported. One death in the Vitamin D/calcium group was reported in the context of rapid HIV disease progression.NotesSource of funding: National Institute of Allergy and Infectious Diseases. The pharmaceutical industry provided supplements and placebos\
Conflict of interest: none\
Ethics: Institutional Review Boards of all participating research sites\
Trial registration: NCT 01403051***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors reported block randomization stratified for baseline 25(OH) vitamin D levels (≤ 20 and \> 20 ng/mL), but the trial authors did not specify the method of generation randomization sequence.Allocation concealment (selection bias)Unclear riskThe trial authors did not report the details regarding the allocation of study supplements.Blinding (performance bias and detection bias) All outcomesUnclear riskBlinding not specified except for participants who received identical supplements.Incomplete outcome data (attrition bias) All outcomesLow riskOverall attrition was 9% (15/167). Reasons for attrition include death (n = 1), non‐adherence to treatment/study visits (n = 2), withdrew consent (n = 1), or lost to follow‐up (n = 11).Selective reporting (reporting bias)Low riskPrimary and secondary outcomes reported were consistent with trial protocol (NCT 01403051).Other biasHigh riskThe pharmaceutical industry sponsored ARTs and supplements, industry representatives served on the study team and reviewed manuscript prior to publication, thus there was a potential conflict of interest.[@CD003650-bbs2-0026]MethodsCountry: Tanzania\
Setting: 5 district health facilities\
Duration of recruitment: August 2001 to July 2002\
Design: placebo‐controlled 2 x 2 factorial trialParticipantsInclusion criteria: HIV‐positive and HIV‐negative people aged ≥15 years with sputum‐positive pulmonary tuberculosis (new or relapsed cases)\
Exclusion criteria: participants who defaulted tuberculosis chemotherapy or those who remained smear‐positive on chemotherapy (failure cases) and those with serious tuberculosis or other disease unlikely to survive; pregnant and lactating women.\
Participants randomized: 530\
213 HIV‐positive\
325 male and 205 female\
Mean age = 35.4 years\
Participants analysed: 499\
Loss to follow‐up/withdrawal: 77 within 244 days post‐treatment\
Exclusions postrandomization: 31InterventionsInterventionS: micronutrient supplement contained vitamin A (1.5 mg), vitamin B1 (20 mg), vitamin B2 (20 mg), vitamin B6 (25 mg), vitamin B12 (50mg), folic acid (0·8 mg), niacin (40 mg), vitamin C (200 mg), vitamin E (60 mg), vitamin D3 (5 mg), selenium (0·2 mg) and copper (5 mg), and zinc tablets contained 45 mg elementary zinc\
Control: placebo (2 x 2 factorial)\
Duration: daily for 8 months.\
All participants received a standard 8 month tuberculosis chemotherapy regimen.OutcomesPrimary outcomes\
All‐cause mortality at 8 months\
Secondary outcomes\
Viral loadCD4 countsWeight gainAdverse eventsNone reportedNotesSource of funding: Danish International Development Assistance***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputerized randomization.Allocation concealment (selection bias)Low riskSealed envelopes, codes unbroken until post‐analysisBlinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blindedIncomplete outcome data (attrition bias) All outcomesHigh riskDifferential attrition rates between treatment groups \> 10% \[Zinc group: 10.3% (6/58); Multivitamin/mineral group: 23.7% (14/59); Multivitamin/mineral plus zinc group: 12.5 % (6/48) Placebo group: 12.5% (6/48)\]Selective reporting (reporting bias)Unclear riskInsufficient information; study protocol not availableOther biasUnclear riskRandomization was not stratified by HIV‐status of participants. Declared no conflict of interest[@CD003650-bbs2-0027]MethodsCountry: USA\
Setting: community‐based clinic\
Duration of recruitment: not stated\
Duration of follow‐up: 4 weeks\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria: HIV‐positive intravenous drug users participating in ALIVE (AIDS Linked to Intravenous Experiences) Cohort (N = 630); ≥ 18 years; not taking vitamin A supplements\
Exclusion criteria: CD4 \> 500 cells/mm³; pregnancy.\
Participants randomized: 120\
89 male and 31 female\
Mean age = 38.2 years\
50% treatment group versus 43% placebo group on ART\
Loss to follow‐up/withdrawal: 8.3% at 4 weeks\
Exclusions postrandomization: 0InterventionsIntervention: single dose of 200 000 IU vitamin A\
Control: placeboOutcomesPrimary outcomes\
Viral loadCD4 count\
Secondary outcomes\
Serum vitamin AAdverse eventsNone reportedNotesSource of funding: USAID***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used a random number table in blocks of 10.Allocation concealment (selection bias)Low riskThe trial used sequentially numbered envelopes to conceal allocation.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesLow riskMissing outcome data were balanced across groups.Selective reporting (reporting bias)Unclear riskThere was insufficient information; the trial protocol was not available.Other biasUnclear riskThe trial authors did not provide any declaration regarding conflicts of interest.[@CD003650-bbs2-0028]MethodsCountry: Malawi\
Setting: 8 community health centres\
Duration of recruitment: July 1999 to October 2004\
Design: placebo‐controlledParticipantsInclusion criteria: HIV‐positive and HIV‐negative adults with smear‐positive pulmonary tuberculosis (new cases)\
Exclusion criteria: prior or current tuberculosis chemotherapy, prior vitamin supplements\
Participants randomized: 1148\
829 HIV‐positive\
336 male and 493 female\
Mean age = 34 years\
Participants analysed: 1148\
Loss to follow‐up: 103 in HIV‐positive group (50 and 53 in micronutrient and placebo groups, respectively)\
Exclusions postrandomization: 0InterventionsIntervention: micronutrient supplement (vitamin A, C, D, E, B6, B12, riboflavin, thiamine, niacin, folate, zinc, iodine, selenium)\
Control: placebo\
Duration: daily for 24 months.\
All participants received a standard 8‐month tuberculosis chemotherapy regimen.OutcomesPrimary outcomes\
All‐cause mortality\
Secondary outcomes\
Serum vitamin A, vitamin E, and seleniumAdverse eventsNot reportedNotesSource of funding: National Institutes of Health and the Fogarty International Centre.***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used blocked randomization.Allocation concealment (selection bias)Low riskThe trial used prepacked sequentially numbered supplements.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskThe attrition rates were greater than 10% and the trial authors did not report the reasons for loss to follow‐up (supplement group 12.3%; placebo group 12.5%)Selective reporting (reporting bias)Low riskThe trial protocol was available; the trial authors reported on all outcomes of interest.Other biasUnclear riskThe trial authors did not stratify randomization by HIV status of participants. The trial authors did not declare their conflicts of interest, if any.[@CD003650-bbs2-0029]MethodsCountry: USA\
Setting: study clinic\
Duration of recruitment: September 2002 to August 2005\
Design: controlled trialParticipantsInclusion criteria: women ≥ 18 years; history of injection drug use (IDU) within past 10 years; hepatitis C (HCV) antibody‐positive; Karnofsky status \> 80%; serum ferritin \< 200 ng/mL\
Exclusion criteria: pregnant; history of liver failure, renal disease, interferon therapy for HCV; haemochromatosis; blood disorders\
Participants randomized: 458\
Mean age = 40 years\
138 (30.1%) HIV‐positive\
Participants analysed: 115 at 12 months\
Loss to follow‐up/withdrawal:151 (33%)\
Exclusions postrandomization: 0InterventionsIntervention: micronutrients with iron (18 mg)\
Control: micronutrients only\
Duration: daily for 12 monthsOutcomesPrimary outcomes\
HaemoglobinIron statusPlasma HCVViral loadLiver enzymesAdverse eventsNot reportedNotesOn HAART: 27/69 (intervention) and 23/69 (control)\
Trial stopped early due to slow recruitment.\
Source of funding: National Institute on Drug Abuse; National Institute on Nursing Research***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial used computerized randomization.Allocation concealment (selection bias)Low riskThe trial used prepacked sequentially numbered study supplements.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesHigh riskThere was high loss to follow‐up (27.7%) in both groups, and the trial authors did not report this information by HIV status.Selective reporting (reporting bias)Unclear riskThere was insufficient information; the trial protocol was not available.Other biasUnclear riskThe trial authors did not provide a declaration on conflicts of interest.[@CD003650-bbs2-0030]MethodsCountry: USA\
Setting: Children's Hospital of Philadelphia, Philadelphia\
Duration of recruitment: July 2011 to June 2013\
Duration of follow‐up: 12 months\
Design: randomized placebo‐controlled trial\
Follow‐up: participants were followed up at 3, 6, and 12 months. At each visit adverse events and compliance were recorded. Blood and urine measurements were also performed for vitamin D (25‐Hydroxy vitamin D, 1,25 Dihydroxy vitamin D), calcium, metabolic parameters, and immunological parameters.ParticipantsInclusion criteria: perinatally acquired HIV infection (PHIV), 5.0 to 24.9 year or behaviorally‐acquired HIV infection (BHIV), 15.0 to 24.9 years; usual state of good health 2 weeks before study entry\
Exclusion criteria: other adverse growth, dietary intake, or nutritional status conditions, pregnancy, lactation, and use of vitamin D3 supplements. If Vitamin D3 supplements were discontinued, participants underwent a 2‐week wash‐out period before trial entry.\
Participants screened: 121\
Participants eligible for randomization: 58\
Participants randomized: 58 (stratified by PHIV/BHIV)\
Mean age at randomization: 20.7 ± 3.7 years\
76% of participants on HAART (vitamin D group:23/30 (77%); placebo group 21/28 (75%))\
The trial authors reported no statistically differences in baseline disease characteristics, vitamin D status, dietary intake, or metabolic parameters.InterventionsIntervention: 7000 IU vitamin D3 daily (those unable to swallow capsules took 0.49 mL daily of 400 IU vitamin D3 drops)\
Control: placebo capsules (those unable to swallow capsules took 0.49 mL daily of placebo drops)\
Duration: 12 months\
Compliance: residual capsules or volume (in the case of drops) were recorded at follow‐up visits. Mean adherence was 92 ± 8% over 12 months with no differences between groups.OutcomesPrimary: blood 25‐Dehydroxy vitamin D levels\
Secondary: HIV load (among participants with a detectable viral load), CD4%Adverse eventsFour participants in the placebo group were withdrawn from the study after 6 months according to prespecified criteria (3 consecutive 25 (OH) vitamin D values \< 11 ng/mL). No participant experienced the predefined serious adverse event of 25 (OH) vitamin D levels \> 80 ng/mL at any time during the follow‐up period. Serum calcium levels increased from 9.5 ± 0.4 to 9.6 ± 0.4 mg/dL after 12 months in the vitamin D group.NotesSource of funding: NIH/National Center for Complementary and Alternative Medicine,National Center for Research Resources, National Center for Advancing Translational Sciences\
Conflict of interest: the trial authors declared no conflict of interest.\
Ethics: Children\'s Hospital of Philadelphia Institutional Review Board\
Trial registration: clinicaltrials.gov (NCT 01475890)***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors stated that participants were randomized in parallel (1:1 ratio) to receive the intervention of the placebo.Allocation concealment (selection bias)Unclear riskThe trial authors did not provide any information in terms of how study supplements were numbered and allocated to participants.Blinding (performance bias and detection bias) All outcomesUnclear riskThe trial authors referred to a \"double blind\" study but it was unclear who was blinded.Incomplete outcome data (attrition bias) All outcomesLow riskAttrition rates were 10% (3/30) in vitamin D group versus 17% (5/28) in placebo group. Three participants were lost to follow‐up (without reasons) in the vitamin D group and 1 participant in the placebo group. Four participants from the placebo group were withdrawn from study (according to prespecified withdrawal rules).Selective reporting (reporting bias)Low riskThe primary outcomes as reported were consistent with the trial protocol from [www.clinicaltrials.gov](www.clinicaltrials.gov).Other biasLow riskThe trial authors declared no conflicts of interest.[@CD003650-bbs2-0031]MethodsCountry: Tanzania\
Setting: 5 outpatient tuberculosis clinics\
Duration of recruitment: April 2000 to April 2005\
Median duration of follow‐up: 30 months (IQR 15 to 41)\
Design: randomized placebo‐controlled trialParticipantsInclusion criteria: HIV‐positive and HIV‐negative adults aged 18 to 65 years with positive sputum smears for acid‐fast bacilli who planned to stay in Dar es Salaam for 2 years\
Exclusion criteria: pregnancy, antituberculosis treatment for \> 4 weeks in previous year, Karnofsky score \< 40%\
HIV‐positive participants randomized: 471\
273 male and 198 female\
Mean age = 34 years\
Loss to follow‐up: 67 in HIV‐positive group (33 and 34 in micronutrient and placebo groups, respectively)\
Exclusions postrandomization: 0InterventionsIntervention: micronutrient supplement (retinol; vitamins B1, B2, B6, B12; niacin; vitamin C; vitamin E; folic acid; selenium)\
Control: placebo\
Duration: daily for 24 months.\
All participants received DOTS antituberculosis chemotherapy.OutcomesPrimary outcomes\
Culture negativity at 1 month after initiation of treatment; mortality during at least 24 months of follow‐up; tuberculosis recurrences.\
Secondary outcomes\
Changes from baseline in viral load, CD4 cell counts, and body weight.Adverse eventsNone reportedNotesSource of funding: National Institute of Allergy and Infectious Diseases; US Department of Agriculture***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used computer‐generated permuted blocks of 20. Randomization was stratified by HIV status of participants.Allocation concealment (selection bias)Unclear riskAll clinical and research staff were unaware of the participants' treatment assignment, but the trial authors provided insufficient information.Blinding (performance bias and detection bias) All outcomesLow riskParticipants and investigators were blinded.Incomplete outcome data (attrition bias) All outcomesUnclear riskThe trial authors did not provide reasons for losses to follow‐up, although they used appropriate statistical analyses.Selective reporting (reporting bias)Unclear riskInsufficient information; the trial protocol was not available.Other biasLow riskThe trial authors declared that they had no conflicts of interest.[@CD003650-bbs2-0032]MethodsCountry: Guinea‐Bissau\
Setting: tuberculosis clinics in urban disease surveillance site\
Duration of recruitment: November 2003 to December 2005\
Duration of follow‐up: 12 months\
Design: placebo‐controlled, parallel groupParticipantsInclusion criteria: tuberculosis participants starting antituberculosis treatment, ≥ 15 years\
Exclusion criteria: none\
Participants randomized: 222 male and 143 female; mean age 37.5 yrs; 131 HIV‐positive\
Participants analysed: 365\
Loss to follow‐up/withdrawal: 84\
Exclusions postrandomization: 2InterventionsIntervention: 100,000 IU cholecalciferol (vitamin D)\
Control: placebo\
Duration: at inclusion; 5 and 8 months after inclusionOutcomesPrimary outcomes: Reduction in a clinical severity score (tuberculosis score)\
Secondary outcomes: 12‐month mortalityAdverse eventsMinor adverse events reported; no difference between groups. There were no reported cases of hypercalcaemia.NotesSource of funding: Aarhus University Hospital; Danish Research Council for Developmental Research***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskThe trial authors used a computer‐generated sequence when performing randomization.Allocation concealment (selection bias)Low riskThe trial used identical, sequentially numbered containers to perform allocation concealment.Blinding (performance bias and detection bias) All outcomesLow riskParticipants, staff, and researchers were blinded to treatment.Incomplete outcome data (attrition bias) All outcomesUnclear riskLoss to follow‐up was unknown in the HIV‐positive subgroup.Selective reporting (reporting bias)Low riskThe trial protocol was available; the trial authors reported on all outcomes of interest.Other biasLow riskThe trial authors did not prespecify the HIV subgroup analyses but proportions were equally distributed; the trial funder and provider had no role in trial design.[@CD003650-bbs2-0033]MethodsCountry:China\
Setting: village in Huaiyang county, Henan province\
Design: randomized placebo‐controlled trial\
Duration of recruitment: June 2008 to November 2008\
Duration of follow‐up: 6 monthsParticipantsInclusion criteria: HIV‐positive people aged 25 to 49 years with BMI 18‐25kg/m2 and CD4 count \> 200 with no clinical symptoms of AIDS\
Exclusion criteria: not stated\
Number randomized: 102\
Mean age at randomization: micronutrient group:37.8 ± 2.9 years; placebo group: 37.3 ± 2.3 years\
50 male and 49 female\
No baseline differences between treatment groups in terms of gender, weight, heightInterventionsIntervention: tablet containing: vitamin A 200 µg, β‐carotene 200 µg, vitamin D 5 µg, thiamin 1 mg, riboflavin 1 mg, vitamin B6 1 mg, folic acid 0.15 mg, vitamin C 100 mg, vitamin E 15 mg, iron 6 mg, zinc 5 mg, selenium 30 µg, calcium 400 mg\
Control: identical placebo daily\
Duration: 6 months\
Compliance: not reportedOutcomesPrimary: change in absolute CD3, CD4, and CD8 counts and of markers of humoral immunity (IgA, IgG, IgM, and C3)Adverse eventsNot reportedNotesSource of funding: not specified\
Conflict of interest: not specified\
Ethics: review board not specified\
Trial registration: not specified***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskThe trial authors did not describe the method of random sequence generation.Allocation concealment (selection bias)Unclear riskThe trial authors did not describe the method of allocation concealment.Blinding (performance bias and detection bias) All outcomesUnclear riskThere was no information from the trial authors on blinding of participants, investigators, or outcome assessors.Incomplete outcome data (attrition bias) All outcomesLow riskThree participants, out of a total number of 102 randomized, were lost to follow‐up.Selective reporting (reporting bias)Unclear riskThe trial protocol was not available.Other biasUnclear riskThe study authors did not provide conflict of interest statements.[^31]

Characteristics of excluded studies \[ordered by study ID\] {#CD003650-sec2-0026}
===========================================================

StudyReason for exclusion[@CD003650-bbs2-0034]Trial participants had highly active antiretroviral therapy (HAART)‐related co‐morbidity[@CD003650-bbs2-0035]Not a randomized controlled trial (RCT)[@CD003650-bbs2-0036]Most trial participants were under 15 years of age[@CD003650-bbs2-0037]The trial intervention was irrelevant to this review[@CD003650-bbs2-0038]Co‐intervention present[@CD003650-bbs2-0039]The trial intervention was irrelevant to this review[@CD003650-bbs2-0040]This study did not report any relevant outcomes[@CD003650-bbs2-0041]Trial participants had HAART‐related co‐morbidity[@CD003650-bbs2-0042]Not a RCT[@CD003650-bbs2-0043]Not a RCT[@CD003650-bbs2-0044]This study did not report any relevant trial outcomes[@CD003650-bbs2-0045]Not a RCT[@CD003650-bbs2-0046]Not a RCT[@CD003650-bbs2-0047]This study did not report any relevant trial outcomes[@CD003650-bbs2-0048]This study did not report any relevant trial outcomes[@CD003650-bbs2-0049]This study did not report any relevant trial outcomes[@CD003650-bbs2-0050]This study did not report any relevant trial outcomes[@CD003650-bbs2-0051]This study did not report any relevant trial outcomes[@CD003650-bbs2-0052]The trial intervention was irrelevant to this review[@CD003650-bbs2-0053]The trial intervention was irrelevant to this review[@CD003650-bbs2-0054]The trial intervention was irrelevant to this review[@CD003650-bbs2-0055]Most trial participants were less than 15 years of age[@CD003650-bbs2-0056]Most trial participants were less than 15 years of age[@CD003650-bbs2-0057]Not a RCT[@CD003650-bbs2-0058]Co‐intervention present[@CD003650-bbs2-0059]The trial intervention was irrelevant to this review[@CD003650-bbs2-0060]The trial intervention was irrelevant to this review[@CD003650-bbs2-0061]Not a RCT[@CD003650-bbs2-0062]Trial participants had HAART‐related co‐morbidity[@CD003650-bbs2-0063]This study did not report any relevant trial outcomes[@CD003650-bbs2-0064]Not a RCT[@CD003650-bbs2-0065]This study did not report any relevant trial outcomes[@CD003650-bbs2-0066]Not a RCT[@CD003650-bbs2-0067]Not a RCT[@CD003650-bbs2-0068]The trial intervention was irrelevant to this review[@CD003650-bbs2-0069]Not a RCT[@CD003650-bbs2-0070]Co‐intervention present[@CD003650-bbs2-0071]The trial intervention was irrelevant to this review[@CD003650-bbs2-0072]Not a RCT[@CD003650-bbs2-0073]The trial intervention was irrelevant to this review[@CD003650-bbs2-0074]The study did not report any relevant outcomes[@CD003650-bbs2-0075]The study did not report any relevant outcomes[@CD003650-bbs2-0076]The trial intervention was irrelevant to this review[@CD003650-bbs2-0077]More than 20% of the trial participants were less than 15 years of age[@CD003650-bbs2-0078]Co‐intervention present[@CD003650-bbs2-0079]The trial intervention was irrelevant to this review[@CD003650-bbs2-0080]The study did not report any relevant trial outcomes[@CD003650-bbs2-0081]Not a RCT[^32]

Characteristics of studies awaiting assessment \[ordered by study ID\] {#CD003650-sec2-0027}
======================================================================

[@CD003650-bbs2-0082]MethodsCountry: Nigeria\
Setting: HIV treatment centre, LagosParticipantsInclusion criteria: HIV‐positive men and women who were eligible for highly active antiretroviral therapy (HAART) and who were HBsAg positive (Hepatitis B virus or HBV)InterventionsIntervention: 200 µg selenium daily plus HAART\
Control: HAART\
Duration: 18 monthsOutcomesChanges in HBV load, HIV load, CD4 cell count, and alanine transaminase (ALT)Notes[^33]

Characteristics of ongoing studies \[ordered by study ID\] {#CD003650-sec2-0028}
==========================================================

[@CD003650-bbs2-0083]Trial name or titleThe role of extended‐release niacin on immune activation and neurocognition in HIV‐positive patients treated with antiretroviral therapy (CTN PT006)MethodsCountry: Canada\
Setting: Chronic Viral Illness Service, Montreal Chest Institute of the McGill University Health Centre (MUHC), and the Cliniquemédicale l'Actuel, Montreal\
Design: randomized cross‐over trialParticipantsInclusion criteria: 21 years or older, viral load \< 50 copies/mL for the last 3 months, CD4+ T‐cell count ≤ 350 cells/μL; and on stable ART (ART unchanged for treatment failure (rebound in viral load)) for more than 12 months.\
Exclusion criteria: prior history of hypersensitivity reaction to niacin or any other component of the study drug; prior history of flushing; liver disease (including coinfection with hepatitis B or C virus) or unexplained persistent elevations of serum transaminases; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or alkaline phosphatase \> 2.5 times the upper limit of normal ; active duodenal or gastric peptic ulcer; active bleeding disorders; history of gout; active AIDS events in the last 3 months as determined by the treating physician; unstable angina or acute phase myocardial infarction; diabetic or potentially diabetic with hypercholesterolaemia; renal dysfunction; co‐enrolment in another study involving neurocognitive evaluation; or pregnant or nursing or planning to become pregnant.InterventionsImmediate versus deferred use of ER niacin for 24 weeks. The administration of ER niacin will be titrated (weeks 0 to 4: 500 mg, weeks 5 to 12: 1000 mg, weeks 12 to 24: 2000 mg). All participants will receive ARTOutcomesPrimary outcome: T cell activation (change in percentage of CD8+ CD38+ HLA‐DR+ T‐cells)\
Secondary outcomes: change in total CD4 cell countStarting dateFebruary 2012Contact informationbertrand.lebouche\@mcgill.caNotes[@CD003650-bbs2-0084]Trial name or titleVitamin D supplements for HIV‐positive patients on cART (NCT01295034)MethodsCountry: USA\
Setting: Mount Sinai Medical Center, New York\
Design: controlled trialParticipantsInclusion criteria: HIV‐positive adults ≥ 18 to 70 yrs, stable highly active antiretroviral therapy (HAART) regimen (at least 12 months) with undetectable viral load (at least 6 months), not consuming more than 2 g calcium and 800 IU vitamin D daily\
Exclusion criteria: receiving vitamin D, current treatment for bone disease, receiving medications known to affect bone mineralization, medical conditions known to affect vitamin D, calcium and phosphate levels, kidney disease, unstable medical condition likely to preclude participation in a 12‐month trial, pregnancyInterventionsIntervention: oral dose of 50,000 IU vitamin D2 weekly for 8 weeks, thereafter 1000 IU vitamin D2 daily for 48 weeks\
Control: oral dose of 2000 to 4000 IU vitamin D3 daily for 12 months, with dose titration as necessary\
Duration: 12 monthsOutcomesPrimary: 25 (OH) vitamin D levels (% of participants who have levels in the range of 30 to 60 ng/mL)\
Secondary: change in CD4 cell countStarting dateMarch 2011Contact informationandrea.branch\@mssm.eduNotes[@CD003650-bbs2-0085]Trial name or titleTrial of Vitamin D in HIV progression (TOV4)MethodsCountry: Tanzania\
Setting: Dar es Salaam\
Design: placebo‐controlled trialParticipantsInclusion criteria: HIV‐positive adults ≥ 18 yrs, initiation of HAART at the time of randomization, 25(OH) vitamin D concentration \< 30 ng/mL\
Exclusion criteria:pregnancy, participation in another micronutrient trialInterventionsIntervention: oral dose of 50000 IU vitamin D3 weekly for 4 weeks, thereafter 2000 IU vitamin D3 daily up to 12 months\
Control: oral dose of placebo weekly for 4 weeks, thereafter 2000 IU vitamin D3 daily up to 12 months\
Duration: 12 monthsOutcomesPrimary: All‐cause death, pulmonary tuberculosis within 12 months of randomization\
Secondary: CD4 cell count, clinical diagnosis of co‐morbidities, weight, calcium, Parathyroid hormone (PTH) and alkaline phosphate (ALP) concentrationsStarting dateFebruary 2014Contact informationmina\@hsph.harvard.edu\
fmugusi\@muhas.ac.tzNotes[@CD003650-bbs2-0086]Trial name or titleFolinic Acid: Supplementation and Therapy (NCT02810275)MethodsCountry: Brazil\
Setting: Hospital de Clinicas de Porto AlegreParticipantsInclusion criteria: HIV infected and HIV‐HCV co‐infected men and women aged 18 to 50 years receiving HAART with undetectable viral load for more than 6 months\
Exclusion criteria: diabetes mellitus, previous CVD: acute myocardial infarction, myocardial revascularization, or stroke,creatinine \> 1.5 mg/dL,clinical diagnosis or ultrasound, endoscopic, or laboratory evidence of liver cirrhosis, on treatment with: statins, fibrates, hormone replacement therapy, sulfonamides, vitamin supplements, or folinic acid in the last 30 days and pregnant women.InterventionsIntervention: 5 mg folinic acid daily\
Control: placebo daily\
Duration: 4 weeksOutcomesChanges in flow mediated dilatation. serum homocysteine levelsStarting dateOctober 2012Contact informationSandra Costa Fuchs, Hospital de Clinicas de Porto AlegreNotes[@CD003650-bbs2-0087]Trial name or titleVitamin D and Calcium Supplement Attenuate Bone Loss Among HIV‐ Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz (NCT02827643)MethodsCountry: Thailand\
Setting: Ramathibodi Hospital, Mahidol University, BangkokParticipantsInclusion criteria: HIV‐1‐infected patients aged 18 to 50 years who start 3TC or FTC, TDF, and EFV within 3 months before enrolment\
Exclusion criteria: CrCl \< 60 mL/min/1.73 m^2^, CaCO~3~ supplement \> 500 mg/day or vitamin D supplement \> 800 IU/day, steroid use (equivalent to prednisolone\> 5 mg/day more than 3 months), osteoporosis treatment, serum calcium \> 10.5 g/dL clinical history of fragility fracture, pregnancy, or breastfeeding, secondary amenorrhoea, hyperthyroidism, history of kidney stone or current active opportunistic infectionInterventionsIntervention: once daily calcium carbonate 1,250 mg (600 mg elemental calcium) and weekly vitamin D2 (20,000 IU) plus TDF/3TC or FTC/EFV therapy\
Control: TDF/3TC or FTC/EFV therapy\
Duration: 24 weeksOutcomesChanges in bone mineral density, 1,25 (OH) vitamin D concentrationsStarting dateJune 2016Contact informationpataweeb44\@gmail.comNotes[@CD003650-bbs2-0088]Trial name or titleZinc Supplementation and Cardiovascular Risk in HIV (NCT02856269)MethodsCountry: USA\
Setting: University Hospitals Cleveland Medical CenterParticipantsInclusion criteria: HIV‐1 infected adults aged ≥ 18 years with blood zinc level ≤ 0.75 mg/L that are receiving a stable antiretroviral regimen with no plans to change during study with HIV‐1 RNA level of ≤ 400 copies/mL and no diarrhoea or nausea/vomiting for the last month\
Exclusion criteria: pregnancy/lactation,presence of inflammatory condition, regular use of agents that may affect inflammation in the last 3 months. regular use of NSAIDS, aspirin, or statins will be allowed as long as dose has been stable for the last 3 months and is not expected to change during the study.\
Presence of active neoplastic diseases requiring chemotherapy and use of immunosuppressive drugs, known cardiovascular disease, uncontrolled diabetes, allergy or intolerance to zinc sulfate. AST, and ALT \> 2.5 x upper normal limit, haemoglobin \< 9.0 g/dLor GFR \< 50 mL/minInterventionsIntervention: 45 mg zinc gluconate daily\
Control: 90 mg zinc gluconate daily\
Duration: 12 weeksOutcomesChanges in blood zinc concentrationsStarting dateSeptember 2016Contact informationmccomsey.grace\@clevelandactu.orgNotes[^34]
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Internal sources {#CD003650-sec2-0023}
================

SACC HIV/AIDS Mentoring Programme, South Africa.South African Cochrane Centre, South Africa.Medical Research Council, South Africa.Liverpool School of Tropical Medicine, UK.

External sources {#CD003650-sec2-0024}
================

Department for International Development, UK.Grant: 5242

Marianne Visser (MV) has no known conflicts of interest. Solange Durao (SD) has no known conflicts of interest. David Sinclair (DS) has no known conflicts of interest. James Irlam (JI) has no known conflicts of interest. Nandi Siegfried (NS) has provided consultancies to several World Health Organization (WHO) guidelines processes within the HIV department including nutritional interventions.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^No serious risk of bias: most trials were at low risk of selection bias and used placebos to prevent performance or detection bias. ^2^No serious heterogeneity: none of the trials found statistically significant effects overall (although one small subgroup from one trial in Tanzania did find a statistically significant difference this is probably a chance finding). ^3^Downgraded by 1 for serious indirectness: although most trials reported this outcome, only one of these (from Uganda using standard dose micronutrients) included a substantial number of adults on ART in line with current recommendations. The other trials used standard or high dose micronutrients and were conducted in ART‐naive adults (in Botswana, Zambia, and Thailand), and adults with concurrent tuberculosis (in Tanzania and Malawi). ^4^Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important effects and no effect. The overall meta‐analysis remains underpowered to confidently exclude effects. ^5^Downgraded by 2 for very serious indirectness: these two trials were conducted in Thailand (high dose micronutrients in ART‐naive adults) and Uganda (standard dose micronutrients in adults on ART). The finding of no effect may not apply to all populations and settings. ^6^Downgraded by 1 for serious inconsistency: in total eight trials reported a measure of CD4+ cell count although we could only include six trials in this meta‐analysis. Of note, one recent trial in Botswana among ART‐naive adults (not included in the meta‐analysis) reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation. This finding is inconsistent with other trials that used similar combinations of micronutrients and selenium. ^7^Downgraded by 1 for serious indirectness: in total four trials in ART‐naive adults, with concurrent TB (in Tanzania and Malawi) or without TB (in Kenia and Thailand), reported viral load. The finding of no effect may not apply to people on ART or other populations and settings. ^8^Downgraded by 2 for serious indirectness: only three trials (from Uganda, Zambia, and Tanzania) reported measures of nutritional status (BMI, weight, mid‐upper arm circumference (MUAC), lean body mass). The finding of no effect may not apply to all populations and settings. ^9^Downgraded by 1 for serious imprecision: we were unable to pool data but the 95% CIs of the individual trials were wide and included clinically important effects and no effect.

[^3]: ^1^Downgraded by 1 for serious risk of bias: one trial in Kenya with 400 participants reported high attrition overall (11.5%) and the trial authors stated that participants who were lost to follow‐up had more advanced HIV disease and were more likely to be vitamin A deficient ([@CD003650-bbs2-0003]). ^2^No serious heterogeneity: none of the trials found statistically significant effects. ^3^Downgraded by 1 for serious indirectness: trials were conducted in the USA and Kenya, and most participants were not on antiretroviral therapy (ART). This may not completely exclude the possibility of effects in some settings or populations. ^4^No serious imprecision: no statistically significant differences were seen. Although two trials were underpowered, one trial in Kenya with 400 participants was adequately powered to reliably detect a clinically beneficial effect on CD4 cell count, viral load, and blood vitamin A concentrations ([@CD003650-bbs2-0003]). ^5^No serious heterogeneity: a statistical significant increase in blood vitamin concentrations was reported in one trial from Kenya with 400 participants. Baseline blood vitamin concentrations of these participants were much lower than the 95 participants in the other two trials in the USA.

[^4]: ^1^No serious risk of bias: the included trials were generally at low risk of bias. ^2^Downgraded by 2 for serious indirectness: only a single trial from Guinea‐Bissau reports the number of deaths after 12 months follow‐up in HIV‐positive participants on treatment for active tuberculosis ([@CD003650-bbs2-0032]). ^3^Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both a relative risk reduction and relative risk increase of greater than 25%. ^4^Downgraded by 2 for serious indirectness: no changes in mean or median CD4 cell counts were reported from these four small trials from Italy ([@CD003650-bbs2-0012]), the USA ([@CD003650-bbs2-0025]), Guinea‐Bissau ([@CD003650-bbs2-0032]), or Denmark ([@CD003650-bbs2-0004]). This doesn\'t exclude the possibility of effects in some populations. ^5^Downgraded by 2 for very serious indirectness: this is a single very small trial from the USA. ^6^Downgraded by 1 for serious imprecision: the trial is very small, and the 95% CI is wide and includes no effect. ^7^No serious heterogeneity: all four studies report a statistical significant increase in blood 25(OH) vitamin D concentrations (ng/mL). ^8^Downgrade by 1 for serious risk of indirectness: all studies were conducted in high income countries (Italy, Canada, Denmark, and the USA).

[^5]: ^1^No serious risk of bias: the included studies were generally at low risk of bias. ^2^Downgraded by 1 for serious indirectness: the available data is from limited settings and populations. The findings are not easily generalized to other populations. ^3^Downgraded by 2 for serious imprecision: the 95% CI around the absolute effect is very wide and crosses 1. The overall meta‐analysis is underpowered to confidently exclude effects. ^4^Downgraded by 2 for very serious indirectness: this finding is from a single study in the USA and may not be applicable to other settings. ^5^Downgraded by 1 for serious imprecision: although the 95% CI does not cross the line of no effect this trial is underpowered to detect or exclude clinically important differences. ^6^Downgrade by 1 for serious inconsistency: one very small trial from Singapore reports a marginal improvement in median CD4 count after 6 months of standard dose supplements ([@CD003650-bbs2-0002]), and one study reports a significant reduction in the risk of decline of CD4+ to \< 200 in those taking standard supplements ([@CD003650-bbs2-0005]). Two other small studies using high dose supplements report no statistically significant difference ([@CD003650-bbs2-0013]; [@CD003650-bbs2-0026]). ^7^Downgraded by 1 for serious imprecision: all three trials were underpowered to include or exclude clinically important effects ([@CD003650-bbs2-0005]; [@CD003650-bbs2-0013]; [@CD003650-bbs2-0026]). ^8^No serious inconsistency: three trials report an increase in blood zinc concentrations over time. The participants in one trial that did not report an increase in blood concentrations after supplementation, were not deficient in zinc at baseline ([@CD003650-bbs2-0013]).

[^6]: ^1^Downgraded by 1 for serious risk of bias: high attrition due to participants with incomplete medical records. In addition, fewer participants in the placebo group compared to the selenium group were on antiretroviral therapy (ART) at baseline ([@CD003650-bbs2-0007]). ^2^Downgraded by 1 for serious indirectness: only a single trial is available from the USA in HIV‐positive intravenous drugs users. This is not easily generalized to other HIV‐positive populations. ^3^Downgraded by 1 for serious imprecision: this trial is underpowered to detect clinically important differences. ^4^Downgraded by 1 for serious risk of bias: two of the three trials reported high attrition rates ([@CD003650-bbs2-0007]; [@CD003650-bbs2-0017]). In one trial fewer participants in the placebo group compared to the selenium group were on ART at baseline ([@CD003650-bbs2-0007]). ^5^Downgraded by 1 for serious imprecision: three of the four trials were underpowered to include or exclude clinically important effects ([@CD003650-bbs2-0007]; [@CD003650-bbs2-0017]; [@CD003650-bbs2-0020]). One trial from Botswana was adequately powered and reported no effect on the decline in CD4 cell counts of ART‐naive participants ([@CD003650-bbs2-0006]). ^6^No serious risk of bias: the included trial was at low risk of selection and performance bias ([@CD003650-bbs2-0006]). The trial authors performed multiple imputation of viral load data. The trial authors did not provide details. ^7^Downgraded by 2 for serious indirectness: only a single trial is available from Botswana in participants not on ART ([@CD003650-bbs2-0006]). ^8^No serious heterogeneity: all three trials reported either an increase in the mean blood selenium concentration of participants or the proportion of participants with selenium concentrations above a certain threshold level. ^9^Downgraded by 1 for indirectness: participants in two of the three included trials were not deficient in selenium at baseline ([@CD003650-bbs2-0007]; [@CD003650-bbs2-0017]). The third trial reported data on participants who were selenium deficient at baseline; however it was a small subsample of the main trial from Botswana (Sales 2010).

[^7]: ^1^Estimated annual risk of death of antiretroviral naive HIV‐infected persons (≥10 years after seroconversion) ([@CD003650-bbs2-0095]). ^2^Estimated annual risk of death of antiretroviral naive HIV‐infected persons (5 to 9 years after seroconversion) ([@CD003650-bbs2-0095]). ^3^Estimated risk of death of HIV‐infected persons after receiving first‐line antiretroviral therapy regimens for 12 months ([@CD003650-bbs2-0108]). ^4^Antiretroviral naive HIV‐infected participants who experience a decline in CD4 count (Kamwesiga 2011a, which is under [@CD003650-bbs2-0020]).

[^8]: Abbreviations: BMI: body mass index; SD: standard deviation.

    ^1^This example is based on data from [@CD003650-bbs2-0030]. This example uses the SD from the control group. ^2^This example is based on data from [@CD003650-bbs2-0030]. This example uses the SD from the supplemented group. ^3^This example uses the SD from [@CD003650-bbs2-0031], but uses a 1 kg/m^2^ mean difference for illustrative purposes. ^4^This example uses the SD from [@CD003650-bbs2-0031], but uses a 2 kg/m^2^ mean difference for illustrative purposes.

[^9]: Abbreviations: HAART: highly active antiretroviral therapy; MMN: multiple micronutrient; TB: Tuberculosis

    ^1^Standard dose supplements provided most of the micronutrients at the level of the Dietary Recommended Intake (DRI). High‐dose supplements provided most of the micronutrients in multiples of the DRI. ^2^[@CD003650-bbs2-0015]: participants who received ART for no longer than 6 months. The rest of the trial participants were initiated on ART at baseline. ^3^[@CD003650-bbs2-0022]: we excluded participants taking HAART from the analysis of CD4 and viral load. ^4^[@CD003650-bbs2-0022] was a cross‐over trial, with cross‐over at the end of 1.9 years. We did not include the outcome data for the period after cross‐over. ^5^[@CD003650-bbs2-0028]: the median duration of follow‐up was 12.5 months, due to the introduction of ART programme.

[^10]: Abbreviations: IU: International units; RDA:Recommended Daily Allowance

    ^1^Standard dose supplements provided most of the micronutrients at the level of the RDA. ^2^High‐dose supplements provided most of the micronutrients in multiples of the RDA.

[^11]: Abbreviations: IQR: Interquartile range; MD: Mean difference; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for end‐point data. ^2^[@CD003650-bbs2-0015]: the trial authors reported a mean difference which is different to our calculation. The reasons for this are unclear. ^3^[@CD003650-bbs2-0021]: the trial authors did not report data that we could include in a meta‐analysis. ^4^[@CD003650-bbs2-0022] was a cross‐over trial, with cross‐over at the end of 1.9 years. CD4+ counts were recorded during the second year of follow‐up. The data for the period after cross‐over is not included in this table. ^5^[@CD003650-bbs2-0026]: data shown are for multiple micronutrients plus zinc versus placebo. There were also no differences for micronutrients without zinc versus placebo. ^6^[@CD003650-bbs2-0031] also reported outcomes at 8 months, with no significant difference between groups. ^7^[@CD003650-bbs2-0006]: data shown are for multivitamins plus selenium versus placebo. The trial authors reported reductions in the risk of CD4+ falling to \< 250 cells/µL for multivitamins plus selenium versus placebo (HR 0.48, 95% CI 0.26 to 0.88 ) and for multivitamins alone versus placebo (HR 0.54, 95% CI 0.3 to 0.98). Multivariate analysis showed that this effect was only apparent with supplementation of both multivitamins and selenium (HR 0.46, 95% CI 0.25 to 0.85).

[^12]: Abbreviations: CI: Confidence interval; IQR: Interquartile range; MD: Mean difference; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for end‐point data. ^2^[@CD003650-bbs2-0006]: multiple imputation of viral load data was performed. The trial authors did not provide details. ^3^[@CD003650-bbs2-0006]: data shown are for multivitamins plus selenium versus placebo. There were also no differences for multivitamins without selenium versus placebo. ^4^[@CD003650-bbs2-0019]: viral load analyses was conducted on the first 140 consecutive participants (29% of participants). ^5^[@CD003650-bbs2-0026]: data shown are for multiple micronutrients plus zinc versus placebo. There were also no differences for micronutrients without zinc versus placebo. ^6^[@CD003650-bbs2-0031] also reported outcomes at 8 months, with no significant difference between groups.

[^13]: Abbreviations: BMI: Body Mass Index; IQR: Interquartile range; MUAC: Mid‐upper arm circumference; MD: Mean difference; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for endpoint data. ^2^[@CD003650-bbs2-0031] also reported outcomes at 8 months, with no significant difference between groups (MD 0, 95% CI −0.2 to 0.3; P = 0.74). ^3^Reference value for vitamin E sufficiency ≥ 11.6 µmol/L. ^4^[@CD003650-bbs2-0019]: the trial authors reported endpoint data on a subset of 44 participants. The trial authors did not state the number of participants for each treatment group. Baseline vitamin E levels (µmol/L) reported for 112 participants. ^5^Reference value for selenium sufficiency: ≥ 0.95 µmol/L. ^6^[@CD003650-bbs2-0019]: the trial authors reported endpoint data on a subset of 54 participants. The number of participants for each treatment group is not stated. Baseline selenium levels (µmol/L) reported for 129 participants. ^7^Reference value for vitamin A deficiency: \< 0.7 µmol/L. ^8^[@CD003650-bbs2-0021]: the trial authors reported that 67% and 55% of participants were deficient in vitamins A and E, respectively, at baseline. ^9^[@CD003650-bbs2-0022] was a cross‐over trial, with cross‐over at the end of 1.9 years. ^10^Reference value for selenium sufficiency: ≥ 0.75 µmol/L. ^11^[@CD003650-bbs2-0028]: the trial authors reported that 60% and 75% of participants were deficient in vitamin A and selenium respectively, at baseline. ^12^Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.

[^14]: ^1^No serious risk of bias: all trials were at low risk of selection bias. Appropriate methods of blinding were used. ^2^No serious heterogeneity: none of the trials found statistically significant effects. ^3^Downgraded by 1 for serious indirectness: the three trials were conducted in Botswana ([@CD003650-bbs2-0006]), Zambia ([@CD003650-bbs2-0022]) and Thailand ([@CD003650-bbs2-0019]).The finding of no effect may not apply to all populations. ^4^Downgraded by 1 for serious imprecision: the 95% CI is wide and includes both clinically important effects and no effect. The overall meta‐analysis is substantially underpowered to confidently exclude effects. ^5^Downgraded by 2 for very serious indirectness: only a single trial is available from Thailand ([@CD003650-bbs2-0019]). The finding of no effect is not easily generalized to other settings. ^6^Downgraded by 1 for serious inconsistency: One trial in Botswana among ART‐naive adults (not included in the meta‐analysis) reported a reduced risk of reaching a CD4+ cell count of less than 250 cells/mm³ after two years of high dose supplementation. This finding is inconsistent with other trials that used similar combinations of micronutrients and selenium. ^7^Downgraded by 1 for serious indirectness: these two trials both used high‐dose multiple micronutrients and were conducted in Kenya (with 6 weeks follow‐up) and Zambia (with 1.9 years follow‐up). TThe finding of no effect may not apply to people on ART or other populations and settings. ^8^Downgraded by 1 for serious indirectness: these two studies both used high dose multiple micronutrients and were conducted in Kenya (with 6 weeks follow‐up) and Thailand (with 48 weeks follow‐up). The finding of no effect may not apply to people on ART or other populations and settings. ^9^Downgraded by 2 for very serious indirectness: only a single trial from Zambia ([@CD003650-bbs2-0022]) reports measures of nutritional status. This does not exclude the possibility of effects in some populations. ^10^Downgraded by 1 for serious imprecision: this trial is underpowered to detect or exclude clinically important differences. The trial reported no difference in BMI, mid‐upper arm circumference (MUAC), lean body mass or fat mass but did not present data.

[^15]: ^1^No serious risk of bias: this trial was at low risk of selection bias. The trial authors used appropriate methods of blinding. ^2^Downgraded by 2 for serious indirectness: this single trial was conducted in Uganda and administered standard dose multiple micronutrients for two years. The finding of no effect may not be applicable to higher dose or the populations or settings. ^3^Downgraded by 2 for serious imprecision: this single trial is significantly underpowered to confidently detect or exclude effects. ^4^Downgraded by 1 for serious imprecision: the 95% CI is wide and includes what may be clinically important effects and no effect.

[^16]: ^1^No serious risk of bias: the trials were at low risk of selection bias, except for two trials that recruited both HIV‐positive and HIV‐negative participants and did not stratify the randomization ([@CD003650-bbs2-0026]; [@CD003650-bbs2-0028]). The trials used appropriate methods of blinding. ^2^No serious heterogeneity: one small subgroup of a trial in Tanzania did find a statistically significant difference ([@CD003650-bbs2-0026]), but larger trials did not. ^3^Downgraded by 1 for serious indirectness: the three trials were conducted in Tanzania and Malawi and most patients were not taking ART. The finding of no effect may not apply to people on ART or other populations and settings. ^4^Downgraded by 1 for serious imprecision: the 95% CI is wide and includes clinically important effects and no effect. ^5^Downgraded by 2 for serious indirectness: data is provided by a single trial from Tanzania and participants were not on antiretroviral therapy (ART).

[^17]: Abbreviations: IDUs: Injection drug users; IU: International units; RDA: Recommended Daily Allowance

    ^1^Reference value for vitamin A sufficiency: \> 1.05 µmol/L. ^2^RDA for a male aged 19 to 70 years is 900 µg (3000 IU) daily. ^3^[@CD003650-bbs2-0009] was a cross‐over trial, with cross‐over at the end of 4 weeks. The baseline and outcome data is not reported for the period before cross‐over and therefore we could not include it.

[^18]: ^1^The number of participants stated is the number assessed for endpoint data. ^2^[@CD003650-bbs2-0027]: the trial authors reported that 110 particpants completed the trial, but did not report the number of participants for each treatment group.

[^19]: ^1^The number of participants stated is the number assessed for endpoint data. ^2^[@CD003650-bbs2-0027]: the trial authors reported that 110 particpants completed the trial, but do not report the number of participants for each treatment group.

[^20]: ^1^The number of participants stated is the number assessed for endpoint data. ^2^[@CD003650-bbs2-0003]: Data converted from µg/dL to µmol/L. ^3^Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.

[^21]: Abbreviations: ART: antiretroviral therapy; IU: International units; TB: Tuberculosis

    ^1^Reference value for vitamin D sufficiency: 25 (OH) vitamin D ≥ 30 ng/mL. ^2^RDA for a male aged 19 to 70 years ranges between 5 to 15 µg (200 to 600 IU) daily. ^3^[@CD003650-bbs2-0012]: only participants with low blood vitamin D concentrations were included in the trial (25(OH)D \< 30 ng/mL). ^4^[@CD003650-bbs2-0025]: all trial participants were intiated on ART at baseline. ^5^[@CD003650-bbs2-0030]: 62% of partcipants had a CD4 cell count \> 500 cells/mm^3^. ^6^[@CD003650-bbs2-0030]: 44% of trial participants presented with a detectable viral load at baseline (vitamin D group:13, placebo group: 11).

[^22]: Abbreviations: MD: Mean difference; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for endpoint data. ^2^[@CD003650-bbs2-0012]: the trial authors also reported no difference in CD4+ cell count at 3, 6, and 9 months. ^3^[@CD003650-bbs2-0025]: the trial authors reported an increase in CD4+ cell count within both treatment groups (P \> 0.001). ^4^[@CD003650-bbs2-0032]: subset of 41 HIV‐positive participants who had CD4+ cell counts at baseline and endpoint.

[^23]: Abbreviations: MD: Mean difference; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for end‐point data. ^2^Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation.

[^24]: Abbreviations: ART: Antiretroviral therapy; RDA: Recommended Daily Allowance; TB: Tuberculosis

    ^1^Reference value for zinc sufficiency: \> 70 µg/L. ^2^RDA for a male aged 18 to 70 years is 11 mg daily. ^3^[@CD003650-bbs2-0002]: the trial authors stratified participants with or without low blood zinc concentrations and randomized them to receive zinc or placebo. ^4^[@CD003650-bbs2-0005]: proportion of trial participants who were on ART and had an undetectable viral load at baseline: 30% ^5^[@CD003650-bbs2-0005]: the trial authors excluded participants with normal baseline blood zinc levels (≥ 75 µg/L) ^6^[@CD003650-bbs2-0023]: the trial authors randomized participants to receive either weekly doses of zinc (90 mg) and vitamin A (5000 IU), zinc (90 mg) and placebo, or a dual placebo.

[^25]: Abbreviations: CI: Confidence interval; IQR: Interquartile range; RR: Relative risk; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for endpoint data.

[^26]: Abbreviations: CI: Confidence interval; SD: Standard deviation; TB: Tuberculosis

    ^1^The number of participants stated is the number assessed for endpoint data.

[^27]: Abbreviations: IQR: Interquartile range; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for endpoint data. ^2^[@CD003650-bbs2-0002]: participants with or without low blood zinc concentrations were stratified and randomized to receive zinc or placebo. ^3^Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. ^4^[@CD003650-bbs2-0005]: regression coefficient adjusted for C‐reactive protein levels (biomarker for inflammation). ^5^[@CD003650-bbs2-0008]: the trial authors reported a smaller proportion of participants in the supplemented group with low zinc levels after 14 days of follow‐up (65.6% versus 93.7%; P = 0.01).

[^28]: Abbreviations: ART: antiretroviral therapy; HAART: Highly active antiretroviral therapy; IDUs: injection drug users.

    ^1^Reference values used to define selenium sufficiency: \> 75 µg/L or \> 85 µg/L ^2^RDA for a male aged 18 to 70 years is 55 µg daily. ^3^Sales 2010 BWA in [@CD003650-bbs2-0006]: Baseline selenium concentrations reported for a sub‐sample of 79 trial participants. ^4^[@CD003650-bbs2-0007]: the trial authors reported fewer ARV naive participants in the selenium group (24%) compared to the placebo group (37%) at baseline. ^5^[@CD003650-bbs2-0007]: participants with low baseline blood selenium levels (≤ 85 µg/L) were excluded from the trial. ^6^[@CD003650-bbs2-0017]: participants with low baseline blood selenium levels (≤ 75 µg/L) were excluded from the trial. ^7^[@CD003650-bbs2-0020]: participants who were eligible for ART were excluded from the trial.

[^29]: Abbreviations: CI: confidence interval; HR: hazard ratio; IQR: interquartile range; RR: risk ratio; SD: standard deviation ^1^The number of participants stated is the number assessed for endpoint data. ^2^[@CD003650-bbs2-0006]: the trial authors reported no reduction in risk of CD4+ falling to \< 250 cells/µL^2^ (HR 0.83, 95% CI 0.48 to 1.42). ^3^[@CD003650-bbs2-0007]: the trial authors reported that 46% of participants in the placebo group versus 25% in the selenium group experienced a decline in CD4 cell count \> 50 cells/mm^3^ (P = 0.01). ^4^[@CD003650-bbs2-0017]: the trial authors reported in a multiple regression model that increased selenium levels predicted a greater decrease in viral load (P \< 0.02), which predicted a greater increase in CD4 counts (P \< 0.04). ^5^[@CD003650-bbs2-0020]: the trial authors reported a 44 % reduction in the rate of CD4+ cell decline per month (MD 1.74, 95% CI 0.31 to 3.17). No reduction in risk of CD4+ falling to \< 350 cells/µL^2^ (RR 0.81, 95% CI 0.61 to 1.09).

[^30]: Abbreviations: MD: Mean difference; SD: Standard deviation

    ^1^The number of participants stated is the number assessed for endpoint data. ^2^Analysis of blood micronutrient concentrations did not include adjustment for biomarkers of inflammation. ^3^[@CD003650-bbs2-0007]: the trial authors reported proportions of participants with blood selenium levels \< 135 µg/L at the end of the trial: 89% versus 47% (P = 0.001). ^4^Sales 2010: data reported on a subsample of trial participants from the trial by [@CD003650-bbs2-0006].

[^31]: Abbreviations: ALT: alanine aminotransferase; ALP: alkaline phosphate; ART: antiretroviral therapy; AST: aspartate aminotransferase; BMI: Body Mass Index; CXR: Chest X‐Ray; ESR: erythrocyte sedimentation rate ; GFR: glomerular filtration rate; HAART: highly active antiretroviral therapy; IDU: injection drug user; HCV: Hepatitis C; INH: isoniazid; IQR: interquartile range; MUAC: mid‐upper arm circumference; NSAIDS: non‐steroidal anti‐inflammatory drugs; PTH:Parathyroid hormone; SD: standard deviation.

[^32]: Abbreviations: HAART: highly active antiretroviral therapy; RCT: randomized controlled trial.

[^33]: Abbreviations: HAART: highly active antiretroviral therapy; HBV: hepatitis B.

[^34]: Abbreviations: ALT: alanine aminotransferase; ALP: alkaline phosphate; ART: antiretroviral therapy; AST: aspartate aminotransferase; GFR: glomerular filtration rate; HAART: highly active antiretroviral therapy; NSAIDS: non‐steroidal anti‐inflammatory drugs; PTH: parathyroid hormone.
